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Hematopoiesis is considered to be a hierarchical process, with the 
hematopoietic stem cell (HSC) residing at the top, giving rise to all mature 
blood cells downstream.1 This rare cell, which mainly resides in the bone 
marrow, possesses the ability to self-renew and/or undergo differentiation. Self-
renewal secures the multipotent stem cell character after division of the mother 
cell, whereas differentiation induces changes in such a way that the progeny 
commits to a certain fate. This commitment can be defined as a progressive 
loss of differentiation potential towards other lineages.2 A concomitant effect of 
increasing differentiation divisions is a decrease in the ability to self-renew.  
 In the past few decades, researchers have constructed a hematopoietic 
lineage tree (fig. 1) in which the long term-HSC (HSCLT) gives rise to a short 
term-HSC (HSCST), followed by a multipotent progenitor (MPP).3;4 The HSC is 
a relatively quiescent cell and upon differentiation towards the MPP its 
proliferation gradually increases from an in vivo population doubling time (77% 
of the cells has incorporated BrdUrd) of 17.8 days to a doubling time of 7.7 
days, as estimated for murine HSCs to MPPs by means of BrdUrd 
incorporation studies.5 Based on these investigations the apparent HSC cell 
cycle time is ~3 to 6 days,5 which is similar to data obtained for human HSCs.6;7 
Approximately 75% of the HSCLT are quiescent in G0 at any time, but are 
recruited regularly, so that 99% of all HSCLT divide on average every 57 days.5 
These cells are, in decreasing order, able to reconstitute the entire 
hematopoietic system and rescue lethally-irradiated mice, confirming their 
multipotent and immature nature.3;4 After this stage, a committing decision is 
made whether to differentiate into a common myeloid progenitor (CMP)8 or to 
differentiate towards a common lymphocyte progenitor (CLP).9 CMPs can 
subsequently further differentiate to granulocyte/macrophage progenitors 
(GMP) and megakaryocytic/erythroid progenitors (MkEP) establishing another 
commitment stage, whereas the CLP has to commit being a pro-B or pro-T cell. 
A final decisive step occurs when the GMP becomes a monocyte/macrophage 
or a granulocyte and the MkEP turns towards a megakaryocytic or an erythroid 
fate. With all bi-potential commitment decisions described above, loss of 
multipotentiality is increased. Recently, this classical model was challenged 
with data indicating that the MkEP branches off earlier at the HSCst stage, 
since a cell type was discovered that lacked megakaryocytic and erythroid 
(MkEP) potential, but retained granulocyte/macrophage (GM) and lymphoid 
potential.10;11 The subsequent remaining multipotent progenitor was termed the 
Lymphoid primed Multipotent Progenitor (LMPP).11 Other researchers have 
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postulated that the LMPP is another differentiation step downstream of the 
MPP and that the lack of MkEP potential was merely due to differences in the 



































Figure 1 Hematopoiesis from Hematopoietic Stem Cell to mature blood cells. 
Schematic representation of mouse and human hematopoiesis with estimated times from the start 
towards the peak emergence of various lineages (shaded areas). Model according to Forsberg et 





Regardless of the precise model, hematopoiesis provides the body with billions 
of mature blood cells every day (~1011 cells per day/adult human, ~108 cells 
per day/adult mouse)13 and since the right type of cell should be provided at the 
appropriate time with the ability to adapt to changes in steady state 
hematopoiesis, it is not surprisingly that hematopoiesis is a highly regulated 
process. Cell extrinsic mechanisms, such as hematopoietic growth factors and 
cell-cell interactions, and cell intrinsic mechanisms, for example transcription 
factor balances and epigenetic modifications, are directing hematopoiesis. 
Although one can argue whether ex- and intrinsic factors actually govern 
lineage choices14 or are merely permissive in nature by providing a survival 
signal,15 changes in signal transduction, with subsequent changes in the 
activity of genetic programmes, ultimately lead to a fine-tuning of processes, 
such as self-renewal, differentiation, proliferation and apoptosis.1;2  
Acute myeloid Leukemia 
When errors occur in the delicate balance between self renewal and 
differentiation, combined with disturbances in proliferation and apoptosis, a 
hematological disorder may develop, such as Acute Myeloid Leukemia (AML). 
AML is characterized by an accumulation of immature blast-like cells in the 
bone marrow resulting in the disruption of normal hematopoiesis.16;17 These 
blast cells are of myeloid origin and are disturbed in their differentiation 
potential to mature cells. 9 types of AML have been classified according to the 
French-American-British (FAB) classification system (table 1).18 
 
Table 1 French-American-British (FAB) classification of AML. 
 
Figure 2 depicts myeloid differentiation downstream of the common myeloid 
progenitor. The gray lines indicate inherent blockades of differentiation with the 
immature FAB M0 with minimal differentiation at the level of the CMP and the 
FAB M1 direct downstream of the CMP. The myeloid AMLs M2 and M3 show 
undifferentiated cells of the granulocytic lineage, M4 and M5 are immature 
monocytic blasts, while M6 and M7 respectively designate immature cells of 
erythroid or megakaryocytic lineage.18;19 The relative occurrence of these AML 
subtypes is shown in table 1.  
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Figure 2 Overview of differentiation blocks in Acute Myeloid Leukemia. 
Grey areas indicate the differentiation stages at which various AML subclassifications are blocked 
in their development according to the French-American-British subclassification, based on 
morphological appearance and histochemical staining.18 
 
The distinction in AML subtypes is based on morphological appearance of the 
blasts combined with various histochemical stains, but does not always reflect 
the genetic diversity of the disease.20;21 With the emergence of molecular 
genetic methods it has been possible to correlate chromosomal aberrations to 
specific FAB subtypes (table 1). Although such chromosomal and 
morphological features demonstrate the heterogeneity of AML, they are also 
used (amongst other parameters) to predict the response to chemotherapy, in 
which these chromosomal abnormalities appear to be a more important 





three prognostic risk groups in AML: Good, Intermediate and Poor risk.20 The 
good prognostic subgroup is identified by the presence of t(15;17), t(8;21) or 
inv(16) abnormalities and these (younger) patients have higher rates of 
complete remission (CR) and a lower risk of relapse.20;22;23 In the poor risk 
group, more than two chromosomal abnormalities are frequently observed or 
monosomies of chromosome 5 or 7 and deletions/ abnormalities of the long 
arm of chromosomes 5 or 3.20;22;23 This is more common amongst older 
patients or patients with secondary AML. The third, intermediate, risk group has 
leukemic blasts with either a normal karyotype or abnormalities that are not 
described in the other two groups. Recently, the World Health Organization 
(WHO) has proposed a new classification system in which genetic and clinical 
features of AML are combined with immunophenotypic and biological criteria of 
the FAB classification.21;24 Again three subgroups are identified: 1) AML with 
recurrent genetic abnormalities, 2) AML with multilineage dysplasia and 3) AML 
and Myelo Dysplastic Syndrome (MDS), therapy related. Of these, subgroup 1 
recognizes the earlier mentioned good risk group, with the addition of AMLs 
with t(16;16) translocations.21;24 If AMLs cannot be classified in one of these 
three groups (table 2), a fourth group (resembling the FAB classification) is 
used to categorize these AMLs.21;24 
 
Table 2 World Health Organization (WHO) classification of AML. 
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Self-renewal and leukemia 
Where normal hematopoiesis is demonstrated to be a polyclonal process, e.g. 
multiple HCSs contribute to hematopoiesis,25-27 AML has been described to be 
a clonal disorder.17;28 This would logically follow from the acquisition of genetic 
alterations, providing the affected cell with an advantage in terms of self-
renewal, cell growth and survival. The normal hematopoietic system carefully 
balances self-renewal in the stem cell compartment and differentiation towards 
more committed progenitors. This differentiation is accompanied by an 
increase in proliferation,5 as the HSC has been demonstrated to be relatively 
quiescent. This quiescence has been postulated to prevent exhaustion of the 
HSC pool during the life time of the host29 and might be evaded by increasing 
self renewal divisions as opposed to differentiation divisions.30;31 For AML cells 
it has been shown that a rare cell exists, termed the leukemic stem cell (LSC), 
which has extensive self-renewal capacity,32;33 thereby giving it an advantage 
over normal HSCs. Some proteins have been shown to enhance and control 
self-renewal of hematopoietic stem cells, such as BMI-1,34;35 STAT5,36;37 and 
various HOX genes,38 which have been shown to be deregulated in leukemic 
cells as well.38-40 
Growth control and leukemia 
Hematopoietic cell growth and cell cycle regulation is balanced by positive and 
negative growth factors. The HSC is kept in a quiescent state by growth 
factors, such as Transforming Growth Factor-β (TGF-β), which is likely to be 
the most potent negative regulator of hematopoiesis, to prevent excessive 
cycling and exhaustion of the system.41;42 Positive growth factors such as 
Granulocyte Macrophage-Colony stimulating factor (GM-CSF) and Interleukin-3 
(IL-3), not only induce differentiation, but also enhance cell-cycle kinetics within 
progenitor cells, subsequently leading to an expanded pool of mature cells.43 It 
was demonstrated years ago that growth of clonogenic AML cells can be 
stimulated with colony stimulating factors, such as Granulocyte-Stimulating 
Factor (G-CSF) or GM-CSF.44 Immature blasts not only respond to 
exogenously delivered growth factors, but have also been shown to produce 
growth factors themselves, such as Interleukin-1 (IL-1),45;46 Interleukin-6 (IL-
6),47 GM-CSF,48 G-CSF48 and Macrophage-Colony Stimulating Factor (M-
CSF),49 which can stimulate autonomous growth in a paracrine or autocrine 
manner. IL-1 has been shown to upregulate autocrine production of GM-CSF 
by AML blasts,50 can alleviate TGF-β-mediated reduction of colony formation51 
or can induce endothelial cells to secrete G-CSF and GM-CSF,45 creating an 





in vitro cell-cycle activation of quiescent leukemic progenitor cells52 and the 
autonomous in vitro growth of AML blasts has been associated with a poorer 
prognosis of AML patients.53  
 Besides activation of the cell-cycle by growth promoting growth factors, 
escape from negative growth control may also occur. In normal hematopoiesis, 
primitive stem/progenitor cells are kept quiescent by inhibitory growth factors 
and cell-cell interactions with the bone marrow micro-environment54;55 and relief 
of these environmental constraints may enhance their cycling potential. TGF-β 
is known as a potent inhibitor of hematopoietic cell-cycle progression41 and in 
various studies resistance of leukemic cells to TGF-β has been observed.56-60 
Whereas cell-cycle progression in normal hematopoietic cells is regulated by a 
balance of positive and negative growth factors, combined with interactions of 
stem and progenitor cells with bone marrow stromal cells,55;61;62 these 
processes might be disturbed in leukemia leading to a growth advantage for 
leukemic cells.  
Apoptosis and leukemia 
Besides through self-renewal, differentiation and cell-cycle progression,   
hematopoiesis is also regulated by programmed cell death or apoptosis. The 
signal transduction pathways downstream of hematopoietic growth factors not 
only promote cell-cycle progression in target cells, but also produce a survival 
signal for these cells by upregulating anti-apoptotic genes or downregulating 
apoptosis-promoting genes.63 Many leukemia-targeting strategies are based on 
the principle of inducing apoptosis, but the growth advantage of the leukemic 
population is partly linked to the constitutive activation of intracellular proteins 
that trigger the function of anti-apoptotic proteins.40;64 This activation of anti-
apoptotic proteins and the absence of pro-apoptotic proteins can hence lead to 
resistance of the leukemic cell to chemotherapy and has been correlated with 
poor diagnosis and clinical outcome.65-67 The relapse of AML after intensive 
chemotherapy may be caused by resistance of a single leukemic cell towards 
apoptotic stimuli. 
 Not only autocrine production of growth factors leads to a disbalance in 
pro- and anti-apoptotic factors, but also the expression of oncogenes, such as 
Ras, or the absence of tumor supressors, such as PTEN can lead to activated 
signal transduction pathways, the subsequent survival of cells and contribute to 
leukemia.68-71 
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Differentiation and leukemia 
Although the above described examples suggest that one single event is 
enough to cause leukemic transformation, the development of cancers and 
leukemias is often being viewed as a succession of multiple events contributing 
to the neoplastic clone.72 In such a multiple hit model, mutations responsible for 
an enhanced self-renewal and block in differentiation are combined with 
mutations causing a proliferative or survival advantage (table 3).73;74 This is 
evidenced for example by overexpression of the AML-ETO translocation, which 
is frequently observed in FAB M2 subclassifications. Overexpression of AML-
ETO can induce a self renewal phenotype,75 but only gives rise to an AML 
when combined with additional mutations.76;77 Furthermore, AML patients in 
remission have indicated the presence of normal cells, but with a relation to the 
original leukemic clone (the original N-Ras mutation was detected in remission 
samples),78 which indicated that the single alterations observed in both the 
AML and normal cells are not the sole cause of the emerging leukemia.  
 











 The events that underlie changes in self-renewal and differentiation often 
affect transcription factors, which play important roles in normal hematopoiesis 
as well. The transcription factor AML1 for example, is involved in the 
emergence of definitive HSCs79 and its disruption will lead to a failure in 
development of all blood lineages. As can be seen in table 1 and 3, the 
transcription factor AML1  is found mutated in rare cases of AML, but is present 
in approximately 40% of AML FAB M2 subclassifications, as a fusion partner of 
ETO, resulting from the t(8;21) translocation. This translocation product has 





recruiting various co-repressors via the ETO fusion.73;74;80 Amongst the genes 
repressed by AML-ETO are C/EBPα and PU.1.80-82 
 The transcription factor C/EBPα is involved in lineage commitment along 
the HSC-CMP-GMP route, since knock-out mice have an effect on HSC 
function and lack granulocyte maturation, whereas overexpression support 
eosinophyl and blocks monocytic lineage commitment.2;83;84 In approximately 
20% of the AML cases mutations are detected, whereas in other cases 
C/EBPα is downregulated or otherwise functionally impaired in its function as 
lineage specific transcription factor.74;80;84;85 The transcription factor PU.1 is 
necessary in both MPP to CMP differentiation, as well as in lineage 
commitment via the CLP stage. The exact phenotype seems to depend upon 
the level of PU.1.2;83;84;86 Although mutations of PU.1 are found in 
approximately 7% of the AML cases, it has been described to be inactivated by 
AML-ETO.74;82 Table 1 and 3 further indicate the presence of various 
translocation products in AML. Of these, CBFβ-MYH11 has been shown to bind 
and repress AML1 and C/EBPα,74;80 RARα fusion proteins have been shown to 
recruit transcriptional co-repressors, which might repress PU.1 and 
C/EBPα,87;88 MLL fusion proteins have been demonstrated to bind to promoters 
and subsequently upregulate HOX genes, involved in self-renewal and lastly, 
NUP98-HOX fusions have been implicated in self-renewal as well.73;74;80  
 The induced mild differentiation block by this first group of mutations (or 
fusion oncogenes) is required, but not sufficient to induce a myeloid leukemia. 
The concomitant enhanced self-renewal however, prevents loss of the clone 
due to differentiation.74 Secondary mutations are necessary for progression into 
AML. This second group of mutations, those that influence the proliferation 
and/or survival of hematopoietic cells, lead to the activation of receptor tyrosine 
kinase signalling, for example due to activated Ras,89;90 Flt3,91;92 c-Kit,93 or an 
inactivated SHP-2 protein (PTPN11).94;95 For these it has been demonstrated to 
enhance proliferation or survival, due to signal transduction via the Ras-Raf-
MEK-ERK, the Pi3K-PKB and the STAT signal transduction pathways (For 
details, see reviews).73;74;80 Table 3 further indicates a large cohort of AMLs 
with mutations in the Nucleophosmin (NPM)96;97 gene, which has functions in 
stress responses, maintenance of genomic stability, regulation of transcription 
and various other processes, but its precise role in leukemogenesis needs to 
be defined.97  In some cases, these mutations are cooperating with alterations 
from the first group in enhancing self-renewal, or down-regulating C/EBPα and 
PU.1 and hence block differentiation.73;74;77;80;95;98;99  
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Processes such as self-renewal vs. differentiation, proliferation vs. 
quiescence and apoptosis vs. survival are all implicated in hematopoiesis and 
complex regulations between these processes is observed. Stimulation of the 
HSC with a certain growth factor will lead to activation of a downstream signal 
transduction cascade, thereby not only amplifying the signal, but also 
expanding the downstream possibilities. Figure 3A is a schematic overview of 





































Figure 3 Hematopoiesis is a balance between intrinsic and extrinsic factors. 
(A) Schematic representation of interactions involved in hematopoiesis. Direct interactions with 
bone marrow (BM) stroma, cell-cycle status, differentiation stage and live/dead (†) cells all 
influence various cell types during the lifespan of a cell. Although not shown for simplicity, most cell 
types produce growth factors and hence modulate the responses of other cells. (B) Hematopoiesis 
is shown as a balance between self-renewal, differentiation, proliferation and apoptosis, in both 
normal and leukemic Hematopoietic Stem Cells (HSC and LSC respectively). Grey areas indicate 
which processes influence a cell at any given moment during its lifetime. 
 
The quiescent, self-renewing HSCLT is residing in the bone marrow in close 
contact with bone marrow stroma. It is thought that this bone marrow niche 
regulates the stem cell property of these HSCs.100;101 Stimulating them for 
example with GM-CSF or G-CSF, not only awakens it from its quiescent state 
to start proliferating (fig. 3A, G0ÆG1ÆS-G2-M, white arrows), but also 
downregulates the self-renewal program (fig. 3A, black arrows), while the 
differentiation program is initiated (fig. 3A, HSCLT Æ HSCST Æ Progenitor Æ 
Mature cell). The interaction with the bone marrow stroma might change upon 
differentiation and progenitors mobilize to the peripheral blood. During the 
course of hematopoiesis, anti-apoptotic proteins are upregulated, growth 
factors are produced and excreted, whereas at the end of its lifespan, the cell is 
programmed to die in an orderly fashion. The growth factor-induced signal 
transduction pathway therefore has multiple downstream events and the 
outcome may depend on cell type, timing, place and combinations of the 
signals (fig. 3A and B). The differentiating cell may therefore be situated 
anywhere in the shaded triangle during its lifespan, balanced by differentiation, 
proliferation and apoptosis (fig. 3B, left). In comparison, AML cells, which may 
be affected at different stages, may react in a different way to a specific 
stimulus as compared to the normal counterpart. The AML “stem cell” (LSC) is 
blocked at certain stages of differentiation, is escaping negative growth 
regulation and is unresponsive to apoptotic stimuli (fig. 3B, right). Furthermore, 
the LSC has self-renewal potential, through which is can propagate the 
disease. The LSC is therefore situated in a smaller space skewed away from 
apoptosis and differentiation, and more around self-renewal and proliferation.  
Leukemic “stem” or “progenitor” cells 
The term leukemic stem cell (LSC) suggests that the transformed cell that 
gives rise to the clonal leukemia is an HSC. The LSC and the HSC have 
indeed in common that they are clonogenic cells, both of them capable of self-
renewal. Phenotypic analysis of transplantable cells in immune-deficient mice 
have indicated that the LSC is found in the rare population of CD34+ CD38- 
cells, a phenotype shared with HSCs.32;33;102-104 Since HSCs already have the 
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self-renewal property activated, the combination with their long life span would 
render them the ideal target for acquiring more mutations. This in contrast to a 
progenitor, which has to gain self-renewal properties and has a relatively short 
life span.1 Although the CD34+ CD38- HSC is found in many leukemias to 
possess the leukemia initiating capacity, some exceptions have suggested that 
multipotent progenitors also may be the target cell. In the case of the AML FAB 
M3 subtype, the transforming PML-RARα translocation is exclusively found in 
the CD34+ CD38+ progenitor cell population and not in the CD34+ CD38- 
cells.105 More recently, it was demonstrated that transformation of a 
Granulocyte-Macrophage Progenitor (GMP) with the MLL-AF9 fusion protein 
gave rise to leukemias, indicating that progenitors can also be the leukemia 
initiating cells.106 Interestingly, while gene expression profiling indicated that the 
induced leukemia contained the progenitor gene signature from which it was 
derived, it also demonstrated that the self-renewal program, found in HSCs, 
was reactivated, since a subset of “stemcell-genes” was re-expressed. Thus, 
whether the self-renewal property is due to the fact that the transformed cell is 
an HSC, which retained its self-renewal property during partial differentiation, 
or that it is a progenitor, with a re-gained self-renewal property, appears to be 
dependent on the transforming events. 
 Besides their clonogenic origin, it has become clear that even within the 
leukemic clone heterogeneity exists.102-104 Since a large proportion of the 
leukemic blasts has a limited proliferative capacity, an apparent contradiction is 
observed: How can the observation of clonogenic cells in a cell cycle arrest be 
reconciled with the appearance of growth advantage? Serial transplantation 
experiments in mice have shown that individual LSCs have different self-
renewal capacities, giving rise to long-term and short-term LSCs, analogous to 
the normal hematopoietic hierarchy.33 This suggests that the target cell for 
leukemic transformation is an HSC and that the normal hematopoietic program 
is not entirely abrogated. The actual leukemia is maintained by a rare LSC with 
higher self-renewal capacity than a normal HSC, but subsequent leukemic 
progenitors are partially blocked in their differentiation and proliferation 
potential, giving rise to the majority of blast cells observed in AML patients. 
 Together, these examples demonstrate the complexity of acute myeloid 
leukemia as a “stem cell” disorder with aberrant self-renewal potential, a lack of 
responses to apoptotic signals, inherent blockades at various stages of 







Signal transduction pathways in hematopoiesis and leukemia  
Apoptosis 
When cells are exposed to stress, for example nutrient withdrawal, UV-
radiation or chemicals, signals are elicited that either mediate survival or signal 
the cell to undergo a form of programmed cell death, called apoptosis. Sending 
two opposite signals in response to one stimulus, ensures some safeguard 
against derailment of this important process, since tilting to either side can 
result in aberrant cellular survival or in inappropriate cell death. The process of 
apoptosis is an essential part of tissue homeostasis in various processes, 
including development.107 Induction of apoptosis can occur via an intrinsic as 
well as an extrinsic signal transduction pathway. The extrinsic apoptosis 
pathway is activated by binding of a family of related ligands, called the TNF-
family, to death receptors (TNF-R family) on the cell surface. The ligand family 
is comprised of 5 family members, called: TNFα, lymphotoxin α (LTα), Fas-
Ligand (also called CD95-Ligand or APO-1-Ligand), APO-3 ligand and TNF-
Related Apoptosis-Inducing Ligand (TRAIL),108  whereas the receptor family 
includes a number of members named: TNF-RI, TNF-RII, Fas, death receptor 
(DR) 4, DR5 and DR6.108 Binding of the ligands, for example TNFα or Fas-L, to 
their cognate receptors results in trimerisation of the receptors and subsequent 
recruitment of the adapter molecule FADD. This adaptor molecule then 
interacts with the apoptosis initiating protein, procaspase-8, forming the death 
inducing signalling complex (DISC, figure 4).107-109 Proteolytic cleavage of 
procaspase-8 into caspase-8 subsequently activates this protein and induces 
activation of downstream effector caspases, such as caspase 3. These will 
cleave specific substrates and eventually, the apoptotic pathway will result in 
cell shrinkage, membrane blebbing, DNA fragmentation and chromatin 
condensation (fig. 4). Lastly, the apoptotic cell will be removed through 
phagocytosis by macrophages or neighboring cells.107;108;110  
 Another apoptosis signal transduction pathway downstream from FAS, but 
independent of FADD is via the recruitment of DAXX to the cytosolic end of the 
CD95/Fas receptor.111;112 DAXX then binds Apoptosis Signal Regulating 
Kinase-1 (ASK1),109 a member of the mitogen-activated protein kinase kinase 
kinase (MAPKKK) family, which in turn activates c-Jun N-terminal Kinase (JNK) 
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Figure 4 Apoptosis signalling pathways in hematopoietic cells.  
Schematic representation of the intrinsic and extrinsic apoptosis pathways and their connection at 
the mitochondria. 
 
The intrinsic pathway of apoptosis is initiated by various apoptotic stimuli 
and converges at the mitochondria. Various anti-cancer drugs and cellular 
stresses induce mitochondrial outer membrane permeabilisation (MOMP), 
which will lead to the release of cytochrome c from mitochondria. This 
cytochrome c subsequently interacts with Apoptosis Protease Activating 
Factor-1 (Apaf-1), which oligomerises and binds to pro-caspase-9.117 The 
formation of this caspase-activating complex, termed the apoptosome, results 
in the activation of caspase-9, which in turn triggers the proteolytic cleavage of 
pro-caspase-3, leading to apoptosis (fig. 4).117 Members of the Bcl-2 family, 
play an important role in regulating the mitochondrial-mediated apoptosis 
pathways. Anti-apoptotic family members, such as Bcl-2 and Bcl-XL and pro-
apoptotic members, such as Bad, Bax, Bim and Bid, translocate to the 
mitochondrial membrane and modulate the permeabilization of the inner and 





family members the balance is shifted and cytochrome c release is controlled, 
either leading to survival or to apoptosis (fig. 4).107;108;110 The extrinsic and 
intrinsic apoptosis pathways also interconnect at the mitochondria. The above 
mentioned DAXX-ASK1-mediated JNK activation can lead to an inhibition of 
the anti-apoptotic Bcl-2 protein by phosphorylation,118;119 thereby inducing 
cytochrome c release from the mitochondrial membrane. Furthermore, ASK1-
mediated p38 and JNK activation may phosphorylate Bim and BAX, hence 
stimulating apoptosis.120-123 Another connection between the intrinsic and 
extrinsic apoptosis pathways can be found at the level of caspase-8. Extrinsic 
signal transduction activates caspase-8, which in turn proteolytically activates 
the pro-apoptotic member Bid. This Bid then translocates to the mitochondrial 
membrane, activates the protein Bad, which in turn leads to MOMP and 
cytochrome c release. Upon formation of the apoptosome, irreversible 
apoptosis is induced (fig. 4).107;108;110 
 As mentioned earlier, evasion of programmed cell-death is one of the 
essential alterations that lead to malignant transformation. Besides 
counterbalancing apoptosis in the onset of a malignancy, this also poses a 
mayor problem in the treatment of the malignancy. In AML cells, many anti-
apoptotic proteins are overexpressed, including Bcl-2, Bcl-XL124 and NF-κB.64 
Autophagy  
Cell growth and stress responses may, apart from apoptosis, also be regulated 
through a process called autophagy, which means “to eat oneself”.125 
Autophagy is the major pathway, through which a cell degrades long-lived 
proteins as well as degrading (damaged) organelles.126 Nutrient starvation, 
hypoxia, overcrowding or accumulation of damaged organelles may induce the 
isolation of parts of the cytoplasm, by wrapping a flat membrane around it, 
which finally will form a closed structure, called the autophagosome (fig. 5).125-
127 This formation of the pre-autophagosomal structure is class III PI3 Kinase 
dependent.127 The autophagosome subsequently fuses with late endosomes, 
multivesicular bodies or lysosomes, in order to deliver the incorporated 
cytoplasm to the endo/lysosomal lumen. Lysosomal hydrolases then degrade 
the contents after which degradation products are transported back to the 
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Figure 5 Autophagy.  
Schematic representation of autophagy and the signal transduction pathways modulating this 
process. 
 
Autophagy has long been recognized as a non-apoptotic form of 
programmed cell death. Whereas apoptotic cell death (type I) is caspase-
dependent and characterized by early collapse of cytoskeletal elements, but 
preservation of organelles until late in the process, autophagocytic cell death 
(Type II) demonstrates early degradation of organelles with a preservation of 
cytoskeletal elements.126 The precise role of autophagy in cancer development 
is still unclear, but it has been suggested that in early stages of cancer 
development, autophagy serves a tumour suppressor function. It is 
hypothesized that in early stages, cancer cells require a higher rate of protein 
synthesis than protein degradation and therefore autophagy might control 





eliminating damaged organelles that induce genotoxic stress through producing 
free radicals.127 On the other side, autophagy may promote tumour 
development in later stages of cancer as a protective mechanism against 
stressfull conditions.127 Although autophagy and apoptosis are mostly viewed 
as separate  mechanisms, tumour cells have been observed to undergo both 
apoptosis and autophagy.127 Crosstalk may occur as inhibition of apoptosis has 
been shown to induce autophagy and vice versa.127 In cancer cells, many of 
the signalling pathways that regulate proliferation and apoptosis, also regulate 
autophagy and have been shown to be deregulated. For example, the Ras-Raf-
MEK-ERK pathway inhibits apoptosis and stimulates autophagy (fig. 5).127 On 
the other side, activated class I PI3 Kinase activates the PKB mTOR pathway 
and subsequently inhibits autophagy.125-127 Thus activated Ras signalling may 
have different effects on autophagy. Furthermore, the anti-apoptotic protein 
Bcl-2, which is frequently activated in many cancers, has also been shown to 
be an inhibitor of autophagy, since downregulation of Bcl-2 in the leukemic cell 
line HL-60 has been shown to enhance autophagy.128;129  
 Although autophagy is predicted to play a major role in cancer, and 
possibly leukemic development, and targets seem to be available for 
therapeutic targeting, much about autophagy is still unclear and needs to be 
clarified. For example, in cancer cells with defective autophagy mechanism, 
autophagy may be restored in order to induce autophagic cell death, or 
inhibition of proliferation. Some therapies indeed induce autophagy in leukemic 
cells,130 but this may also be an indication of stress survival. In such a case, 
autophagy needs to be inhibited, demonstrating the importance of clarifying the 
role of autophagy in cancer.126;127 
Cell-cycle progression 
The cell cycle is composed of 4 phases: the G1, S, G2, and M phase 
respectively. If the extracellular conditions are favourable and the signals to 
divide are present, cells will progress through the G1 phase of the cells cycle, 
pass the restriction point, after which cells are committed to complete the cell 
cycle and enter the S phase. During S-phase, the genomic DNA is replicated. 
In the G2-phase the cell prepares to divide. In the M (mitosis)-phase the actual 
cell division takes place by segregating the two copies of the genome into 
separate daughter cells followed by cytokinesis where the cytoplasm is divided 
between the two daughter cells (fig. 6A). The cells enter the G1 phase again 
and decide to proceed, pause or exit the cell-cycle based on growth promoting 
or inhibitory signals it receives. When the cell ceases to proliferate, a non-
dividing, quiescent state can be entered, known as G0.131-133  
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Figure 6A Cell cycle progression.  
Schematic representation of cell cycle progression and the involvement of various Cyclins, Cyclin 
dependent kinases (CDK) and Cyclin dependent kinase inhibitors (CDKi) at various point during the 
cell cycle. R indicates the Restriction Point. Positive and negative regulation is indicated by + (←) 
or – (├) signs respectively. 
 
The cell-cycle is controlled by proteins known as cyclins, which associate 
and activate cyclin-dependent kinases (CDK). Besides their synthesis and 
destruction at designated points in the cell-cycle, is their activity regulated by 
cyclin-dependent kinase inhibitors (CDKi).131 In mammalian cells, 16 cyclins 
have been discovered and 9 CDKs. The CDKis consist of two families. The first 
family is known as the Cip/Kip family, made up by p21, p27 and p57. The 
second family is the INK4 family, consisting of the members p16, p15, p18 and 
p19, respectively called INK4a to d.131 Table 4 summarizes interactions 
between cyclins, CDKs and CDKis as far as their function is correlated to a 
cell-cycle event.131;134-136  
 








 When G0 cells receive mitogenic signals from the extracellular 
environment, for example growth factor-induced Ras-Raf-MEK-ERK signalling, 
the cell cycle is initiated via upregulation of D-type cyclins.137-139 Normally, 
Cyclin D is kept inactive by phosphorylation through GSK-3β, leading to 
enhanced nuclear export and accelerated degradation through an ubiquitin-
dependent proteasomal event.138 However, Ras activation also induces 
activation of PI3K-PKB signalling, which effectively inhibits GSK-3β.132;138 Next, 
complex formation with CDK 4 and 6 is enhanced by the CDKis p21, p27 and 
p57 (fig. 6A and B),131;133;134;140 but in order to being activated and start the 
transition from G1 into S-phase, the phosphatase CDC25A dephosphorylates 
the Cyclin D-CDK4/6 complex. 141;142 The primary substrate for the activated 























Figure 6B Cell cycle progression.  
Schematic representation of complex formation during cell cycle progression and the subsequent 
modulations on retinoblastoma (Rb) activity. Signal transduction pathways involved in the onset of 
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This Rb protein functions as an inhibitor of the E2F family of transcription 
factors and prevents the expression of genes involved in cell-cycle progression 
and DNA synthesis, such as Cyclin E, A, CDK2 and many others.131 Upon Rb 
phosphorylation by the Cyclin D-CDK4/6 complex, E2F is released and can 
start transcription of Cyclin E (fig. 6A and B). Cyclin E subsequently forms a 
complex with CDK2, which is required to make the final G1-to S-phase 
transition. This complex hyperphosphorylates the Rb protein, thereby 
enhancing the positive feedback loop for the accumulation of active E2F.131 
The Rb protein remains hyperphosphorylated during the cell-cycle, until the late 
M-phase.143;144 The next target of E2A, Cyclin A is being expressed and 
associates with CDK2 initially, but later in S-phase with CDK1.131;133 Cyclin A-
dependent kinase activity is not only necessary for the completion of the S-
phase and entry into M-phase, but also to phosphorylate the E2F partner 
DP1,131;132 which results in shutdown of the transcriptional activity of this 
complex. The M-phase is regulated by CDK1 in association with Cyclin A, B1 
and B2. In order to exit the M-phase, Cyclin A and B are rapidly degraded, 
upon which the cells can enter the next cycle again (fig. 6A and B) 
Furthermore, at the end of the M-phase, a phosphatase called PP1 
dephosphorylates the hyperphosphorylated Rb protein, so it can bind E2F 
again.144;145 
Cell-cycle inhibition 
When a cell in G1-phase exits the cell-cycle due to growth inhibitory signals, 
such as TGF-β or removal of growth factors, the CDKis come into play. 
Although the Cip/Kip family was above described to assemble the Cyclin D-
CDK4/6 complex and hence activate the cell-cycle, they are more famous for 
their inhibitory actions on the Cyclin E-CDK2 complex. The function for the 
Cyclin D-CDK4/6 complex is therefore dual: Not only does it initiates the first 
phosphorylation step of the Rb protein, but it also forms a sink for the Cip/Kip 
family of CDKis, which therefore are unable to inactivate their target: the Cyclin 
E-CDK2 complex.135;139 Upon receiving a growth inhibitory signal, the INK4 
family of CDKis associates and inhibits the Cyclin D-CDK4/6 complexes (fig. 
6A). A second event directly following from this, is the displacement of Cip/Kip 
family members from Cyclin D-CDK4/6 to Cyclin E-CDK2 complexes, where it 
can now start its inhibitory function (Fig 6A).139 Both Cyclin D and Cyclin E (with 
their respective CDKs) complexes are now inhibited, which results in an 
inhibition of phosphorylation of Rb protein. The resulting hypophosphorylated 
Rb then binds and deactivates E2F again, resulting in cell-cycle arrest in the 





 Abortion of cell-cycle progression is limited to the early G1-phase. A point 
of no return was suggested as early as 1974.146 Nutrient withdrawal before this 
point, termed the Restriction point, led cells back to the G0-phase of the cycle, 
but beyond this point cell-cycle progression has become inevitable.132;133 
Although beyond the Restriction point return to G0 is impossible, the Cip/Kip 
family of CDKis not only inhibits Cyclin E-CDK2 complexes during G1 phase, 
but also Cyclin A-CDK1/2 and Cyclin B-CDK1 complexes later in the cell-cycle 
during S and G2-M phase transitions (table 4). This seems to be necessary for 
G2 checkpoints and prevent reduplication of the genome before mitosis has 
finished, but will not be further discussed in detail here.131;136;139;147;148  
 Overexpression of cyclins A, D and E, as well as overexpression of CDK4 
and 6 have been observed in human cancer and in some forms of leukemia, 
which may lead to inappropriate Rb inactivation and hence cell-cycle 
progression.131;132;149;150 Furthermore, loss of control due to absence of 
expression of CDKis is frequently observed as well. The INK4 family members 
p15 and 16 have shown frequent deletions or promoter hypermethylation in 
ALL and AML, 131;132;135;151 whereas p16 and p14 (p19 in mice) have also 
shown to be upregulated in AML and ALL, which, when combined, indicates 
highly aberrant regulation of these proteins.152-154 The Cip/Kip family members 
p21 and p27 have been shown to deleted or mislocalized to the cytoplasm in 
various forms of leukemia as well, which also leads to a loss of cell-cycle 
control.131;132;155-157 The above described complex regulation of cell-cycle 
progression and arrest thus provides various levels at which mutations can 
occur, leading to uncontrolled growth and hence to a form of cancer. 
TGF-β signal transduction 
As mentioned earlier, TGF-β can inhibit hematopoietic cell growth. TGF-β 
directly inhibits the first proliferation divisions of HSCLT, as well as the 
differentiation of daughter cells.41;42;158-162 Three TGF-β isoforms exist, TGF-β1, 
-β2 and -β3, with TGF-β1 being universally expressed. Platelets are an 
abundant source of TGF-β.163 Binding of TGF-β to the type II TGF-β receptor, 
results in recruitment of the type I TGF-β receptor. The type II receptor 
phosphorylates the type I receptor and activates its kinase activity. This 
subsequently leads to the activation of Receptor-Smad proteins 2 and 3, which 
are efficiently recruited to the activated receptor by the SARA (Smad Anchor 
for Receptor Activation) protein. These R-Smads form a heterodimeric complex 
with the co-Smad, Smad4, and this complex translocates to the nucleus where 
it modulates the transcription of many target genes, including genes that affect 
cell fate (fig. 7).158;159  
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Figure 7  TGF-β signal transduction.  
Schematic representation of TGF-β signal transduction. Binding of TGF-β to the TGF-β type II 
receptor, leads to dimerization with the TGF-β type I receptor. Subsequent tetramerization recruits 
SARA-Smad complexes to the receptor, which facilitates complex formation of  Smad4/Smad2 and 
Smad4/Smad3 complexes. Subsequent translocation towards the nucleus leads to DNA binding 
and transactivation of TGF-β target genes. 
 
One of the earliest effects of TGF-β-induced cell cycle arrest is 
downregulation of c-myc expression by inhibition of transcriptional initiation in 
early G1, by a complex consisting of Smad3, E2F, the E2F-partner DP1 and 
the co-repressor p107.42 Later in G1, expression of various CDKis, including 
p15Ink4B 164;165, p21Waf1/Cip1 166;167, p27Kip1 168;169 and p57Kip2 170 is 
upregulated. Furthermore, the expression and activity of additional proteins 
such as c-Myc, cyclin A, CDK4/6 and the phosphatase cdc25A are suppressed 
by TGF-β.171;172 These events eventually lead to decreased activity of the 
Cyclin D-CDK4/6 and Cyclin E-CDK2 complexes and ultimately result in cell 





 Loss of cell-cycle responsiveness to TGF-β and a possible contribution to 
the leukemogenic process may occur through inactivating mutations in TGF-β 
receptors or Smad proteins.58;158;173 FAB M2 AML subtypes with a t(8;21) 
translocation (AML-ETO) have been shown to resist TGF-β-mediated 
transcription, since the AML-ETO fusion protein binds and inactivates 
Smad3.174 Furthermore, in FAB M3 subtypes of acute promyelocytic leukemia 
(APL) it has been demonstrated that the occurring fusion protein PML-RARα 
can sequester cPML from SARA/Smad2/3 complexes. This cPML is necessary 
for correct association between SARA, Smad2/3, TGF-β receptor type I and 
type II interactions and therefore for correct TGF-β signalling.175 In Chronic 
myeloid leukemia (CML), the Smad3-transcriptional repressor Evi-1 is 
upregulated during blast crisis,176 and the t(3;21) AML-Evi-1 translocation also 
has been observed to inhibit Smad3-mediated TGF-β-induced growth 
inhibition.177 TGF-β-mediated cell cycle arrest can also be blocked by 
oncogenic Ras. This has been attributed to Map Kinase-dependent 
phosphorylation of Smad 2/3 and subsequent impaired nuclear translocation, 
degradation of Smad 4, or mislocalization of p27 to the cytoplasm.171;178;179  
 Although the above described possibilities in abrogation of TGF-β-
mediated growth inhibition in vitro may contribute to the process of 
leukemogenesis, in vivo data from the conditional TGF-β receptor type I knock-
out suggest that hematopoietic cells are fully functional, despite a growth 
advantage in vitro.180 This discrepancy between in vitro and in vivo studies 
might be explained trough compensational signalling in vivo via ALK-1 (another 
Type 1 TGF-β Receptor), endoglin (a TGF-β co-receptor) or activins, that have 
been shown to activate Smad2/3 signalling.162;180 Therefore, differences 
between in vivo and in vitro studies are likely the result from responses of the 
microenvironment, also since other signal transduction events between HSCs 
and the bone marrow micro environment, such as Tie2 with Ang-1 respectively, 
have been shown to render the HSC quiescent.55 
CDKis and hematopoiesis 
In hematopoietic cells other cell biological characteristics, such as apoptosis, 
differentiation and self-renewal may be affected by regulation of the cell cycle 
and proliferation by multiple CDKis. The CDKis p21 and p27 for example have 
been implicated in performing anti-apoptotic functions181-183 and furthermore 
has the differentiation of monocytic cells been coupled to the CDKi p21.183;184                          
 In the process of self-renewal, p21 has been implicated to maintain the 
quiescent state of murine HSC, with a subsequent exhaustion of the stem cell 
pool upon deletion of p21, but this may be dependent upon the mouse 
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strain.29;185 The CDKi p18 has been shown to have opposite effects on HSC 
self-renewal, with a maintenance function upon deletion.30 Combining both 
knock-out models indicates that the increased self-renewal after p18 deletion is 
able to compensate for the exhaustion of stem cells upon deletion of p21.31 
Other INK4 family members, p16 and p19, have shown to be elevated upon 
BMI-1 deletion,34 which is a major determinant of self-renewal. The roles of p16 
and p19 downstream of BMI-1 are suggested to control proliferation and 
survival of HSCs during self-renewal divisions, as overexpression of these 
CDKis have demonstrated a senescent or apoptotic phenotype respectively. 
Indeed, cells induced to become leukemic loose such an ability upon BMI-1 
deletion, due to an elevated proportion of cells in G1 phase of the cell cycle 
and elevated levels of apoptotic cells.186 Consistent with this model is the fact 
that high proliferative clones, which are able to escape this phenotype, have 
decreased levels of not only p16 and p19, but also decreased levels of p21, 
p27 and p57.186  
 The CDKi p27 has been implicated in the control of progenitor cell 
proliferation, instead of HSC pool control as described above, since knock-out 
mice for p27 have demonstrated an increased progenitor pool.187 Although 
HSCs from these mice appear normal in number and cycling activity, upon 
entering the progenitor stage cycling activity is enhanced with a resulting 
growth advantage over normal progenitors. Interestingly, more than 9 months 
after transplantation of p27 deficient cells, a complete dominance was 
observed in the peripheral blood, whereas the stem cell compartment appeared 
to be dominated by normal cells.187 This suggests that the large pool of cells in 
the periphery is derived from a small pool of cells in the bone marrow. This may 
resemble an AML, in which a small number of LSCs gives rise to the 
overwhelming amount of immature progeny. Although p27 deficient mice do not 
develop leukemia, similar to p21 deficient mice, in concert with other oncogenic 
hits it may contribute to a leukemia-like phenotype. In AML patients the 
cytoplasmic to nuclear ratios of p27 have been shown to be a strong prognostic 
factor for disease free survival (DFS) and overall survival (OS). In patients with 
high cytoplasmic (and hence low nuclear) p27, both DFS and OS were 
significantly shorter than in patients with low cytoplasmic to nuclear p27 
ratios.155 Cytoplasmic p27 does not contribute to cell cycle arrest and thus 
correlates to the observed cycling activity of p27 deficient cells. Although the 
progenitor phenotype of p27 deficient mice was reproducible, others have also 
reported an HSC phenotype, especially in combination with deletion of Mad1, 






Trancription factors in hematopoiesis and AML 
Nuclear factor-κB 
The transcription factor NF-κB has also been implicated to play an important 
role in cell growth and oncogenesis.189 In hematopoietic malignancies this is 
demonstrated by the finding that NF-κB can be constitutively expressed in 
myeloid leukemic progenitor cells.64 The dimeric transcription factor NF-κB 
consists of proteins that are members of the rel family, which comprises five 
major proteins: p50, p65 (RelA), c-rel, p52 and RelB.190;191 The most abundant 
NF-κB dimer is the p50/p65 heterodimer.  
 There are multiple signals that can activate NF-κB, including cytokines, 
pathogens, stress and chemotherapeutics.110;192 As described above, TNFα not 
only elicits an apoptotic response through the extrinsic pathway, but also anti-
apoptotic responses are activated, such as activating NF-κB.193 In response to 
for example, TNFα, LPS or IL-1, a variety of cell surface receptors activate the 
classical NF-κB pathway, through the IKK/IκB/NF-κB signalling pathway (fig. 
8).194;195 Although different receptors often use distinct combinations of 
intracellular proteins to initiate NF-κB activation, the signals converge into a 
common pathway that leads to activation of the IκB kinase (IKK) complex.196-198 
This complex consists of a heteromer of related IκB Kinases, IKK1 and IKK2 
(Also named IKKα and IKKβ) and the regulatory protein NEMO (also IKKγ).199-
202 This activated complex phosphorylates the inhibitor of NF-κB (IκB) protein, 
which in an unphosphorylated form, binds to and sequesters NF-κB in the 
cytoplasm. Upon phosphorylation, IκB is ubiquitinylated and targeted for 
proteolytic degradation by the proteasome.203 NF-κB is subsequently released, 
translocates to the nucleus where it can bind to target DNA sequences in the 
promoters of target genes (fig. 8).199;204 Among the target genes of NF-κB are 
many anti-apoptotic proteins, such as: IAPs (Inhibitor of Apoptotic Proteins; 
inhibits caspases), Bcl-XL, Bcl-2, cFLIP (FLICE Inhibitory Protein; inhibits 
caspase-8 activation),199;205 various growth and differentiation promoting 
cytokines, such as GM-CSF, G-CSF and EPO206-208 and various proteins 
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Figure 8  NF-κB signal transduction.  
Schematic representation of NF-κB signal transduction via the classical  and the alternative 
pathways. After proteolytic degradation of the inhibitor of NF-κB, IκB, or proteolytic processing of 
p100 to p52 respectively, subsequent nuclear translocation of activated transcription factor 
complexes occurs, which results in transactivation of target genes. 
 
A second NF-κB pathway exist which only depends upon IKK1 (fig. 8). A 
homodimer of IKK1 phosphorylates p100, which is subsequently processed to 
p52. In combination with RelB, an active transcription complex translocates to 
the nucleus, where it binds to DNA-target sequences.204;214 In AML aberrant 
regulation of the classical NF-κB pathway through IKK2 signalling has been 
shown to lead to increased NF-κB activity,215 which has been observed in the 
majority of the AML cases and resulting in resistance to apoptosis inducing 





Signal Transducer and Activator of Transcription 5 
A transcription factor involved in many of the above described processes in 
hematopoiesis is STAT5, a member of the Signal Transducer and Activator of 
Transcription (STAT) family. This family contains 7 members, STAT 1 to 6, with 
STAT5 comprising STAT5A and STAT5B.217 Induction of STAT5 
transactivation has been demonstrated to occur after stimulation with multiple 
growth factors and cytokines, including FLT3-L, SCF, G-CSF, GM-CSF, IL-3, 
IL-6, EPO and TPO and affects differentiation, self-renewal, apoptosis and 
proliferation of human hematopoietic stem/progenitor cells.218-224 These 
differences in outcome after STAT5 activation find their origin in differences in 
cell type, (combinations of) cytokine signals and concentrations of 
cytokines.225;226 Upon binding of growth factors or cytokines to their receptors, 
dimerization of the receptor takes place. Since cytokine receptors and many 
growth factor receptors lack intrinsic kinase activity, Janus Kinases (JAKs) are 
recruited to the receptors. Cross-phosphorylation in turn activates the tyrosine 
kinase activity of these JAKs, which then phosphorylate tyrosine residues in the 
cytoplasmic tail of the receptor. These phosphorylated tyrosine residues act as 
docking sites for STAT molecules, which subsequently become phosphorylated 
by JAKs as well. These phosphorylated STAT5 monomers dimerize, 
translocate to the nucleus, bind to specific sequences in the promoter of target 
genes and activate transcription (fig. 9).217;225-227 Among the STAT5 targets are 
genes for cell-cycle regulation: Cyclin D1, D2, D3, p21;228-232 anti-apoptotic 
genes: Bcl-2, Bcl-XL and XIAP;37;233 genes involved in (erythroid) differentiation 
such as hemoglobin genes37 and many more. Although the upregulation of p21 
seems odd to progress cell-cycle, STAT5 has been shown to induce low 
expression of p21, necessary for assembly of Cylin D-CDK4/6 complexes and 
the promotion of cell-cycle134;232  
 Since constitutive STAT5 activation has been observed in many AML 
patients,40;234 which may be due to activating mutations in upstream kinases235-
237 or alternatively result from autocrine growth factor production,40 it is 
interesting to further investigate the role of STAT5 in AML. From the presence 
of normal peripheral blood counts in STAT5AB knock-out mice it may be 
concluded that STAT5 is either not necessary or redundant for hematopoiesis, 
even though cytokine responsiveness was abrogated in STAT5AB knockout 
cells238 and colony assays demonstrated reduced numbers of cytokine-
responsive myeloid progenitors.239 In competitive repopulation experiments 
however, these cells demonstrated a severe impairment in engraftment, 240;241 
suggestive for a role of STAT5 in self-renewal. This was demonstrated when 
constitutively activated STAT51*6 caused a self-renewal phenotype in human 
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and mouse HSCs, which developed into  a myeloproliferative disease (MPD) in 
murine transplantation models.36;37 Besides effects on self-renewal and 
proliferation in hematological diseases,37 STAT5 activation may contribute to 
anti-apoptosis, since in a model for Polycythemia Vera (PV), it was recently 
shown that downregulation of either STAT5 or its target gene Bcl-XL was 
sufficient to inhibit erythroid colony formation in the absence of EPO. This was 
demonstrated to occur upon mutation of JAK2, one of the upstream kinases of 
STAT5.242;243 Interestingly, the overexpression studies of constitutively 
activated STAT51*6 have shown a predominant erythroid differentiation 
program, which is consistent with EPO-independent growth of PV.37 
 
Figure 9 STAT5 signal transduction.  
Schematic representation of STAT5 signal transduction. Cytokine-induced receptor dimerization 
leads to activation of JAK kinases. Phosphorylation of the receptor forms a docking site for STAT5 
monomers, which can subsequently be phosphorylated. Phosphorylated STAT5 hence forms 
dimers and translocates to the nucleus, where the complex can bind DNA and transactivate 





CCAAT enhancer binding protein  (C/EBP) α  
Besides the above described transcription of target genes and subsequent 
changes in apoptosis and proliferation, it was recently shown that STAT5 
activation can also reduce the expression of the transcription factor 
C/EBPα.37;244 C/EBPα is leucine zipper containing transcription factor, via 
which it can homo- or heterodimerize245 and is decisive for myeloid 
differentiation in the hematopoietic system, through inducing differentiation, 
arresting the cell-cycle and enhance cell-survival.246-249 C/EBPα expression is 
upregulated when CMPs and GMPs develop.8;246 Overexpression in cells with 
GMP potential indicated that C/EBPα can induce granulocytic differentiation 
and subsequently block the monocytic differentiation program,246 although 
recently overexpression studies indicated that C/EBPα could direct monocytic 
development as well.247 The reduced C/EBPα expression hence correlates with 
the block in myeloid differentiation and enhanced erythroid differentiation 
observed in STAT51*6 overexpressing cells. The C/EBPα reduction is not only 
necessary for reduction of expression of myeloid genes, normally expressed 
through C/EBP, but it was demonstrated that STAT5 and C/EBPα have 
opposite effects on cell-cycle as well.244 C/EBPα cooperates with p21 to induce 
a cell-cycle arrest250 and high levels of p16 have been correlated to high levels 
of C/EBPα as well.251 Furthermore has C/EBPα been shown to interact with 
E2F, CDK2 and CDK4 to slow G1 progression.252 
 Furthermore, like STAT5, C/EBPα has been implicated in the regulation of 
HSC self-renewal, since the repopulating ability of HSCs lacking this 
transcription factor was increased as compared to wildtype (wt) HSCs.253 Also, 
these mice demonstrated an accumulation of immature myeloid blasts in the 
bone marrow upon transplantation with C/EBPα-/- HSCs,253 which is consistent 
with an AML-like phenotype. Interestingly, C/EBPα is negatively regulated in 
various AML subtypes. Mutations in the N-terminus have been described to 
occur in patients with a FAB M1 subtype as well as in FAB M2 without AML-
ETO translocation.81;254;255 These N-terminal mutations give rise to a truncated 
dominant negative form of C/EBPα , which interferes with DNA-binding and 
transactivation of the wt C/EBPα.254 C-terminal mutations of C/EBPα have been 
described in FAB subtypes M1, M2 and occasionally in M4 and result in 
deficiency in DNA binding of C/EBPα. 256;257 AMLs with an AML-ETO 
translocation have been demonstrated to downregulate C/EBPα at the 
transcriptional level,81 although some studies have also shown that AML-ETO 
can associate with and inhibit C/EBPα function.258 In AML patients with Flt3-
ITD mutations, suppression of C/EBPα expression was demonstrated,259 
whereas functional inhibition of C/EBPα through Flt3-ITD-induced 
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phosphorylation has also been reported.260 Lastly, the fusion gene AML1-
MDS1-EVI1, observed in patients with AML, MDS or CML, has been 
demonstrated to suppress DNA binding of C/EBPα (fig. 10).261 The interference 
with C/EBPα function in myeloid differentiation of many AMLs, combined with 
constitutive activation of STAT5, indicates the importance of an appropriate 
balance between these two transcription factors in normal hematopoietic stem 









Figure 10 Mechanisms of C/EBPα inhibition.  
Schematic representation of various mechanism present in leukemic cells to impair transcription of 
C/EBPα target genes. Shown are: 1) N-terminal dominant negative mutations of C/EBPα, 2) C-
terminal dominant negative mutations, 3) AML-ETO-mediated transcriptional downregulation of 
C/EBPα mRNA, 4) AML-ETO binding to C/EBPα and subsequent interference with DNA binding, 5) 
Flt3-ITD-mediated phosphorylation, 6) suppression of C/EBPα expression in Flt3-ITD positive 
AMLs by an unknown mechanism and 7) inhibition of C/EBPα translation as well as the 





Scope of this thesis 
 
As is evident from the above described pathways, normal hematopoiesis as 
well as Acute Myeloid Leukemic hematopoiesis is a complex integration of 
various signals, both resulting from extrinsic influences, e.g. growth factor 
signalling or interactions with the microenvironment and intrinsic cues, such as 
epigenetic modifications and many more. During the last years, considerable 
progress in the understanding of protein expression, localization, activation and 
their involvement in processes such as proliferation, apoptosis, differentiation 
and self-renewal has been made. Although more and more data are available 
and many more proteins have been assigned a role in specific signal 
transduction pathways, the overall picture has also become more complex. 
Signal transduction pathway activation has gained a cell-type and localization 
specific dimension. And previously unexpected roles of proteins have now 
been assigned in other processes then those widely assumed. For example: 
anti-apoptotic roles of cyclin-dependent kinase inhibitors when localized in the 
cytoplasm of specific cell types is significantly different from the assigned 
growth inhibitory actions when situated in the nuclear compartment of almost 
all cell-types.  
 To understand the molecular mechanisms that are involved in the process 
of leukemic transformation, as well as in understanding how these derailments 
from normal hematopoiesis can potentially be counteracted by clinical 
treatment, detailed analysis and intervention studies are of considerable 
importance. However, AML is a complex and multi-facetted disease, which 
makes it difficult to study. Studies that focus solely on one process such as 
apoptosis, proliferation, differentiation or self-renewal might highlight some 
aspects that underlie the development of leukemia, but will most certainly 
underestimate how the interplay of multiple molecular signal transduction 
pathways ultimately results in the disease. This thesis involves studies 
regarding apoptosis, proliferation, differentiation and self-renewal, with an 
attempt to reconcile observations in primary AML blasts with detailed molecular 
mechanisms from other studies. Since AML blasts have shown resistance to 
apoptotic stimuli and the transcription factor NF-κB is frequently found to be 
activated, in chapter two we investigated the signal transduction pathway 
involved in activation of this transcription factor.  
 Since this transcription factor is so frequently activated in AML and a 
multiplicity of constitutively activated signal transduction pathways converges 
on NF-κB, chapter three investigates what the effects of constutive activation 
of NF-κB are on normal hematopoiesis. Is NF-κB activation sufficient as a 
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single hit to impair normal hematopoiesis, as has been suggested by 
inactivation studies in normal hematopoietic cells? Overexpression studies of 
constitutive active mutants are used to investigate apoptosis, proliferation, 
differentiation and self-renewal of cord blood-derived CD34+ stem and 
progenitor cells. 
 The cyclin-dependent kinase inhibitor p21 has been shown to direct 
monocytic differentiation, due to an anti-apoptotic function when 
cytoplasmically localized. This prompted us to investigate whether AMLs from 
the monocytic subclassifications demonstrated aberrant cytoplasmic 
localization of p21 and whether they were less susceptible to apoptotic insults 
as a result from cytoplasmic localization of p21. This has been described in 
chapter four.  
 Aberrant expression of Heat Shock Proteins has been observed in AML as 
well as in other malignancies and the last few years coupled to the inhibition of 
apoptosis via various pathways. We wondered whether HSP27 was differently 
expressed in AML and if it contributed to the insensitivity towards 
chemotherapeutics. In chapter five we describe the use of RNA interference to 
study the apoptotic pathways inhibited by HSP27. 
 As shown in chapter 2, Ras signal transduction is frequently activated in 
AML blasts. Ras is activated in response to many growth factors and has a 
cell-cycle promoting effect. Because multiple studies in hematopoietic cells 
have indicated the importance of TGF-β as an inducer of cell-cycle arrest and 
AML cells are unresponsive towards TGF-β, chapter six investigates via which 
intermediates Ras signal transduction inhibits the response towards TGF-β. 
 AML is thought to emerge from hematopoietic stem cells with, amongst 
others, aberrant self-renewal and limited differentiation capacities. Recently, 
the transcription factor STAT5 was shown to be involved in self-renewal and to 
induce a block in myeloid differentiation. Since STAT5 is activated in 
approximately 66% of the AML cases, we investigated what the effects of down 
regulation of STAT5 protein levels would be on normal and leukemic stem 
cells. This has been described in chapter 7. 
 Furthermore, STAT5 activation resulted in the downregulation of C/EBPα, 
a transcription factor that is involved in myeloid differentiation. This C/EBPα 
has been shown to be deregulated in almost all AML subtypes and therefore it 
would be interesting to investigate what would happen if C/EBPα levels were to 
be restored in leukemic stem cells. The effects on differentiation, growth and 
self-renewal were examined and described in chapter 8. 
 In the last chapter, chapter 9, the data are summarized and put in 
perspective of the field of hematology. 
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In the present study we aimed to elucidate the mechanism responsible for 
constitutive NF-κB DNA binding activity in AML cells. Intervening in aberrant 
signalling pathways provides a rational approach for in vivo targeting of AML 
cells. Constitutive NF-κB DNA binding activity was observed in 16 of 22 (73%) 
investigated AML cases and was in general associated with resistance to 
spontaneous apoptosis. Indeed, inhibition of NF-κB activity by the NF-κB 
inhibitor SN-50 peptide resulted in enhanced chemotherapy-induced apoptosis. 
In the majority of the cases constitutive NF-κB activity was mediated by a 
Ras/PI(3) Kinase/Protein Kinase B (PKB)-mediated pathway. The PI3-K 
inhibitor Ly294002 and the Ras inhibitor L-744832 both inhibited PKB 
phosphorylation and NF-κB DNA binding activity. The constitutive activation of 
Ras GTP-ase was in 29% of the cases caused by mutations in the gene 
encoding for N-Ras. The constitutive NF-κB activity could so far not be 
ascribed to the autocrine production of growth factors or to mutations in the Flt3 
receptor since anti-GM-CSF,-IL-1, -IL6, -TNFα or the tyrosine kinase inhibitor 
AG1296 did not affect the NF-κB DNA binding activity. 
The present study demonstrates that Ras activation is an important pathway for 
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Introduction 
 
The transcription factor nuclear factor kappa B (NF-κB) has been studied 
intensively for its role in controlling expression of genes involved in immune 
and inflammatory function.192;194;262 Recently, NF-κB has also been implicated 
to play an important role in cell growth and oncogenesis.189 In hematopoietic 
malignancies this is demonstrated by the finding that NF-κB can be 
constitutively expressed in myeloid leukemic progenitor cells.64 NF-κB is a 
dimeric transcription factor that consists of  proteins that are of members of the 
rel family, which comprises five major proteins: p50, p65 (RelA), c-rel, p52 and 
RelB.190;191 The most abundant NF-κB dimer is the p50/p65 heterodimer.  
There are multiple signalling pathways that can potentially activate NF-κB. 
First, the IKK/IκB/NF-κB signalling pathway can be activated through 
stimulation of a variety of cell surface receptors.194;195 Although different 
receptors often use distinct combinations of intracellular proteins to initiate NF-
κB activation, the signals converge into a common pathway that leads to 
activation of the IκB kinase (IKK) complex.196-198 In acute myeloid leukemia 
(AML) aberrant regulation of IKK signaling has been shown to lead to 
increased NF-kappaB activity.215 In addition to the classical NIK/IKK/IκB 
pathway, induced by IL-1 or TNFα, it has been described that downstream 
effectors of the small Ras-GTP-ase can also interfere with the NF-κB 
pathway.263-265 
 Activating point mutations of the Ras genes have been demonstrated in 
20%- 30% of acute myeloid leukemia cases, which are mostly mutations in the 
N-Ras gene, but occasionally mutations in K-Ras have been described.266;267 
Ras activation of the Raf serine/threonine kinases and the activation of the 
ERK mitogen-activated protein kinases (MAPKs) remains a key signalling 
pathway that is important for many aspects of Ras effector functioning.268 An 
additional signal transduction effector of Ras is the PI3-K/PKB signalling 
pathway.269 PI3-K can also activate the Rac GTP-ase, and this Rho family 
protein is an important mediator of oncogenic Ras transformation.270 PKB, but 
also Rac, facilitates Ras activation of NF-κB in some cellular settings, and 
serves an anti-apoptotic role in Ras function.270 271 This is in line with 
observations which describe that in the AML-derived HL60 cell line the PI3-K/ 
PKB pathway plays an important role in chemoresistance, which is distinct from 
interactions between the pro-apoptotic protein Bad with Bcl-2 family members. 
Thus the PI3-K/PKB pathway is suggested to have different targets.272  
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 It has previously been reported that NF-κB is constitutively activated in 
leukemic progenitor cells. More importantly, the activation of NF-κB is a major 
distinguishing characteristic between normal and leukemic stem cells and 
provides leukemic cells a growth advantage over the normal hematopoietic 
stem cell. Therefore, it is important to clearly identify the role and especially the 
regulation of NF-κB in AML. The identification of these signaling cascades 
might lead to a more rational approach to interfere with the aberrant 
proliferation and cell survival characteristics of leukemic cells. The results of 
the present study demonstrate that constitutive PI(3)K dependent activation of 
NF-κB DNA binding activity in AML is triggered by Ras activation in the majority 




Materials and methods 
 
Patient population and isolation of AML cells - Peripheral blood cells or bone 
marrow cells from 22 adult, untreated, patients with AML were studied after 
informed consent. The AML cases were defined according to the classification 
of the French-American-British (FAB) committee as M0-M6.18 AML blasts were 
isolated by density-gradient centrifugation. The cells were cryopreserved in 
aliquots of 20-30 x 106 cells in RPMI 1640 (Flow, Rockville, MD) supplemented 
with 10% dimethylsulfoxide (DMSO; Sigma, St. Louis, MO) and 10% fetal 
bovine serum (FBS; Hyclone, Logan, Utah), employing a method of controlled 
freezing and storage in liquid nitrogen. After thawing, T lymphocytes were 
depleted by 2-aminoethylisothioronium bromide (AET)-treated sheep red blood 
cell (SRBC) rosetting. The cell population consisted of more than 98% AML 
blasts as determined by May-Grünwald-Giemsa staining. Fluorescence-
activated cell sorting (FACS) analysis demonstrated <1% CD3 (Becton 
Dickson, Sunnyvale, California, USA) positive cells. AML blasts were cultured 
at 37°C at a density of 1x106/ml in RPMI 1640 media supplemented with 100 
U/ml penicillin, 100 µg/ml streptomycin (ICN, Costa Mesa, CA, USA), 6 ng/ml of 
colistine and 10% FBS. 
 
Cell culture - The human erythroleukemia cell line TF-1 was cultured in RPMI 
1640 supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin (ICN, 
Costa Mesa, CA, USA), 6 ng/ml of colistine, 5% FBS and 10 ng/ml IL-3 
(Genetics Institute Cambridge, MA). The human monocytic cell line THP-1 was 
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cultured in RPMI 1640 supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin (ICN, Costa Mesa, CA, USA), 6 ng/ml of colistine and 10% FBS. 
 
Combined annexin V/PI staining procedure - Viability was assessed by using 
an annexin V staining kit (IQ Products, Groningen, The Netherlands) according 
to the manufacturer’s recommendations. Briefly, after 24 hours of culture in 
RPMI 1640 medium supplemented with 10% FBS with or without addition of  
VP-16 (50µg/ml) (TEVA Pharma) or the specific NF-κB inhibitor SN-50 
(100µg/ml) (Biomol, Plymouth Meeting, PA, USA), cells were harvested, 
resuspended in 100 µl calcium buffer containing 5 µl of annexin V and 
incubated for 20 min at 4°C in the dark. Cells were washed with 5 ml calcium 
buffer and subsequently incubated in 300 µl calcium buffer containing 2.5 µl of 
propidium iodide (PI) for 10 min in the dark. Subsequently, binding of 
fluorescein-conjugated annexin V and PI was measured by fluorescence-
activated cell sorting (Becton Dickinson, Sunnyvale, CA). The specificity of the 
SN-50 effect was tested by stimulating monocytes with the phorbol ester PMA 
(50 nM, Sigma, St. Louis, MO, USA) during 6 hours that were pre-incubated 
with or without SN-50. Subsequently the NF-κB activity was studied by EMSA 
and p21 (Transduction Laboratories, Lexington, KY, USA) by western blotting. 
 
Western blotting - The amount of ERK, PKB, p21, actin and the degree of 
phosphorylated ERK,  PKB and STAT5 were determined by western blotting. 
AML blasts were cultured for 24 hours in RPMI 1640 supplemented with 10% 
FBS, with or without 50µM L-744832 (Biomol, Plymouth Meeting, PA, USA), 
5µM Ly294002 (Alexis Biochemicals, Switzerland), 20μM AG1296 
(Calbiochem,La Jolla, CA, USA) or 10µM PD98059 (Calbiochem,La Jolla, CA, 
USA) at a density of 1x106 cells/ml. TF-1 cells were cultured overnight in RPMI 
1640 supplemented with 1% FBS and subsequently stimulated for 5 minutes 
with IL-1β (10 ng/ml) or conditioned AML medium (prepared by incubating AML 
cells at a density of 3x106 cells/ml for 3 days). 3x106 cells were harvested and 
total cell extracts were prepared by resuspending the cells in 100 µl 1x Sample 
buffer (containing 2% SDS, 10% glycerol, 2% ß-mercapthoethanol, 60mM Tris-
HCl pH6.8 and bromophenol blue). Cell extracts were directly boiled for 5 
minutes and proteins were fractionated by SDS PAGE. The proteins were 
electrophoretically transferred to PVDF membrane (Millipore, Bedford, MA) and 
probed with antibodies against phospho Thr308-PKB, phospho Ser473-PKB, 
phospho Ser32-IκB-α, phospho Thr202/Tyr204-ERK (E10) (which recognizes 
both residues on both ERK1 and 2)(New England BioLabs, Beverly, MA, 
USA)or phospho Tyr694/Tyr699-STAT5 (Upstate, Charlottesville, VA, USA) 
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(which recognizes the phosphorylated tyrosine 694 residue of STAT5A and the 
phosphorylated tyrosine 699 residue of STAT5B), PKB (New England Biolabs, 
Beverly, MA, USA), IκB-α (C-15) or ERK (K23) (Santa Cruz, CA, USA), 
STAT5A, STAT5B (Upstate, Charlottesville, VA, USA) or monoclonal antibody 
against Actin (C4) (ICN Biomedicals, Inc., Aurora, Ohio, USA). 
Immunocomplexes were detected using enhanced chemiluminescence (ECL, 
Amersham). Relative protein levels were quantified using the gelscan program 
Diversity One (Pharmacia,Uppsala, Sweden). 
 
Electrophoretic mobility shift assay - AML blasts were cultured for 24 hours in 
RPMI 1640 supplemented with 10% FBS, with or without addition of Ly294002 
(5µM), L-744832 (50µM), PD98059 (10µM), SB203580 (1µM), AG1296 
(20µM), anti-GM-CSF antibody (1µg/ml) (R&D Systems, UK), anti-IL-6 (1:500) 
(gift from Dr. L. Aarden, CLB, Amsterdam), anti-IL-1β ( 0.1μg/ml), anti-TNFα 
(1:100). The diluted polyclonal antisera were maximally effective at the used 
concentrations as studied with in vitro dose-response curves. TF-1 cells were 
cultured overnight in RPMI 1640 supplemented with 1% FBS and subsequently 
stimulated for 15 minutes with conditioned AML medium (prepared by 
incubating AML cells at a density of 3x106 cells/ml for 3 days) or IL-1β (10 
ng/ml). THP-1 cells were cultured overnight in RPMI 1640 supplemented with 
1% FBS and subsequently stimulated with Flt3 ligand (100ng/ml) (a friendly gift 
from Immunex Corporation, Seattle, WA). Nuclear extracts were prepared 
according to the mini-scale procedure described.273 Nuclear extracts were 
divided into small aliquots and stored at -80°C. Cytoplasmic extracts were 
normalized for protein content and analyzed for the amount of phosphorylated 
IκB by western blotting. 
  Double-stranded synthetic oligonucleotide probes containing the NF-κB 
(NF-κB: 5'-AGCTGCGGGGATTTTCCCTG-3') consensus sequence 
(underlined) were used in the gel retardation assay. Fifty ng of HPLC-purified 
single-stranded oligonucleotide were labeled with T4-polynucleotide kinase and 
[α32p]dATP (3000 Ci/mmol, Amersham), separated from non-incorporated 
radiolabel by sephadex G50 chromatography, ethanol precipitated, dried, and 
dissolved in 20 μl of 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 1 
mM EDTA, and 1 mM DTT, containing a four fold excess of the opposite 
strand. Annealing of the two complementary strands was performed by heating 
the mixture for 2 minutes at 90°C and slow cooling to room temperature. Five 
μg of nuclear extract and 0.1 ng double-stranded labeled oligonucleotide were 
incubated in 20 mM HEPES (pH 7.9), 60 mM KCl, 0.06 mM EDTA, 0.6 mM 
DTT, 2 mM spermidine, 10 % glycerol, supplemented with 2 μg poly(dI-dC). 
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The binding reaction was performed at 26°C for 25 minutes. The samples were 
loaded on pre-run (30 min, 100 V) 4% (30:1) polyacrylamide gels and run for 1 
hour at 150 V in 0.5 x TBE at room temperature. Gels were dried and exposed 
to Kodak XAR films at -80°C with an intensifying screen. Quantification of 
protein binding was performed by densitometry using a Phospho Imager 
(Molecular Dynamics, Sunnyvale, CA). Cold competition (cc) experiments were 
performed by adding a 100 fold molar excess of unlabeled self double-stranded 
oligonucleotides. Supershift experiments were performed by incubating the 
nuclear extracts with polyclonal antibodies against p50 and p65 subunits of NF-
κB (Santa Cruz). 
 
Ras binding reaction - AML cells (5x106) and cell lines were incubated in 2 ml 
RPMI 1640 medium supplemented with 0.5% FBS for 24 hours. Subsequently, 
cells were harvested and lysed in 400 µL lysis buffer (10% glycerol, 1% NP-40, 
50mM Tris/HCl pH 7.5, 200mM NaCl, 2mM MgCl2, 2µg/mL aprotinin and 
protease inhibitors) for 10 minutes on ice. Cell lysates were clarified for 10 
minutes at 4°C by centrifugation at 10,000g and incubated for 1 hour with 10 
µg of Raf-GDS glutathione-S-transferase-Ras binding domain (GST-RBD) 
precoupled to glutathione-sepharose beads (Pharmacia). Subsequently, the 
beads were washed once with lysis buffer and 20µL of SDS-sample buffer was 
added to the beads. The bound proteins were resolved on 15% SDS-PAGE gel 
and detected by immunoblotting using N-Ras antibody (Santa Cruz). 
Bacterial expression and purification of the Raf-GDS GST-RBD fusion protein 
(a friendly gift from P. Coffer, Utrecht, The Netherlands) has previously been 
described.274  
 
Mutation analysis of N- and K-Ras - Mutation analysis of N-Ras was performed 
by single-strand conformation polymorphism (SSCP). Genomic DNA was 
extracted from AML cells as previously described.40 PCR analysis was 
performed using primers 1FW 5’-CAGGTTCTTGCTGGTGTG-3’ AND 1BW 5’-
GCTACCACTGGGCCTCAC-3’ for amplification of a 149-bp exon 1 fragment 
containing codons 12 and 13.  
The primers 2FW 5’-CAAGTGGTTATAGATGGTG-3’ and 2BW 5’-
ATAATGACTCCTAGTACCTG-3’ were used to amplify a 181bp exon 2 
fragment containing codon 61. The PCR reaction was performed using 200 ng 
of genomic DNA in a total volume of 25 µl using 0.5U of Taq polymerase 
(Gibco BRL, Grand Island, NY) and 0.1µl label (32Pd-CTP) according to 
manufacturers recommendations. For SSCP analysis 5 µl PCR product was 
denatured for 2 minutes at 96°C with an equal volume stop solution (95% 
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Formamide, 10 mM NaOH, 0.25% Bromophenol Blue, 0.25% Xylene Cyanol) 
and then placed on ice. A volume of 5µl sample was loaded onto a 0.5xMDE 
polyacrylamide gel (FMC Bioproducts) and electrophoresed at room 
temperature for 16 hours at 250V. After electrophoresis a Kodak film was 
exposed to the gel for 16 to 24 hours. Samples that demonstrated shifted 
single stranded DNA fragments were amplified again without radiolabeling, and 
purified using a PCR purification kit (Qiagen Inc, Chatsworth, CA). 
Subsequently, DNA fragments were sequenced in both directions using an ABI 
377 automated sequencer. 
Mutation analysis of the complete coding region of the K-Ras gene was 
performed according to a protocol using denaturing gradient gel 
electrophoresis (DGGE) analysis as described before.275  
 
Immunoprecipitation - 2x107 AML blasts were cultured for 24 hours in RPMI 
1640 medium supplemented with 10% FBS. Cells were harvested, washed with 
ice-cold PBS containing 1 mM sodium orthovanadate and subsequently lysed 
in 500µl lysis buffer (50 mM HEPES, pH 7.4, 10% glycerol, 150 mM NaCl, 1% 
Triton X-100, 1mM EDTA, 1mM EGTA, 25 mM NaF, proteinase inhibitors 
(Complete: Boehringer Mannheim, Germany), 1µM pepstatin, 1mM sodium 
orthovanadate) for 10 min on ice. Cell lysates were clarified at 20 000g for 20 
min and then precleared with 30 µl Protein A Sepharose beads (50% slurry) for 
1 hour at 4°C. After 5 min centrifugation at 380 rpm, the cell lysates were 
incubated with 5 µL Flt3 antibody (C-20: Santa Cruz, CA, USA) rotating 
overnight at 4°C. Protein A sepharose beads (30µl) were added to each 
sample and incubated for another 4 hours at 4°C.  The immune complex was 
washed 3 times with lysis buffer. 1/10th of the precipitate was analyzed for the 
amount of precipitated Flt3 protein and 9/10th of the precipitate was analyzed 
for the degree of tyrosine phosphorylated Flt3. The immune complexes were 
heated in sample buffer, separated by SDS PAGE, immunoblotted on PVDF 
membrane (Millipore, Bedford, MA) and incubated overnight with either anti-
phosphotyrosine (4G10, Upstate Biotechnology, Lake Placid, NY) or anti-Flt3 
antibody. Immunocomplexes were detected using ECL (Amersham, UK). 
 
Analysis of the internal tandem duplication of the Flt3 gene - Genomic DNA 
was extracted from AML cells and Flt3 gene duplications were identified by 
allele specific PCR amplification followed by PAGE analysis.40 Therefore, PCR 
amplification was performed by using the forward primer for exon 11: 5’-
GCAATTTAGGTATGAAAGCCAGC-3’ and the reverse primer for exon 12: 5’-
CTTTCAGCATTTTGACGGCAACC-3’ comprising the complete exon 11-12 
region of the Flt3 gene which contain internal tandem duplications as described 
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by previous studies.40;235;276 The PCR was performed using 200ng of genomic 
DNA in a total volume of 50 µl using 1U of Taq polymerase (Gibco BRL, Grand 
Island, NY) according to manufacturers recommendations. 
The amplified PCR product was run on a 7.5% acryl/bisacrylamide gel 
(29:1) cut out from the gel and dissolved in 40 µl H20 overnight at 4°C. 20µl of 
this dissolved PCR product was used for another PCR reaction under the same 
conditions as described above. The amplified PCR product was purified with a 
PCR purification kit (Qiagen Inc, Chatsworth, CA) and directly sequenced using 
the forward primer for exon 11. 
 
Statistical analysis - The student t-test was used to determine the significance 
of the apoptosis data in conjuction with NF-κB positive and negative samples. 
To determine if levels of phosphorylated PKB after L-744832 and Ly294002 
treatment differed from control cells, densitometric analysis was followed by a 
student t-test. To demonstrate a correlation between the expression patterns of 
different proteins the Spearman’s Rank correlation coefficient was determined. 
  
Table I FAB classifications, percentage of apoptotic cells, phosphorylation and activation 
patterns and Ras and Flt3 gene mutations of patients with AML.  
 
FAB = French-American-British classification, NF-κB = analysis of NF-κB DNA binding activity as 
determined by EMSA, described in material and methods; Ras activity is determined by the Ras 
binding reaction described in material and methods; Ras mut. =  Mutation of Ras as is determined 
by the analysis described in material and methods, (12), (13), (61) = N-Ras mutation in codon 12, 
13 or 61; ERK phos. = analysis of phosphorylated Thr202/Tyr204-ERK; PKB phos. = analysis of 
phosphorylated Ser473-PKB; Flt3 mut. = analysis of internal tandem duplications (ITD) as 
described in material and methods; Flt3 = analysis of Flt3 receptor activation as described in 
material and methods, nd = not done. 
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Constitutive NF-κB DNA binding activity in AML blasts 
Blasts of 22 patients with AML (FAB classifications: M1 (n=5), M2 (n=8), M4 
(n=7), M5 (n=1), M6 (n=1)) and two cell lines (TF-1, THP-1) were studied with 
regard to their constitutive NF-κB DNA binding activity by means of 
electrophoretic mobility shift assays (EMSA). The specificity of the NF-κB DNA 
binding was shown by competition assay by adding a 100 fold molar excess of 
unlabeled oligonucleotide (fig. 1B). In addition no difference was observed for 
NF-κB expression in fresh AML samples versus in cells studied after thawing 
and culturing. In 16 (73%) cases constitutive NF-κB DNA binding activity could 
be demonstrated, while 6 cases showed no or only minor levels of NF-κB DNA 
binding activity (representative data are shown in figure 1A and summarized in 
table I). Supershift experiments performed with 4 different AML cases with 
antibodies specific for the p50 and p65 subunits of the NF-κB family indicated 
that the NF-κB complexes consisted of these subunits (fig. 1B). The 
constitutive NF-κB DNA binding activity could not be correlated with distinct  






















Figure 1 Constitutive NF-κB DNA binding activity in AML blasts.  
(A) AML cells were cultured for 24 hours in RPMI 1640 medium with 10% FBS. Nuclear extracts 
were prepared according to the mini-scale procedure, normalized for protein content and NF-κB 
DNA binding activity was determined by Electrophoresis mobility shift assay (EMSA), using  
double-stranded synthetic oligonucleotide probes containing the NF-κB (NF-κB: 
5'-AGCTGCGGGGATTTTCCCTG-3') consensus sequence (underlined). (Representative data 
from 11 AML cases are shown). (B) Supershift experiments were performed by incubating the 
nuclear extracts with polyclonal antibodies against p50 and p65 subunits of NF-κB. Slower 
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migrating bands are indicative for the presence of that particular subunit in the complex and thus 
demonstrate the composition of the NF-κB complex. The specificity of the NF-κB DNA binding was 
performed with a cold competition assay (cc) as described in materials and methods. (1 
representative case is shown) (C) The NF-κB inhibitor SN-50 specifically inhibits NF-κB DNA 
binding activity. Monocytes were stimulated with PMA after being preincubated with medium or SN-
50. NF-κB activity was studied by EMSA and in order to confirm specificity, total p21 expression 
was analysed by Western blotting. Actin was used as loading control. Densitometric analysis (using 
the gelscan program Quantity One (Bio-Rad, Hercules, CA, USA)) revealed a 3-fold inhibition of 
NF-κB DNA binding activity after SN-50 treatment (Data not shown). 
Low spontaneous apoptosis of AML blasts correlated with constitutive 
NF-κB DNA binding activity 
Since it has been described that NF-κB plays an important role in cell 
survival,189 we examined whether also for AML cells constitutive NF-κB DNA 
binding activity had an effect on the viability of the cells. AML cells were 
cultured for 24 hours in 10% FBS and the percentage of apoptotic cells was 
determined by Annexin V/PI staining. As is shown in table I, AML cases with 
distinct NF-κB activity (n = 16) demonstrated a significant lower percentage of 
apoptotic cells (28 ± 13.9%) versus the 6 cases with no NF-κB activity (54.3 ± 
14.9% p < 0.001). 
 In order to confirm that NF-κB DNA binding effectively protects AML blasts 
against apoptosis, we used a specific NF-κB inhibitor, the SN-50 peptide, that 
protects nuclear import of NF-κB. To this end, AML cells with high constitutive 
NF-κB DNA binding activity were incubated with the SN-50 peptide and the 
percentage of apoptotic cells was determined. Addition of SN-50 (100 μg/ml) 
enhanced the VP-16 (50 µg/ml) induced apoptosis by 13% ± 5% after 24 hours 
of culture in 5 of 7 cases. VP-16 is an etoposide that induces apoptosis due to 
inhibition of  the resealing activity of topoisomerase II.277 The inhibitory effect of 
SN-50 was specific since SN-50 inhibited the PMA induced NF-κB activity 
without an effect on the PMA induced p21 expression (fig. 1C). 
 
Constitutive Ras activity in AML blasts 
In order to elucidate the underlying mechanism responsible for NF-κB 
activation, we examined whether N-Ras might be constitutively activated in the 
AML cases. Constitutive N-Ras activity was examined by using the Ras binding 
domain (RBD) of Raf fused to glutathione S-transferase as an activation 
specific probe. Western blotting using N-Ras antibodies was performed to 
detect the binding of GTP-Ras with GST-RBD. As demonstrated in figure 2 and 
summarized in table I, 15 AML cases demonstrated constitutive N-Ras activity.  
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This constitutive Ras activity  correlated with constitutive NF-κB DNA binding 
activity (p < 0.05). In addition, the expression level of the N-Ras protein was 
studied for the different AML cases, demonstrating that the amount of Ras 
protein varied strongly between the different AML cases. The specificity of the 
Ras pull-down assay was studied by activating AML cells with and without GM-
CSF. Upon stimulation with 15 minutes a strong increase in Ras-GTP was 
shown (fig. 2B). 
                                                                                         Figure 2 Constitutive Ras activity in 
AML blasts.  
(A) AML blasts were cultured for 24 hours 
in RPMI 1640 medium with 0.5% FBS. Cell 
lysates were normalized for protein content 
and subsequently GTP-bound Ras was 
precipitated from equal amounts of cell 
lysates using the Ras binding domain of 
Raf-GDS fused to glutathione S-
transferase as an activation specific probe. 
The bound proteins were analysed by 
SDS-PAGE gel and detected by 
immunoblotting using N-Ras antibody 
(upper lane). As control for an estimate of 
the amount of protein used in the pull-down 
assay, equal amounts of total cell lysates 
before precipitation were western blotted 
and immuno-detection was performed 
using antibodies against N-Ras (Ras input, 
middle lane) and actin (bottom lane). 
(Representative data from 15 cases are 
shown). (B) The specificity of the Ras pull-
down assay was studied by activating AML 
cells with and without GM-CSF  (+ and – 
control respectively) for 15 minutes. Ras-    
GTP activity was determined as described 
 in A. 
 
 The most commonly observed mutations in N-Ras arise at sites critical for 
gene regulation, namely codons 12, 13, and 61.266;267 In order to identify the 
origin of constitutive Ras activity we screened for mutations in codon 12, 13, or 
61 of the N-Ras gene by PCR-SSCP analysis and DGGE analysis to identify 
possible mutations in the K-Ras gene. As shown in table I, only 4 of 22 AML 
cases demonstrated a mutation in the N-Ras gene, including the TF-1 cell line. 
Mutations were identified in codon 12 (n=2), 13 (n=1) and 61 (n=2). 
Furthermore, no mutations were detected in the K-Ras gene.  
 These data demonstrate that constitutive NF-κB DNA binding activity 
coincided with constitutive Ras activity, but did not correlate with activating 
mutations in codon 12, 13, and 61 of the Ras gene. 
 
Ras/PI3-K/PKB-dependent pathway mediates NF-κB DNA-Binding 
  53 
Constitutive ERK phosphorylation 
The classical downstream target of Ras is the Raf/MEK/ERK pathway.268;270 In 
addition, some studies have described that a lower percentage of apoptosis in 
the erytholeukemic TF-1 cell line is associated with higher ERK1/2 activity278 
and the ERK pathway has also been described to be involved in activating NF-
κB DNA binding activity.264;279 Therefore, we investigated whether Ras activity 
coincided with constitutive ERK activity (Western blots not shown). As 
summarized in table I, constitutive ERK activity was observed in 17 of 22 AML 
cases. Although in 12 out of these 17 cases  constitutive ERK activity 
corresponded with constitutive Ras activity, this correlation was demonstrated 
not be significant. 
 
Figure 3 L-744832 and Ly294002 inhibit NF-κB 
DNA binding activity.  
AML cells were cultured for 24 hours in RPMI 
1640 medium with 10% FBS supplemented with or 
without L-744832 (50µM, Ras inhibitor), Ly294002 
(5µM, PI3-K inhibitor), AG1296 (20μM, Tyrosine 
kinase inhibitor) or PD98059 (10µM, MEK1/2 
inhibitor). Nuclear extracts were prepared, 
normalized for protein content and NF-κB DNA 
binding activity was determined by EMSA. Four 
representative cases are shown. 
 
 
L-744832 and Ly294002 inhibit NF-κB DNA binding 
In order to investigate the link between Ras and NF-κB in more detail and to 
elucidate the downstream effectors of Ras facilitating NF-κB activity, we 
examined the effect of chemical inhibitors, specific for different downstream 
targets of the Ras pathway, on constitutive NF-κB DNA binding activity. AML 
blasts were cultured with or without addition of L-744832 (a farnesyl-
transferase inhibitor, which blocks Ras activation), PD98059 (MEK1/2 
inhibitor), Ly294002 (PI3-K inhibitor), and AG1296 (tyrosine kinase inhibitor). 
The concentrations used were able to block the respective kinases. In 5 of 7 
cases tested the Ras inhibitor L-744832 and the PI3-K inhibitor Ly294002 were 
able to inhibit constitutive NF-κB DNA binding activity, while AG1296 and 
PD98059 had no or limited effect. The results of 4 different cases are depicted 
in figure 3.  
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These data demonstrate that the ERK kinase, the classical downstream 
effector of Ras, is not involved in the constitutive NF-κB DNA binding activity. 
In contrast, both L-744832 and Ly294002 inhibited constitutive NF-κB DNA 
binding activity, suggesting that Ras might mediate NF-κB DNA binding activity 
by a PI3-K mediated pathway.  
 
Figure 4  Constitutive PKB  
phosphorylation in AML.  
(A) AML cells were cultured for 
24 hours in RPMI 1640 medium 
with 10% FBS. Total cell 
extracts were prepared and 
equal amounts of cell lysates 
were subjected to SDS-PAGE. 
Western blot analysis was 
performed using an antibody 
against phospho-PKB (Ser473). 
As a control, equal amounts of 
total cell lysates were western 
blotted and immuno-detection 
was performed using antibodies 
against total ERK1/2. 
(Representative data from 15 
cases are shown). (B) Cell 
lysates of AML cases with and 
without PKB Ser473 
phosphorylation were western 
blotted and subjected to immuno-detection using antibodies against phospho-PKB (Thr308). Total 
PKB (PKB tot) and actin immuno-detection were performed for loading control. 9 representative 
cases are shown. 
 
Constitutive PKB phosphorylation in AML 
The classical downstream target of PI3-K is PKB/Akt, a protein which is known 
to prevent apoptosis.280 Recently, several studies described the involvement of 
PKB in activation of IKK, the upstream IκB kinase.281,282 Therefore, we 
examined whether PKB is constitutively activated in those AML cases that 
demonstrate constitutive NF-κB  activity. In 14 of 22 investigated AML cases, 
constitutive PKB serine 473 phosphorylation correlated with constitutive NF-κB 
DNA binding activity (p < 0.05, fig. 4A, table I). Since activation of PKB not only 
involves phosphorylation at the serine 473 residue, but also phosphorylation at 
the threonine 308 residue,283 9 AML samples with and without serine 473 
phosphorylation were also investigated for threonine 308 phosphorylation. As is 
shown in figure 4B, almost all AML samples exhibited threonine 308 
phosphorylation, thus leaving phosphorylation of serine 473 a good indicator of 
activated PKB. Although in 11 cases constitutive PKB activity coincided with 
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both constitutive Ras activity and NF-κB DNA binding, no significant correlation 
could be found between Ras and PKB activity. 
 
 
Figure 5 L-744832 and Ly294002 inhibit 
constitutive PKB phosphorylation in AML.  
(A) AML cells were cultured for 24 hours in RPMI 
1640 medium with 10% FBS supplemented with or 
without L-744832 (50µM, Ras inhibitor) or Ly294002 
(5µM, PI3-K inhibitor). Total cell extracts were 
prepared and equal amounts of cell lysates were 
subjected to SDS-PAGE. Western blot analysis was 
performed using an antibody against phospho-PKB 
(Ser473), phospho-PKB (Thr308) and total PKB 
(PKB tot). In order to show that the L-744832 
compound is an effective Ras inhibitor, immuno-
detection was performed against on of the 
downstream effectors of Ras,Phospho Erk1/2 
(Thr202/Tyr204).  As a control, equal amounts of 
total cell lysates were subjected to immuno-detection 
using antibodies against ERK1/2 and actin. The data 
presented is representative for 4 individual cases.  
(B) Densitometric analysis was performed  on the 
western blots of P-Ser473 PKB and P-Thr308 PKB 
using the gelscan program Quantity  One (Bio-Rad, 
Hercules, CA, USA) and normalized against total 
PKB. Untreated samples were set to 100%. A 
significant reduction of phosphorylated Ser473 PKB and phosphorylated Thr308 PKB were 
observed after treatment with  the L-744832 and Ly294002 compounds(*, **, *** and **** = p < 
0.0001). The data presented is averaged from three independent experiments, with error bars 
denoting standard deviations. 
L-744832 and Ly294002 inhibit PKB phosphorylation in AML 
In order to elucidate whether the constitutive activation of the PI3-K/PKB 
pathway in AML is due to constitutive Ras activation, we examined the effect of 
the Ras inhibitor L-744832 on spontaneous PKB phosphorylation of 4 AML 
cases with high constitutive Ras, PKB and NF-κB activity. As demonstrated in 
figure 5A, addition of L-744832 strongly inhibited the spontaneous PKB 
phosphorylation, both on the serine 473 and the threonine 308 residue. 
Similarly, addition of Ly294002 strongly reduced PKB phosphorylation on both 
residues. Western blots for total and phospho-Thr202/Tyr204 ERK1/2 are 
shown as evidence that the L-744832 compound is effective in inhibiting Ras.  
Densitometric analysis showed that this treatment with L-744832 and 
Ly294002 significantly reduced the levels of serine and threonine 
phosphorylated PKB (*, **, *** and **** p < 0.0001, fig. 5B). The inhibition of 
Ras and PKB was also reflected  at the level of NF-κB DNA binding (fig. 3). 
Both inhibition of Ras by L-744832 or PKB by Ly294002 resulted in a strong 
reduction of NF-κB DNA binding activity.  
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Constitutive NF-κB activity is not caused by autocrine growth factor 
production 
To study whether autocrine growth factor production by AML blasts was 
responsible for NF-κB activation, a subset of AML blasts with high constitutive 
NF-κB and Ras activity (no. 2, 6, 10, 5) were cultured for 24 hours in 10% FBS 
and cell-free supernatant was collected. Subsequently, TF-1 cells, which are 
highly responsive for IL-1, IL-6, TNFα and GM-CSF, were stimulated for 10 
minutes with conditioned AML medium (66%) and the effect on IκB 
phosphorylation and NF-κB DNA binding activity was examined. As a positive 
control (to show that IL-1 can actually activate NF-κB in these cells) TF-1 cells 
were stimulated for 10 minutes with 10 ng/ml IL-1ß. In addition, TNFα also 
strongly induced NF-κB DNA binding activity in TF-1 cells (data not shown). As 
shown in figure 6A, none of the AML supernatants induced IκB phosphorylation 
or distinct NF-κB DNA binding activity, while incubation with IL-1 strongly 
induced both.  
 To exclude the possibility that the assay was not sensitive enough, the 
effect of neutralizing antibodies against IL-1, IL-6, GM-CSF and TNFα on the 
constitutive NF-κB DNA binding activity of 4 different AML cases was 
examined. Although the antibodies were capable of inhibiting the cytokine 
induced Erk phosphorylation (data not shown), after 24 hours of cell culture no 
significant effect was observed on NF-κB DNA binding activity by any of these 
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Figure 6 Constitutive NF-κB DNA binding activity is not due to autocrine growth factor 
production.  
(A) In order to investigate whether an autocrine produced growth factor is responsible for NF-κB 
DNA binding activity, TF-1 cells were cultured in 1% FBS overnight and subsequently stimulated 
for 10 minutes with the conditioned medium of the indicated AML cases or IL-1β (10 ng/ml), as 
described in the results. Nuclear extracts were prepared, normalized for the amount of protein and 
NF-κB DNA binding activity was determined by EMSA (upper panel). Total cell extracts were 
prepared and equal amounts of cell lysates were subjected to SDS-PAGE. Western blot analysis 
was performed using an antibody against phospho Ser32-IκB-α and total IκB-α (middle and lower 
panel). (B) AML blasts were cultured for 24 hours in RPMI 1640 medium with 10% FBS 
supplemented with or without neutralizing antibodies against IL-1β, IL-6, GM-CSF or TNFα to 
exclude the possibility that the assay was not sensitive enough. Nuclear extracts were prepared, 
normalized for protein content and NF-κB binding activity was determined by EMSA (two 
representative examples are shown). 
 
Constitutive NF-κB DNA binding activity is not due to Flt3 activity 
Recently, several reports demonstrated a significant role for the Flt3 tyrosine 
kinase receptor in the resistance of AML blasts against apoptosis.40;276 In 
addition, internal tandem duplication (ITD) mutations in this receptor result in 
constitutive activation of the receptor and the subsequent activation of several 
downstream signal transduction cascades, e.g. STAT5 and ERK pathway.235 
Therefore, we investigated whether constitutive NF-κB activity might be due to 
activation of the Flt3 receptor. First, we examined whether activation of the Flt3 
receptor by its ligand could activate NF-κB DNA binding activity. Stimulation of 
THP-1 cells with Flt3 ligand induced a distinct increase in NF-κB DNA binding 
activity (fig.7A). In our subset of AML cases, 10 of 22 investigated AML cases 
demonstrated an internal tandem duplication in the Flt3 gene (see table I). 8 of 
the 10 cases with an ITD demonstrated constitutive activation of the receptor, 
while 4 cases demonstrated constitutive Flt3 activation without a mutation 
(table I). It appeared that in 9 of 12 cases constitutive Flt3 phosphorylation 
coincided with constitutive NF-κB DNA binding activity. However, addition of 
the Flt3 inhibitor AG1296 had no effect on the constitutive NF-κB DNA binding 
activity of the investigated AML blasts (two representative samples are shown 
in fig.7B), but inhibited significantly the Flt3 mediated STAT5 A/B tyrosine 
694/699 phosphorylation as depicted in figure 7B.  









            Chapter 2 
58 
Figure 7 Constitutive NF-κB DNA 
binding activity is not due to Flt3 
activity.  
(A) THP-1 cells were cultured overnight in 
1% FBS and subsequently stimulated with 
Flt3 ligand for the indicated periods of time 
in order to test whether activation of the Flt3 
receptor by its ligand could induce NF-κB 
DNA binding activity. Nuclear extracts were 
prepared, normalized for protein content 
and NF-κB binding activity was determined 
by EMSA. (B) AML blasts were cultured for 
24 hours in RPMI 1640 medium with 10% 
FBS supplemented with or without AG1296 
(20µM, Flt3 inhibitor). Nuclear extracts were 
prepared, normalized for protein content 
and NF-κB binding activity was determined by EMSA. Although the used concentration of AG1296 
(20μM) did not inhibit NF-κB DNA binding activity, it was effective since it inhibited the Flt3 (FL) 




Several lines of evidence suggest that NF-κB family members are involved in 
tumor growth.189 Hodgkin’s lymphoma cell lines contain constitutively active 
NF-κB and inhibition of NF-κB by overexpression of a non-degradable IκBα 
molecule inhibits proliferation and tumorigenesis of these cells.284 In addition, 
activation of NF-κB by tumor necrosis factor, ionizing radiation and 
chemotherapeutic agents was found to protect tumor cells from cell killing.285;286 
Conversely, inhibition of this transcription factor enhanced apoptotic killing by 
these reagents, demonstrating that persistent activation of NF-κB represents a 
unique mechanism by which cells express genes that can protect against 
apoptotic stimuli.  
 In the present study we demonstrate that of the investigated AML cases 
NF-κB was frequently constitutively activated. This constitutive NF-κB activity 
was associated with a lower percentage of spontaneous apoptosis, compared 
to AML cases that had no or low nuclear NF-κB expression. In addition, the 
expression is in general associated with a reduced sensitivity for chemotherapy 
induced apoptosis. 
 Selective targeting of leukemic cells through inhibition of NF-κB might be 
an effective way to enhance the therapeutic effect of existing AML treatment 
modalities. However, the most rational approach to inhibit NF-κB activity may 
require the identification of upstream activators. The Ras protein has been 
shown to be frequently mutated in AML, resulting in the constitutive activity of 
this GTP-ase,266;267 and is linked with cellular transformation. Here, we 
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demonstrate that Ras activation was significant correlated with the NF-κB DNA 
binding activity in AML blasts. In 68% of the investigated AML cases 
constitutive N-Ras activity was observed, which was in 27% of the cases 
associated with mutations in the N-Ras gene. The difference in Ras-GTP 
activity and the frequency of Ras mutations indicate that alternative causes are 
also of relevance. Recently a mutation was identified in a Ras-guanine 
exchange factor in an AML case.287 Whether these mutations or unidentified 
growth factors are responsible for the Ras activity will require further studies.  
The finding that Ras activation is much more frequent than Ras-mutation is of 
interest and suggests that the in-vivo application of Ras inhibitors should not be 
restricted to patients with a mutated Ras gene but that an effect can also be 
expected in a much larger group of patients. 
 The classical downstream target of Ras is the Raf/MEK/ERK 
pathway.268;270 Several studies described involvement of the ERK pathway in 
activating NF-κB DNA binding and transactivation.264;279 In addition, inhibition of 
the MAPK pathway by several MEK inhibitors resulted in impaired cell growth 
and survival of acute myeloid leukemia cell lines and primary AML samples 
with constitutive MAPK activation.288 However, although ERK was frequently 
constitutively activated in the AML cases, we did not find any effect of the MEK 
inhibitor PD98059 on NF-κB DNA binding activity which doesn’t exclude the 
possibility that Erk might effect the NF-κB transactivation potential.264 In 
contrast, we demonstrate that Ras mostly mediates NF-κB activation by a PI3-
K/PKB dependent pathway. In a number of the cases with constitutive NF-κB 
DNA binding activity both Ras and PKB were constitutively activated. The link 
between Ras and the PI3-K/PKB pathway was further confirmed by the fact 
that the farnesyl-transferase inhibitor L-744832 strongly inhibited PKB 
phosphorylation. In addition, L-744832 and Ly294002 both strongly inhibited 
NF-κB DNA binding activity. These data implicate that a Ras/PI3-K/PKB-
mediated pathway can mediate constitutive NF-κB DNA binding activity. In 
addition, it appeared that the constitutive NF-κB DNA binding activity was 
unlikely caused by production of autocrine growth factors.289 Furthermore, 
although aberrant IKK signaling in AML has been described to lead to 
increased NF-kappaB activity,215 this could not be detected in the present 
study, since AML supernatants did not induce IκB phosphorylation. Also the 
frequently mutated and constitutively activated Flt3 receptor tyrosine kinase 
was not responsible for NF-κB activation. Therefore, an alternative mechanism, 
upstream of Ras, is responsible for the constitutive NF-κB activity. We 
speculate that a yet unknown GTP exchange factor, upstream kinase, or 
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receptor is mutated resulting in constitutive activation of this signal transduction 
pathway.   
 Our  results and other findings indicate that a number of different signaling 
routes are triggered in AML cells with distinct and overlapping activities, 
including the STAT3 and STAT5 pathways,40;47 p21 expression in monocytic 
blasts182-184;290 and the RAS/PI3-K/NF-κB pathway in these experiments as well 
as by other investigations.64;276;284;291 In some cases, activation of these 
pathways might be triggered by the autocrine production of growth factors and 
hence lead to enhanced survival and proliferation of the AML blast.40;47;290;292;293 
These findings are in line with the ‘two-hit’ model whereby two or more triggers 
are required for cellular transformation. The data also implicate that only a 
limited success will be obtained if a single inhibitor is used that targets only a 
small selection of genes.  
 In summary, our study demonstrates that two crucial anti-apoptotic 
signaling molecules, Ras and PKB, interfere with the NF-κB pathway and  
result in constitutive activation of this transcription factor which confers 
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Since NF-κB is frequently activated in AML, we questioned whether active NF-
κB affected the cellular properties of cord blood (CB) CD34+ cells. The results 
demonstrated that NF-κB activation did not influence growth or differentiation 
properties. Furthermore, NF-κB activation was not sufficient to induce changes 
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Constitutive activation of Nuclear Factor-κ B (NF-κB) has been observed in a 
number of patients with Acute Myeloid Leukemia (AML).294 Predominantly in 
the myelomonocytic and monocytic subtypes,215 in contrast to normal CD34+ 
cells.64 With a multiplicity of signal transduction pathways converging on NF-
κB, this protein is therefore suggested to play a relevant role in disturbed 
hematopoiesis in AML. Various reports have indicated that constitutive 
activation of NF-κB is sufficient to induce cellular transformation,295;296 however, 
limited information is available on the role of NF-κB in regulating normal 
hematopoiesis.297;298 Its role in primary hematopoietic cells is based mainly on 
inactivation studies using chemical inhibitors, gene knock-outs or 
overexpression of dominant negative constructs.297;298 Furthermore, these 
studies largely focused on the anti-apoptotic properties of NF-κB, where effects 
on other important cell-biological characteristics such as proliferation, 
differentiation and self-renewal were underexposed. Therefore, we established 
a model in which influences were studied of constitutive NF-κB activation on 
hematopoiesis of primary human CD34+ cells. 
 Transfection experiments in 293T HEK cells demonstrated that 
overexpression of wt p65 or a constitutive active IKK-2 (IKK2SE), a kinase 
upstream of NF-κB,200 is sufficient to activate an NF-κB responsive luciferase 
reporter construct (fig. 1A) as compared to control-transfected cells (MIGR1). A 
TF-1 cell-line, stably transfected with p65, demonstrated enhanced DNA-
binding of p65 in EMSAs as well as enhanced NF-κB luciferase reporter activity 
(2.6-fold for p65 compared to mock transfected cells, data not shown). In 
addition, Q-PCR for the NF-κB target gene IL-8 demonstrated a 12-fold 
increase in IL-8 mRNA expression in p65-expressing TF-1 cells (data not 
shown). Together these data demonstrated that overexpression of either p65 or 
IKK2SE resulted in an activated NF-κB signal transduction pathway. 
 Long term co-cultures of transduced cord blood (CB)-derived CD34+ stem- 
and progenitor cells on MS-5 stromal cell layers indicated no proliferative 
advantage for p65 or IKK2SE-transduced cells as demonstrated by stable GFP 
percentages (fig. 1B, dotted lines) compared to MIGR1 transfected cells. 
Cumulative cell counts from these cultures gave comparable results (fig. 1B, 
solid lines). Parallel flow-cytometric analysis demonstrated no significant 
changes in the percentage of GFP+ cells positive for the myeloid differentiation 
markers CD11b, CD14, CD15 and CD36, when compared to either GFP- cells 
within the same culture or to MIGR1 transfected cells (N=3, a representative 
example is shown in fig. 1C).  
 In addition, progenitors were enumerated in CFC assays in limiting dilution. 





MIGR transduction in progenitor frequencies (14.5% vs. 13.7% respectively, 
data not shown). In separate CFU-GM and BFU-E assays also no differences 
were observed (data not shown).  
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Figure 1 NF-κB activation does not alter growth, differentiation or self-renewal capacity of 
cord blood (CB) CD34+ cells on MS-5 long-term co-cultures. 
(A) 293T HEK cells were co-transfected with MIGR1, p65 or IKK2SE mutant constructs together 
with a luciferase vector containing 3 NF-κB responsive elements (NREs). PMA-stimulated (50 nM, 
16 hrs) cells were used as positive control and Mut NRE (in which the 3 NREs are mutated)-
luciferase vector transfected cells as negative control. Experiments were performed in triplicate 
(N=3). A representative example is shown. Data is presented as average with standard error of the 
mean (SEM) and a student’s T-test was performed to calculate significance levels. (B) MS5 co-
culture experiment with MIGR1, p65 and IKK2SE transduced CB CD34+ cells. Dotted lines indicate 
GFP percentages, with errors bars representing SEM, (N = 3). Solid lines indicate cumulative cell 
counts. An average of 3 independent experiments is shown. Error bars represent SEM. (C) FACS 
analysis of a representative week 3 MS5 co-culture experiment with MIGR1, p65 or IKK2SE 
transduced CB CD34+ cells. Shown are percentages of CD15, CD14, CD11b and CD36 positive 
cells in either untransduced cells or in transduced GFP+ cells, (N = 3). (D) LTC-IC assay with 
MIGR1, p65 or IKK2SE transduced CB CD34+ cells. After 5 weeks on MS5 co-culture, medium was 
changed to methylcellulose for another two weeks. At week 7 colonies were scored. An average of 
3 independent experiments is shown. Error bars denote SEM. 
 
In order to investigate whether active NF-κB affected the self-renewal 
capacity of hematopoietic stem cells, LTC-IC assays were performed with 
MIGR1-, p65- and IKK2SE-transduced CB CD34+ cells, by adding methyl-
cellulose to a week 5 MS-5 co-culture (as described previously)244 and 
determining the number of colonies at week 7. No significant difference in 
colony formation between p65-, IKK2SE- or MIGR1-transduced cells was 
detected (fig. 1D). Together these findings indicate that in human CD34+ cells, 
constitutively activation of NF-κB is not sufficient to change their differentiation 
potential. Others have shown that a reduction of NF-κB activity in murine fetal 
liver cells or ES-derived hematopoietic progenitors results in severely disturbed 
myeloid differentiation.297;298 Apparently NF-κB activation is required for normal 
myelopoiesis, but its increased activity is not sufficient to impair differentiation. 
 In normal and leukemic stem and progenitor cells it has been demonstrated 
that NF-κB antagonizes (ROS-mediated) apoptosis.64;298 In contrast, we did not 
detect a reduced level of apoptosis (by Annexin V staining, data not shown) in 
p65 or IKK2SE transfected CB CD34+ cells compared to control cultures. 
Additionally, IL-3 deprivation of p65 expressing stable TF-1 cell lines did not 
show reduced apoptosis (data not shown). This is in line with data from 
Romano et al,299 demonstrating that constitutive NF-κB activity is not relevant 
for sustained basal cell survival of CB CD34+ and AML cells, but only when the 
cells are triggered with a stress response, e.g. exposure to chemotherapy.  
 Together these data demonstrate that constitutive activation of NF-κB as a 
single “hit” is not sufficient to induce changes in steady-state hematopoiesis 
with regard to proliferation, differentiation, self renewal and apoptosis, which 
could potentially bias cells towards a more leukemogenic phenotype. Whether 





functions on hematopoiesis needs to be further defined, in order to gain insight 
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In the present study, we analysed the expression and localization of p21Waf1/Cip1 
in normal and malignant hematopoietic cells. We demonstrate that in normal 
monocytic cells, protein kinase C (PKC)-induced p21 gene activation, which is 
Nuclear Factor-κB (NF-κB) independent, results in predominantly cytoplasmic 
localized p21 protein. In acute monocytic leukemia (M4, M5), monocytic blasts 
(N=12) show constitutive cytoplasmic p21 expression in 75% of the cases, 
while in myeloid leukemic blasts (N=10) low nuclear and cytoplasmic 
localization of p21 could be detected, which is also PKC dependent. 
Constitutive p21 expression  in monocytic leukemia might have important anti-
apoptotic functions. This is supported by the finding that in U937 cells 
overexpressing p21, VP16-induced apoptosis is significantly reduced (20.0% ± 
0.9 vs. 55.8% ± 3.8, p<0.01, N=5), reflected by a reduced phosphorylation of 
p38 and JNK. Similar, AML blasts with high cytoplasmic p21 were less 
sensitive to VP16-induced apoptosis as compared to AML cases with low or 
undetectable p21 expression (42.25% vs. 12.3%, p<0.01). Moreover, complex 
formation between p21 and ASK1 could be demonstrated in AML cells by 
means of co-immunoprecipitation. In summary, these results indicate that p21 
has an anti-apoptotic role in monocytic leukemia and p21 expression is 
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Introduction 
 
Acute myeloid leukemia (AML) is characterized by an accumulation of 
immature cells in the bone marrow resulting in the disruption of normal 
hematopoiesis.16;17;300 The growth advantage of the leukemic population is in 
part linked to the constitutive activation of intracellular proteins that trigger the 
function of anti-apoptotic proteins.40;64 Recent studies have indicated that 
Nuclear Factor-κB (NF-κB) is constitutively expressed in AML cells which is 
due to the activation of the Ras/PI3 kinase pathway.64;276;284;291 A recent study 
in normal monocytes has suggested that the anti-apoptotic function of NF-κB is 
in part mediated by cytoplasmic p21Waf1/Cip1 (p21) protein.182;183 So far p21, a 
member of the family of cyclin-dependent kinase (CDK) inhibitors, was defined 
as a nuclear protein. These proteins function by inhibiting CDK1, -2, -4 and -6 
and induce cell cycle arrest at the G1/S boundary. This process allows the cells 
to exit the cell cycle and differentiate.301-306 Localization of p21 in the cytoplasm 
has been connected to monocytic differentiation and is implicated in anti-
apoptotic functions.182-184 Cytoplasmic p21 can form a complex with apoptosis 
signal regulating kinase 1 (ASK1), preventing the activation of the mitogen 
activated protein (MAP) kinase cascade.182 In addition p21 can bind to pro-
caspase 3, preventing the induction of apoptosis in HepG2 cells.307;308 Finally, 
p21 has been shown to be a downstream target of protein kinase B (PKB 
(AKT)). Two sites in the carboxyl terminus of p21 are phosphorylated by PKB 
which enhance the stability of the p21 protein and modulate binding of p21 to 
target proteins.309;310  
 In view of the link between p21 and apoptosis we questioned whether p21 
expression and localization is perturbed in malignant hematopoietic cells and 
whether cytoplasmic localization of p21 protects against the cytotoxic effects of 
chemotherapy. The results demonstrate that p21 is not expressed in 
unstimulated hematopoietic cells of monocytic and myeloid origin. In addition it 
is demonstrated that PMA is capable of inducing p21 expression in a protein 
kinase C (PKC) dependent manner. In monocytic leukemia, p21 is 
constitutively expressed and cytoplasmic localized, in contrast to myeloid 
leukemia where no cytoplasmic p21 was detected. We postulate that 
cytoplasmic p21 protects these cells against the effects of cytotoxic agents, as 
is reflected by a decrease in VP16-induced apoptosis in p21 overexpressing 








Materials and methods 
 
Patient population and isolation of AML cells - Peripheral blood cells or bone 
marrow cells from 22 adult untreated patients with AML were studied after 
informed consent. The AML cases were defined according to the classification 
of the French-American-British (FAB) committee as M0-M6.18 AML blasts were 
isolated by density-gradient centrifugation. The cells were cryopreserved in 
aliquots of 20-30 x 106 cells in RPMI 1640 (Biowhittaker, Verviers, Belgium) 
supplemented with 10% dimethylsulfoxide (DMSO; Sigma, St. Louis, MO) and 
10% fetal bovine serum (FBS; Bodinco, Alkmaar, the Netherlands), employing 
a method of controlled freezing and storage in liquid nitrogen. After thawing, T-
lymphocytes were depleted by 2-aminoethylisothioronium bromide (AET)-
treated sheep red blood cell (SRBC) rosetting. The cell population consisted of 
more than 98% AML blasts as determined by May-Grünwald-Giemsa staining. 
Fluorescence-activated cell sorting (FACS) analysis demonstrated <1% CD3 
(Becton Dickinson, Sunnyvale, California, USA) positive cells.  
 
Preparation of monocytes and granulocytes - Peripheral blood cells were 
obtained from healthy volunteer blood donors, and mononuclear cell 
suspensions were prepared by Ficoll-Hypaque density-gradient centrifugation. 
T- lymphocytes were depleted by AET-treated SRBC rosetting. Monocytes 
were further enriched by plastic adherence (1h, 37°C, 5% CO2) and 
demonstrated a purity >95% detected by FACS analysis with anti-CD14 
antibody (Becton Dickinson, Sunnyvale, CA).  
 Peripheral blood from healthy volunteers, anti-coagulated with 0.32% 
sodium citrate, was used to isolate granulocytes as described by Koenderman 
et al.311 In short, mononuclear cells were removed by centrifugation over 
Fycoll-Paque (Amersham, Upsala, Sweden) and erythrocytes were lysed with 
ice-cold NH4Cl solution. Granulocytes were allowed to recover for 30 min at 
37°C in RPMI 1640 (Bio Whittaker, Verviers, Belgium) supplemented with 0.5 
% human serum albumin (HSA; CLB, Amsterdam, The Netherlands). Before 
stimulation, cells were resuspended in incubation buffer (20 mM HEPES, 132 
mM NaCl, 6 mM KCl, 1 mM MgSO4, 1.2 mM KH2PO4, 5 mM glucose, 1 mM 
CaCl2, 0.5% HSA). In all cases, the cell population isolated consisted of >95% 
granulocytes as determined by May-Grünwald Giemsa staining. 
 
Cell culture - AML blasts were cultured at 37°C, 5% CO2 at a density of 
1x106/ml in RPMI 1640 media supplemented with 100 U/ml penicillin, 100 
µg/ml streptomycin (ICN, Costa Mesa, CA, USA) and 10% FBS. Monocytes 
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were cultured at 37°C, 5% CO2 at density of 1 x 106 /ml in RPMI 1640 and 10% 
FBS. The human growth factor dependent cell lines AS-E2 312 and GF-D8 
313were cultured in RPMI 1640 supplemented with 5% FBS and 10 ng/ml IL-3 
(Genetics Institute Cambridge, MA). The human cell lines U937 (ATCC, 
Product No. CRL-1593.2), THP-1 (ATCC, Product No. TIB-202) and HL-60 
(ATCC, Product No. CCL-240) were cultured in RPMI 1640 supplemented with 
10% FBS. The primitive human cell line KG1a (ATCC, Product No. CCL-2461) 
was cultured in IMDM (ICN) with 20% FBS. In addition U937 cells stable 
transfected with a ZnCl2 (180 μM, 3 days) inducible p21 construct were used in 
conjunction with a mock transfected cell line for studying the cellular function of 
p21.182;184 
 
Reagents and antibodies - Antibodies against phosphorylated Extra-cellular-
signal Regulated Kinase (ERK), Protein Kinase B (PKB), p38 and c-jun N-
terminal kinase (JNK) were obtained from New England Biolabs (Beverly, MA, 
USA). Antibodies against p38, JNK, ASK1 and an antibody-agarose conjugate 
for immunoprecipitation of p21 (C-19) were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). p21 antibody was purchased from 
Transduction Laboratories  (Lexington, KY, USA), and an antibody against 
actin was obtained from Boehringer Mannheim (Mannheim, Germany). 
Supershift antibodies for p50 and p65 were purchased from Santa Cruz 
Biotechnology, as well as the Rb antibody. Horse radish peroxidase (HRP)-
labeled secondary antibodies were obtained from DAKO (Glostrup, Denmark). 
Recombinant human (Rh) interleukin (IL)-1ß was obtained from Mekesson 
HBOC Bioservices (Rockville, MD, USA). Rh IL-3 and Granulocyte Monocyte-
Colony Stimulating Factor (GM-CSF) were purchased from Genetics Institute 
(Cambridge, MA, USA) and phorbol 12-myristate 13-acetate (PMA) was 
obtained from Sigma (St. Louis, MO, USA) as well as Actinomycin D. The p38 
MAPK inhibitor SB203580 and the NF-κB inhibitor SN-50 were obtained from 
Biomol (Plymouth Meeting, PA, USA). The PI3K inhibitor Ly294002 was 
obtained from Alexis (San Diego, CA, USA). MAP kinase/ERK kinase (MEK) 1 
inhibitor U0126 was obtained from Promega Corp. (Leiden, the Netherlands). 
The PKC inhibitors Bisindolylmaleimide I (BIM or GF 109203X), Chelerythrin 
and Calphostin-C were obtained from Calbiochem (Darmstadt, Germany). 
VP16 was purchased from TEVA Pharming (Mijdrecht, The Netherlands). 
Radio-nucleotides and the random hexamer primers p(CNA)6 were obtained 
from Amersham (Buckinghamshire, UK). H2O2 was obtained from Merck ( 
Darmstadt, Germany). M-MLV-RT polymerase and RNAse inhibitor were 
obtained from MBI Fermentas (St.Leon-Rot, Germany). Tri Reagent was 





The Quantitect SYBR Green PCR Kit was obtained from Qiagen GmbH 
(Hilden, Germany). The dNTP’s were purchased from Invitrogen BV (Breda, 
The Netherlands). 
 
Combined annexin V/PI staining procedure - Viability was assessed using an 
annexin V staining kit (IQ Products, Groningen, The Netherlands) according to 
the manufacturer’s recommendations. Briefly, after 24 hrs of culture in RPMI 
1640 medium supplemented with 10% FBS with or without addition of VP16 
(20 µg/ml), cells were harvested, resuspended in 100 µl calciumbuffer 
containing 5 µl of annexin V and incubated for 20 min at 4°C in the dark. Cells 
were washed with 5 ml calciumbuffer and subsequently incubated in 300 µl 
calciumbuffer containing 2.5 µl of propidium iodide (PI) for 10 min in the dark. 
Finally, binding of fluorescein-conjugated annexin V and PI was measured by 
fluorescence-activated cell sorting (Becton Dickinson, Sunnyvale, CA). 
Apoptosis was also analysed by measuring active caspase 3 levels by flow 
cytometry using a FITC-labeled antibody (BD Biosciences, Alphen aan den 
Rijn, The Netherlands) against the active form of caspase 3. The cells were 
fixed and permeabilized with fix and perm obtained from BD Biosciences.  
 
Preparation of protein extracts and Western blotting - The amount of p21, 
ASK1, p38, JNK, and actin and the degree of phosphorylated p38 and JNK 
were determined by western blotting on whole cell extracts, cytoplasmic or 
nuclear extracts.  U937 cell-lines were cultured for 3 days in RPMI 1640 
supplemented with 10% FBS, with or without ZnCl2 (180 µM) and overnight 
with VP16 (20 µg/ml) or H2O2 (300 μM). Cells were harvested and total cell 
extracts were prepared by resuspending the cells in sample buffer (2% SDS, 
10% glycerol, 2% ß-mercapthoethanol, 60 mM Tris-HCl pH 6.8 and 
bromophenol blue). Cell extracts were directly boiled for 5 minutes and proteins 
were fractionated by running on SDS-PAGE gel. The proteins were 
electrophoretically transferred to PVDF membrane (Millipore, Bedford, MA, 
USA) blocked with TBS buffer containing 0.1% Tween-20 and 5% non-fat milk 
prior to incubation with antibodies, diluted in 5% bovine serum albumin. Binding 
of each antibody was detected by HRP labeled secondary antibodies using 
enhanced chemiluminesence (ECL) according to the manufacturers 
recommendations (Amersham Life Sciences, Buckinghamshire, UK). 
 Monocytes and AML blasts were cultured for 24 hrs in RPMI 1640 
supplemented with 10% FBS with or without PMA (50 nM), IL-1ß (10 ng/ml), IL-
3 (10 ng/ml), GM-CSF (10 ng/ml), Ly294002 (5 µM), SB203580 (1 µM), U0126 
(5 µM), BIM (1 µM), Chelerythrin (6 µM) or Calphostin-C (100 nM) at a density 
of 1x106 cells/ml. Cells were harvested and cytoplasmic and nuclear extracts 
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were prepared according to the “mini extracts” method.273 The extracts were 
normalized for protein content prior to SDS-PAGE. Proper fractionation and 
lack of leakage of nuclear proteins to the cytosol was determined with western 
blotting against the nuclear protein Retinoblastoma (Rb).  
 To investigate the role of an autocrine growth factor, AML blast were 
cultured for 24 hrs in RPMI 1640 supplemented with 10% FBS and 
subsequently stimulated for 6 hrs with conditioned AML medium (prepared by 
incubating AML cells at a density of 3.106 cells/ml for 3 days) or 50 nM PMA as 
a control. 
 
RNA extraction, preparation of cDNA and Real-Time PCR - 5 x 106 monocytes 
were cultured for 24 hrs in RPMI 1640 supplemented with 10% FCS and 
subsequently stimulated for 0, 1, 2 or 3 hrs with 50 nM PMA, in the presence 
and absence of 1 μg/ml Actinomycin D. Cells were lysed in 1 ml Tri Reagent, 
and RNA was isolated according to the manufacturers recommendations. 
Briefly, 0.2 ml chloroform was added to the Tri reagent cell mixture, and after 5 
minutes at room temperature the RNA was phase separated into the aqueous 
phase by centrifuging at 12000 x g for 15 minutes at 4°C. The  RNA was 
precipitated from the aqueous phase by mixing and centrifuging with 1 volume 
of isopropanol for 10 minutes at 12000 x g at 4°C. After washing the RNA pellet 
with 1 ml 75% ethanol, it was dried and dissolved in DepC-treated H2O.  
The isolated RNA was used to make cDNA. Briefly, annealing of the random 
hexamer primers (p(CNA)6) was performed by incubating 5 μl of RNA for 10 
minutes at 65°C in the presence of the random hexamer primers, and 
immediately putting them on ice afterwards. 
 The synthesizing of the cDNA was then completed by incubating the 
samples at 37°C for 1 hour in the presence of 0.5 mM dNTP’s, M-MLV-RT 
polymerase and RNAse inhibitor.  
A real-time pcr analysis of p21 expression was performed using the Quantitect 
SYBR Green PCR Kit from Qiagen, following the manufacturers instructions on 
the Light Cycler system from Roche. The p21 values were normalised  against 
values obtained by real-time pcr for HPRT. Primers used: p21 FOR: 
tcaccgagacaccactggag, p21 REV: cttccaggactgcaggcttc. HPRT FOR: 
tggcgtcgtgattagtgatg, HPRT REV: gatgtaatccagcaggtcag. 
 
Electrophoretic mobility shift assay - Monocytes were cultured for 24 hrs in 
RPMI 1640 supplemented with 10% FBS, with or without addition of SN-50 





extracts were prepared according to the “mini extracts” procedure as previously 
described, divided in small aliquots and stored at -80°C. 
 Double-stranded synthetic oligonucleotide probes containing the NF-κB 
(NF-κB: 5'-AGCTGCGGGGATTTTCCCTG-3') consensus binding sequence 
were used in the gel retardation assay. The consensus sequence for binding of 
the nuclear factors is underlined. 50 ng of high performance liquid 
chromatography (HPLC)-purified single-stranded oligonucleotide was labeled 
with T4-polynucleotide kinase and [α32P] dATP (3000 Ci/mmol), separated from 
non-incorporated radiolabel by sephadex G50 chromatography, ethanol 
precipitated, dried, and dissolved in 20 μl of 10 mM Tris-HCl (pH 7.5), 50 mM 
NaCl, 10 mM MgCl2, 1 mM EDTA, and 1 mM DTT, containing a four fold 
excess of the opposite strand. Annealing of the two strands was performed by 
heating the mixture for 2 minutes at 90°C and slow cooling to room 
temperature. 5 μg nuclear extract and 0.1 ng double-stranded labeled 
oligonucleotide were incubated in 20 mM HEPES (pH 7.9), 60 mM KCl, 0.06 
mM EDTA, 0.6 mM DTT, 2 mM spermidine, 10 % glycerol, supplemented with 
2 μg poly(dI-dC). The binding reaction was performed at 26°C for 25 minutes. 
The samples were loaded on pre-run (30 min, 150 V) 4% (30:1) polyacrylamide 
gels and run for 1 hr at 150 V in 0.5 x TBE at room temperature. Gels were 
dried and exposed to Kodak XAR films at -80°C with an intensifying screen. 
Quantification of protein binding was performed by densitometry using a 
Phosphor Imager (Molecular Dynamics, Sunnyvale, CA). Competition 
experiments were performed by adding a 100-fold molar excess of unlabelled 
double stranded oligonucleotides. Supershift experiments were performed by 
incubating the nuclear extracts for 30 minutes with polyclonal antibodies 
against the p50 and p65 subunits of NF-κB. 
 
Immunoprecipitation - 107 AML blasts were cultured for 16 hrs in RPMI 1640 
medium supplemented with 10% FBS with or without 50 nM PMA. As positive 
control 107 cells of the human growth factor dependent cell-line AS-E2 were 
cultured for 16 hrs in RPMI 1640 supplemented with 5% FBS and 10 ng/ml IL-
3. These were cultured in the presence of 50 nM PMA to induce p21 
expression. Cells were harvested, washed with ice-cold PBS containing 1 mM 
sodium orthovanadate and subsequently lysed in 500µl lysisbuffer ( 20 mM 
TrisHCl pH 7.6, 100 mM NaCl, 10 mM EDTA, 1% NP-40, 10% glycerol, 2 mM 
Na3VO4, 2 mM PMSF, 1 µM pepstatin and 1 mM DTT) for 15 min on ice. Cell 
lysates were clarified at 10 000g for 20 min and incubated with 10 µl p21 
agarose conjugate (p21 (C-19) AC Santa Cruz, CA, USA) rotating O/N at 4°C. 
The immune complex was washed 3 times with lysisbuffer and heated in 
Cytoplasmic p21 affects apoptosis in monocytic leukemia 
  75 
sample buffer, separated by SDS-PAGE, immunoblotted on PVDF membrane 
(Millipore, Bedford, MA) and incubated with anti-p21 and anti-ASK1 antibodies. 
Immunocomplexes were detected using ECL (Amersham, UK). 
 
Statistical analysis - The student t-test for paired samples was used to 
determine statistical significance of the apoptosis data in the U937 cell-line. 
The Mann-Whitney U test was used to determine statistical significance 





Expression and regulation of p21 in normal monocytes and myeloid cells 
To obtain more information regarding expression, localization and regulation of 
p21 in normal hematopoietic cells and especially whether p21 is a downstream 
target of NF-κB, as is reported earlier,183 monocytes from healthy donors were 
stimulated with IL-1ß, GM-CSF, IL-3 and the phorbol ester PMA for 4, 6 and 24 
hours. As depicted in fig. 1A, in unstimulated cells no p21 protein could be 
detected while PMA, IL-3 and GM-CSF all induced p21 expression, with a 
predominant cytoplasmic localization. Correct fractionation is indicated by the 
absence of leakage of the nuclear Rb protein to the cytoplasm. Stimulation with 
IL-1ß did not result in the appearance of p21 protein, despite the fact that IL-1 
is capable of inducing NF-κB DNA binding activity.194;278;293;314-316 Since the 
appearance of p21 could reflect increased p21 gene expression or a 
diminished p21 protein degradation,317 a Real-Time PCR was performed on 
PMA stimulated monocytes. Treatment of monocytic cells from healthy donors 
with PMA up to 3 hours clearly showed an upregulation of p21 gene 
expression, which could effectively be blocked by treatment with the 
Polymerase II inhibitor Actinomycin D (fig. 1B). This indicates that PMA can 
regulate p21 at the level of gene expression. Next we determined whether NF-
κB is activated by PMA and is required for PMA-induced p21 expression. 
Monocytes were stimulated with PMA and IL-1 and analysis of DNA binding by 
NF-κB was performed with an Electrophoretic Mobility Shift Assay (EMSA) as 
described in material and methods. PMA and IL-1 both induce NF-κB binding 
to its consensus binding sequence (fig. 1C). Supershift experiments with 
antibodies directed against the NF-κB subunits p50 and p65 resulted in 
complexes with a decreased mobility, indicating the presence of NF-κB in the 
observed complexes. Addition of a molar excess of unlabelled probe resulted in 





analyse if the PMA induced NF-κB activation is involved in the upregulation of 
p21 expression, monocytes were stimulated with PMA in the absence and 
presence of the NF-κB inhibitor SN-50. As demonstrated in fig. 1D, SN-50 
inhibited the induction of NF-κB DNA binding activity in response to PMA 
stimulation, but did not affect the PMA-induced p21 expression. These data 
indicate that in monocytes NF-κB is not required for PMA-induced p21 
expression.  
 
Figure 1 Expression and localisation of p21 in monocytes.  
(A) Monocytes from healthy donors were isolated and cultured as described in material and 
methods, and stimulated with 50 nM PMA, 10 ng/ml IL-1ß, 10 ng/ml IL-3 and 10 ng/ml GM-CSF for 
24 hrs. Nuclear and cytoplasmic fractions were analysed by SDS-PAGE. Rb is used as a 
fractionation control. The data presented are representative for 5 individual experiments. (B) 5 x 
106 monocytes were cultured for 24 hrs in RPMI 1640 supplemented with 10% FCS and 
subsequently stimulated for 0, 1, 2 or 3 hrs with 50 nM PMA, in the presence and absence of 1 
μg/ml Actinomycin D. RNA was isolated and cDNA was synthesized as described in material and 
methods. This cDNA was subjected to Real-Time PCR in order to analyse p21 gene expression, 
and was normalized  against HPRT. The data presented is averaged from two individual 
experiments. (C) Monocytes were cultured for 6 hrs in the presence of 50 nM PMA or 10 ng/ml IL-
1ß. EMSA’s were used to detect DNA binding activity of NF-κB in nuclear extracts. Controls with α-
p50 en α-p65 antibodies for supershifts and cold probe competition are shown for IL-1 treated 
samples in order to verify that the observed complex is specific and contains NF-κB. The data 
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presented is representative for 3 individual experiments. (D) After culturing monocytes for 6 hrs in 
the presence 50 nM PMA with or without pre-treatment with the specific NF-κB inhibitor SN-50 (100 
μg/ml), nuclear extracts were analysed for DNA binding capacity of NF-κB in an electrophoretic 
mobility shift assay. Cytoplasmic extracts were analysed for p21 content by SDS-PAGE. The data 
presented is representative for 2 individual experiments. Cyto = cytoplasmic. 
 
To further investigate the expression and role of p21 in cells of monocytic and 
myeloid origin, granulocytes and the cell lines KG1a, HL-60, AS-E2, GF-D8 
and U937 were stimulated with GM-CSF or PMA. In none of the unstimulated 
cell-lines p21 could be detected in the nucleus or cytoplasm. Upon stimulation 
with PMA during 6 hours, an increase in cytoplasmic and nuclear p21 was 
demonstrated in all cell-lines studied, which was most prominent in the 
monocytic cell line U937 (fig. 2A). In the primitive KG1a cell line and in 
granulocytes, PMA or GM-CSF induced p21 expression was low or 
undetectable compared to monocytic cells (fig. 2B). These findings indicate that 
in hematopoietic cells, p21 expression is absent in unstimulated cells, and can 
be significantly upregulated after induction with PMA, GM-CSF or other 
cytokines, with the exception of the KG1a cells and granulocytes. In addition, 
while cells of the myeloid lineage showed comparable amounts of cytoplasmic 
and nuclear p21, monocytes were observed to have more p21 protein localized 
in the cytoplasm after PMA and GM-CSF treatment (fig. 1A and 2A). 
 
Figure 2 Expression and localisation of 
p21 in hematopoietic cells.  
(A) Expression of p21 protein in U937, HL-60, 
GF-D8 and AS-E2 cells. After culturing these 
cells in the presence or absence of 50 nM 
PMA for 6 hrs, nuclear and cytoplasmic 
extracts were analysed for p21 levels by SDS-
PAGE. The data presented are representative 
for 2 individual experiments. Cyto = 
cytoplasmic, nuc = nuclear. (B) Expression of 
p21 in the primitive cell-line KG1a and 
granulocytes. Granulocytes were obtained 
from healthy donors and stimulated with 50 nM 
PMA or 10 ng/ml GM-CSF for 6 hrs. KG1a 
cells were stimulated with 50 nM PMA or 10 
ng/ml GM-CSF for 6 hrs. Western blot analysis 
of whole extracts was performed to 
demonstrate p21 expression upon GM-CSF 
and PMA treatment. Monocytes stimulated 
with PMA and GM-CSF were used as positive 
controls. Actin was used as loading control.  
The data presented is representative for 4  
individual experiments. 
 
 Using chemical inhibitors, the role of various intracellular signaling routes in 
regulating p21 expression in monocytes was investigated. Inhibitors used were: 





(MEK1), p38 kinase and the PI(3)K activity, respectively. In monocytes, neither 
U0126, SB203580, nor Ly294002 affected PMA (fig. 3A) and GM-CSF (data 
not shown) induced p21 expression, while the used inhibitors effectively 
interfered with the activation of downstream effectors (fig. 3B). The PKC 
inhibitors BIM and Chelerytrine however strongly inhibited p21 expression. Low 
concentrations of BIM display activity on typical and atypical PKC isoforms.318 
Similar findings  have been described for Chelerytrine.319 The PKC inhibitor 
Calphostin-C, which has been described to act on classical and novel PKC 
isoforms,319-321 had no effect on p21 expression (fig. 3A). In all cases, 
localization of the p21 protein was not affected by the use of different inhibitors. 
The absence of nuclear p21 after treatment with BIM and Chelerythrin is 
probably due to the lowered expression levels, instead of re-localization. These 
findings indicate that in monocytic cells, a PKC-dependent pathway is 
responsible for the expression of the p21 protein, although it remains to be 
determined  which PKC isoform is the main effector of this process. 
 
 
Figure 3 Inhibition of p21 expression  
(A) Expression of p21 in monocytes is inhibited by the PKC 
inhibitors BIM and Chelerythrin. Monocytes from healthy 
donors were isolated and cultured as described and pre-
treated for 1 hour with 1 μM BIM, 6 μM Chelerythrin, 100 nM 
Calphostin-C, 5 μM U0126, 5 μM Ly29002 and 1 μM 
SB203580 and stimulated with 50 nM PMA for 6 hrs. Nuclear 
and cytoplasmic fractions were analysed for p21 levels by 
SDS-PAGE. The data presented are representative for 3 
individual experiments. Actin is used as a loading control and 
proper fractionation is demonstrated by the lack of Rb 
immunoreactivity in the cytoplasmic fraction. Cyto = 
cytoplasmic, nuc = nuclear. (B) Validation of the effectiveness 
of the used inhibitors. Monocytes were pretreated with 5 μM 
U0126, 5 μM Ly29002 and 1 μM SB203580 for 1 hour and 
stimulated for 30 minutes with 50 nM PMA. P-Erk, P-PKB and 
P-p38 are shown. Actin is shown for loading control. The 
expression of p21 protein in the same samples was analysed 
after 6 hours. Tot = total. 
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p21 expression in Acute Myeloid Leukemia 
In hematopoietic cells, p21 is not expressed in unstimulated cells but can be 
induced by PMA in the monocytic lineage in a PKC-dependent fashion. In order 
to see if a similar expression pattern exists in the malignant counterpart, p21 
was studied in cryopreserved AML cells of either monocytic or myeloid origin. 
In contrast to normal unstimulated monocytes, a high constitutive expression of 
p21 was observed in 75% of the monocytic leukemia (M4-5, N=12) with a 
predominant cytoplasmic localization (fig. 4A). In 50 % of  the myeloid 
leukemia’s (M1-2, N=10) p21 expression could not be detected without 
stimulation, or a low expression of p21 was observed, which was localized in 
both the nucleus and cytoplasm (fig. 4A and data not shown). These findings 
link aberrant p21 expression primarily to cells of monocytic origin. To 
demonstrate whether  PKC is also involved in the spontaneous expression of 
p21 in AML cells, blast cells (N=5) with a high cytoplasmic p21 localization 
were exposed to the PKC inhibitors BIM and Chelerythrin. Chelerythrin reduced 
p21 expression in all studied cases, while BIM inhibited the p21 expression in 4 
of 5 studied cases (fig. 4B). The use of PKC inhibitors only affected the 
expression of p21, and not the localization as is demonstrated in fig. 4B. Rb 
was used as a fractionation control. These results underscore a role for PKC-
dependent activation of p21 expression in malignant monocytic cells. 
 Next, we investigated whether the activated signal transduction pathway 
leading to constitutive p21 expression might be due to the autocrine production 
of a growth factor or a cell-autonomous effect. Therefore, after 3 days of culture 
conditioned medium of monocytic AML blasts (M4-5) cultures (supernatant) 
was added to cultures of myeloid AML blasts (M1-2), and p21 expression was 
analysed (fig. 4C). In one case, monocytic AML conditioned medium induced 
p21 expression in myeloid AML blasts, while in the additional cases no effects 
were observed. Since these myeloid AML cells might have some inherent 
blockade, the conditioned medium was also added to monocytes of healthy 
donors. The AML conditioned medium now induced p21 expression in normal 
monocytes, although not as high as PMA or GM-CSF induced p21 expression 
(fig. 4C). These results suggest that in monocytic leukemia the autocrine 
production of growth factors could lead to constitutive p21 expression. In 
addition, a cell-autonomous mechanism of p21 expression can not be excluded 






























Figure 4 Expression of p21 in AML blasts.  
(A) AML blasts were isolated and cultured as described. Cytoplasmic and nuclear fractions were 
analysed for p21 content by SDS-PAGE. 8 representative cases are shown. The data presented is 
representative for 2 individual experiments. (B) AML blasts (M4 -M5) were isolated and cultured for 
24 hrs in the presence of 1 μM BIM or 6 μM Chelerythrin. The p21 protein was detected in 
cytoplasmic fractions by means of SDS-PAGE. As controls for sub-cellular fractionation Rb protein 
was used. Two representative cases are shown. The data presented are representative for 2 
individual experiments. (C) AML blasts (M1-2) were cultured for 24 hrs and stimulated with 50 nM 
PMA or conditioned AML medium from M4-5 cultures to study the role of autocrine growth factors 
leading to p21 expression. Conditioned AML medium was obtained by culturing 3x106 AML blasts 
(M4 -5) for 3 days. The same conditioned media were added to normal monocytes in order to 
analyse p21 expression. Stimulation with 50 nM PMA or 10 ng/ml GM-CSF was used as positive 
control. Actin is shown as loading control. The data presented are representative for 2 individual 
experiments. Cyto = cytoplasmic, nuc = nuclear. 
 
Cellular function of p21 
It has been demonstrated that cytoplasmic p21 has anti-apoptotic properties in 
response to stress due to the interaction between p21 and ASK1.182  To 
investigate whether this applies also to the effects of cytostatic agents, U937 
cells overexpressing p21 and neomycin transfected control cells were exposed 
to VP16 or H2O2. A significant lower percentage of apoptotic cells was 
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observed in response to VP16 exposure in p21-overexpressing cells compared 
to control cells (20.0% ± 0.9 vs. 55.8% ± 3.8, N=8, p<0.01) (fig. 5A). In addition 
p21 negative (N=6) and p21 positive (N=7) AML blasts were subjected to VP16 
treatment. As a measure of the apoptotic response, levels of activated caspase 
3 were detected, as well as combined annexin V/PI stainings, which were both 
measured using flow cytometry. The group of AML blasts with high cytoplasmic 
p21 expression (N=7), was significantly less sensitive to VP16-induced 
apoptosis as compared to AML blasts with low p21 expression levels (N=6), 
both for the active caspase 3 assay (respectively, 12.3% vs. 42.3%, p<0.01) 
and the combined annexin V/PI experiments (respectively, 8.5% vs. 25.8%, 
p<0.01) (fig. 5B). Next it was investigated whether the reduced apoptosis 
corresponded with a reduced phosphorylation, and hence activation of known 
downstream targets of ASK1, p38 and JNK, since these have been shown to 
be effectors of ASK1 mediated apoptosis.115;322;323 As depicted in fig. 5C, the 
protective effect of p21 in the U937 cell-line was associated with a reduced 
phosphorylation of p38 and JNK in p21 overexpressing cells in response to VP-
16 triggering. Similar results were obtained with the stress response activator 
H2O2 (fig. 5D). To further underscore the connection between p21 and ASK1, 
co-immunoprecipitations were performed with p21 and ASK1 in two AML cases 
with high cytoplasmic p21 levels. For this co-immunoprecipitation, an anti-p21 
antibody conjugated to agarose beads was used. As control for p21 expression 
and p21-ASK1 complex formation, untreated AS-E2 cells stimulated with 50 nM 
PMA for 16 hours were used. As negative control unstimulated AS-E2 cells 
were used, since unstimulated AS-E2 cells do not express p21 (fig. 2A). After 
16 hours of PMA (50nM) stimulation, complex formation between p21 and 
ASK1 could be observed in the AS-E2 cell-line, indicating that ASK1 co-
precipitates with the p21 protein. (fig. 6). In the AML blasts, ASK1 
coprecipitated with p21 in all conditions shown. Although in the M5 AML cells 
PMA treatment resulted in more ASK1 immunoreactivity, this is probably due to 
increased p21 expression in response to PMA. The complex formation 
between p21 and ASK1 itself however, does not appear to be PMA dependent, 
since ASK1 can also be detected in p21 precipitates from untreated M5 AML 
cells.  In short, we show that in monocytic leukemias cytoplasmic p21 functions 
as an anti-apoptotic protein. This is demonstrated by a lowered sensitivity 
towards VP16-induced apoptosis, which is reflected by a decreased 
phosphorylation of known downstream targets of ASK1, p38 and JNK. The 


















Figure 5 The p21 protein affects apoptosis induced by VP16 or H2O2.  
(A) Mock transfected U937 cells or U937 cells stable transfected with a ZnCl2 inducible p21 
construct were cultured for 3 days in the presence of 180 μM ZnCl2 to induce p21 expression. Next, 
the cells were exposed to 20 μg/ml VP16 for 24 hrs and afterwards apoptosis was measured using 
the combined annexin V/PI staining procedure as described in materials and methods. The data 
presented are averaged from eight independent experiments, with error bars denoting standard 
errors. * = P<0.01. (B) AML blasts were isolated and cultured as described. After 24 hours of 
exposure to 20 μg/ml VP16, apoptosis was measured using the combined annexin V/PI staining by 
flow cytometry. Also levels of activated caspase 3 were measured using flow cytometry as 
described in material and methods. For both experiments * = P<0.01. (C) The mock and stable 
transfected U937 cells expressing p21 were cultured for 3 days with 180 μM ZnCl2 and apoptosis 
was induced by culturing in the presence of 20 μg/ml VP16. Activation of JNK and p38 were 
studied in total cell extracts by western analysis. The data presented are representative for 5 
individual experiments. (D) Apoptosis was induced in U937 cells stable overexpressing p21, by 
culturing these cells 24 hrs in the presence of 300 μM H2O2. Whole extracts were assayed for 
phosphorylated JNK by western analysis. The data presented are representative for 5 individual 
experiments. 
 
Figure 6 The p21 protein forms a complex with 
ASK1 in monocytic AML blasts and AS-E2 cells. 
107 AML blasts (M4 -5) were cultured in the absence 
or presence of 50 nM PMA for 16 hrs as indicated. Cell 
lysates were subjected to p21 immunoprecipitation (IP) 
using an α-p21 antibody, conjugated to agarose 
beads. Immunoblotting was performed using α-p21 
and α-ASK1 antibodies. Expression of ASK1 in all 
samples was confirmed by immunoblotting of total cell 
extracts, see the “input” panel. As negative and 
positive controls, 107 AS-E2 cells were grown in the 
absence or presence of 50nM PMA respectively and 
IP was performed. The data presented are 
representative of five individual experiments. 
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Discussion 
 
The role of nuclear p21 as cell cycle regulator by interaction with several cyclin 
dependent kinases is well established.302-306 Recent studies have indicated that 
p21 might have an additional function when the protein is localized in the 
cytoplasm. Cytoplasmic p21 is linked to the anti-apoptotic process by 
interacting with ASK1 or pro-caspase 3.182;308;324;325 The present study indicates 
that in differentiating hematopoietic cells of monocytic and myeloid lineage, p21 
can selectively be upregulated by a number of cytokines, which in monocytic 
cells, is a PKC-dependent but NF-κB-independent process. A recent study in 
monocytes indicated a link between NF-κB activation and p21 upregulation, 
suggesting that p21 might accomplish the anti-apoptotic effects of NF-κB.183 
However, in the present study it is shown that NF-κB activity is not required for 
p21 expression. In monocytic leukemia, constitutive expressed p21 is 
frequently observed in contrast to myeloid leukemia, which is a PKC dependent 
process. This is likely linked to the autocrine production of growth factors. 
However, it is not strictly excluded that a yet unknown upstream kinase or 
receptor mutation results in constitutive activation of this signal transduction 
pathway leading to constitutive p21 expression. The PKC-dependent 
expression of p21 is not linked to the MEK1 or PI(3)K signaling pathways. This 
is in contrast with other reports, where it was shown that p21 protein stability is 
enhanced by phosphorylation through PKB,309 and, where PMA-induced p21 
expression is linked to nuclear distributed ERK.326 In addition, phosphorylation 
of p21 on Thr145 is suggested to be a prerequisite for its cytoplasmic 
localization.327 Whether the localization of p21 is dependent on the 
phosphorylation status of the protein in conjunction with the cellular setting is 
the subject of further research. 
 Finally it is shown that p21 overexpression inhibits VP16-mediated 
apoptosis as is reflected by the inhibitory effects on the phosphorylation of p38 
and JNK, known downstream targets of ASK1. In addition, p21 and ASK1 form 
a complex in cell-lines and AML blasts, underscoring a strong connection 
between the anti-apoptotic function of p21 and ASK1-mediated apoptosis. The 
obtained results in monocytes are in disagreement with findings by Asada and 
co-workers, who demonstrated that unstimulated monocytes express p21.182 
The cause of this difference is unclear but might be related to the used isolation 
procedure.  
 The data presented here and other findings indicate that in leukemic cells 
anti-apoptotic proteins are regulated by different signaling routes including the 





and in monocytic blasts also at the level of p21 expression.182-184 These 
findings illustrate that, until a single oncogenic defect is defined which is 
responsible for the total spectrum of activation signals, combination of inhibitors 
have to be used for chemotherapeutic interference with the distinct and 
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Objective. To investigate 1) the signal transduction pathways affected by heat 
shock protein 27 (HSP27) expression; and 2) the expression and regulation of 
HSP27 in acute myeloid leukemia (AML).  
Materials and methods. RNA interference studies for HSP27 in leukemic TF-1 
cells were used to investigate the effects on downstream signal transduction 
and apoptosis after VP-16 and CD95/Fas treatment. HSP27 expression and 
activation was investigated in AML blasts through western blot analysis. 
Results. RNA interference for HSP27 resulted in a twofold increase in VP-16-
induced apoptosis, which was preceded by enhanced p38 and c-Jun 
phosphorylation and a two-fold increased cytochrome c release into the 
cytoplasm. DAXX co-immunoprecipitated with HSP27 suggesting an inhibitory 
role of HSP27 in VP-16-mediated activation of the ASK1/p38/JNK pathway. 
CD95/Fas-induced apoptosis however was unaffected by HSP27 siRNA, due 
to upregulation of HSP27. Although HSP27 was highly expressed and 
phosphorylated in primitive monocytic AML blasts (M4-M5, 91%, N = 11) and 
undetectable in myeloid blasts (M1-M2, N = 5), VP-16-mediated apoptosis 
correlated moderately with HSP27 expression. This is likely due to the co-
expression of p21Waf1/Cip1, which is in the majority of the monocytic AML M4-M5 
blasts constitutively localised in the cytoplasm. Overexpression of cytoplasmic 
p21 inhibited the enhanced p38 phosphorylation after HSP27 RNAi, suggesting 
a predominant anti-apoptotic role of p21 over HSP27.  
Conclusion.  1) HSP27 inhibits VP-16-mediated phosphorylation of p38 and c-
Jun, cytochrome c release and subsequent apoptosis; 2) HSP27 is expressed 
and activated in monocytic AML blasts; 3) Cytoplasmic expression of p21 
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Introduction 
 
Acute myeloid leukemia (AML) is characterized by an accumulation of 
immature cells in the bone marrow, resulting in the disruption of normal 
hematopoiesis.16;17;300 The leukemic population possesses a growth advantage 
that is in part linked to the constitutive activation of intracellular proteins that 
trigger the activation of anti-apoptotic proteins.40;64;290;294 The small heat shock 
protein 27 (HSP27) is a member of the heat shock protein (Hsp) family, whose 
expression is transiently induced in response to stress. It has been 
demonstrated that HSP27 levels change during cellular stress328 and 
differentiation,329-331 both on the transcriptional and posttranslational level.328 In 
normal cells, HSP27 mainly exists in large oligomeric units up to 800 kDa in 
size. Stress leads to changes in the multimeric status of the protein due to 
phosphorylation of HSP27 on three serine residues,117 that can change the 
activity of the protein.332 HSP27, besides being involved in cytoskeletal stability, 
cell motility and its function as a chaperone,328;332-334 has been implicated in 
apoptosis.113;114;331;335-337  
 Induction of apoptosis can occur via an intrinsic as well as an extrinsic 
signal transduction pathway. The classical intrinsic pathway is initiated through 
the release of cytochrome c from mitochondria. Cytochrome c interacts with 
Apoptosis Protease Activating Factor-1 (Apaf-1), which oligomerises and binds 
to pro-caspase-9.117 The formation of this caspase-activating complex, termed 
the apoptosome, results in the activation of caspase-9, which in turn triggers 
the proteolytic cleavage of pro-caspase-3, leading to apoptosis.117  
Binding of ligands to death receptors on the cell surface (e.g., CD95/Fas) not 
only results in the formation of the death inducing signaling complex (DISC) via 
the recruitment of the adapter molecule FADD, but also to the recruitment of 
DAXX to the cytosolic end of the CD95/Fas receptor.111;112 DAXX then binds 
Apoptosis Signal Regulating Kinase-1 (ASK1), which in turn activates c-Jun N-
terminal Kinase (JNK) and p38, leading to cytochrome c release and activation 
of caspases.113-116  
 The mode of HSP27 action in apoptosis is still unclear but could exert its 
effect at the level of mitochondrial stability336;338 or DAXX signaling.113;114  
Since HSP27 expression has been observed in multiple malignancies339;340 
including AML341;342 and HSP27 expression is frequently correlated with 
unfavorable prognosis,343 we questioned whether HSP27 plays an important 
role in the protection of AML blasts against CD95/Fas- or VP-16-induced 





 Here we demonstrate that HSP27 is predominantly expressed and 
phosphorylated in AML blasts of the monocytic lineage. RNA interference 
indicates that HSP27 affects the VP-16-induced DAXX pathway through the 
modulation of JNK and p38117;290 activation, resulting in the enhanced 
cytochrome c release and induction of apoptosis. Additionally, our results also 
indicate that in monocytic leukemia, HSP27 is not the determining anti-
apoptotic factor, since cytoplasmic localized p21Waf1/Cip1 is able to reverse the 
enhanced VP-16-induced phosphorylation of p38 after RNAi for HSP27. 
 
 
Materials and methods 
 
Patient population and isolation of AML cells - Peripheral blood cells or bone 
marrow cells from 16 adult untreated patients with AML were studied after 
informed consent. The AML cases were defined according to the classification 
of the French-American-British (FAB) committee as M0-M6.18 AML blasts were 
isolated by density-gradient centrifugation. The cells were cryopreserved in 
aliquots of 20-30 x 106 cells in RPMI 1640 (Biowhittaker, Verviers, Belgium) 
supplemented with 10% dimethylsulfoxide (DMSO; Sigma, St. Louis, MO) and 
10% fetal bovine serum (FBS; Bodinco, Alkmaar, the Netherlands), employing 
a method of controlled freezing and storage in liquid nitrogen. After thawing, T-
lymphocytes were depleted by 2-aminoethylisothioronium bromide (AET)-
treated sheep red blood cell (SRBC) rosetting. The cell population consisted of 
more than 98% AML blasts as determined by May-Grünwald-Giemsa staining. 
Fluorescence-activated cell sorting (FACS) analysis demonstrated <1% CD3 
(Becton Dickinson, Sunnyvale, California, USA) positive cells.  
 
Preparation of monocytes, granulocytes and CD34+ BM cells - Peripheral blood 
cells were obtained from healthy volunteer blood donors, and mononuclear cell 
suspensions were prepared by Ficoll-Hypaque density-gradient centrifugation. 
T- lymphocytes were depleted by AET-treated SRBC rosetting. Monocytes 
were further enriched by plastic adherence (1h, 37°C, 5% CO2) and 
demonstrated a purity >95% detected by FACS analysis with anti-CD14 
antibody (Becton Dickinson, Sunnyvale, CA).  
 Peripheral blood from healthy volunteers, anti-coagulated with 0.32% 
sodium citrate, was used to isolate granulocytes as described by Fuhler et al 
(and references therein).344  
 CD34+ cells were isolated from bone marrow from healthy donors by first 
making mononuclear cell suspensions followed by incubation of the suspension 
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with phycoerythrin-labelled anti-CD34+ antibody for 30 minutes at 4°C and 
subsequent FACS sorting using the MoFlo (DakoCytomation, Carpinteria, Ca, 
USA). CD34+/CD36- and CD34-/CD36+ cell populations were obtained by 
incubating the AML blasts with phycoerythrin-labelled anti- CD34+ and FITC-
labelled anti- CD36+ antibodies for 30 minutes at 4°C. Subsequently, the 
different cell populations were isolated by FACS sorting using the MoFlo. 
 
Cell culture, viral vectors and transfections - AML blasts were cultured at 37°C, 
5% CO2 at a density of 1x106/ml in RPMI 1640 media supplemented with 100 
U/ml penicillin, 100 µg/ml streptomycin (ICN Biomedicals, Aurora, Ohio, USA) 
and 10% FBS. Isolated CD34+ cells were cultured in IMDM medium (ICN 
Biomedicals, Aurora, Ohio, USA) supplemented with 10% FBS, 100 U/ml 
penicillin, 100 µg/ml streptomycin. Monocytes were cultured at 37°C, 5% CO2 
at density of 1 x 106 /ml in RPMI 1640 and 10% FBS. The human cell lines 
U937 (ATCC, Product No. CRL-1593.2), THP-1 (ATCC, Product No. TIB-202) 
and HL-60 (ATCC, Product No. CCL-240) were cultured in RPMI 1640 
supplemented with 10% FBS. The human cell line TF-1 (ATCC, Product No. 
CRL-2003) was cultured in RPMI 1640 supplemented with 10% FBS and 10 
ng/ml GM-CSF (Genetics Institute Cambridge, MA). 
 pMSCV-p21dNLS was constructed by removing the C-terminal bipartite 
Nuclear Localization Signal (NLS; RKRR) via PCR from pCMV-p21 (kindly 
provided by Prof. Dr R.H. Medema and Dr. P. Coffer) and ligating the XhoI-
EcoRI fragment into pMSCV-iGFP (kindly provided by Dr. J.J. Schuringa). TF-1 
cells were transduced with viral particles collected from 293T cultures 
transfected with pCL-AMPHO and pMSCV-p21dNLS using FuGENE6 (Roche, 
Almere, The Netherlands). GFP positive TF-1 cells were isolated by FACS 
sorting using the MoFlo. 
 
Reagents and antibodies - An antibody against phosphorylated p38 was 
obtained from New England Biolabs (Beverly, MA, USA). Antibody against 
HSP27 was purchased from Stressgen (Victoria BC, Canada), anti-actin (C4) 
was obtained from ICN Biomedicals (Aurora, Ohio, USA). Antibodies against c-
Jun, cytochrome c and GAPDH were obtained from Santa Cruz biotechnology 
(Santa Cruz, Ca, USA), pan Serine from Zymed Laboratories (San Francisco, 
Ca, USA). Anti-FLAG (M2) was obtained from Sigma. Antibody against p21 
was bought from Transduction Laboratories (Lexington, KY, USA). Anti CD34-
HPCA2-PE was obtained from Becton Dickinson. And CD36 FITC was 
obtained from IQ products (Groningen, The Netherlands). Recombinant human 
(Rh) interleukin (IL)-1ß was obtained from Mekesson HBOC Bioservices 





(GM-CSF) were purchased from Genetics Institute (Cambridge, MA, USA). The 
VP-16 was obtained from TEVA (Haarlem, The Netherlands) and the apoptosis 
inducing monoclonal antibody CD95/Fas (7C11) was obtained from 
Immunotech (Marseille, France). 
 
Preparation of protein extracts and Western blotting - The amount of HSP27, 
GAPDH, p21Waf1/Cip1 and actin and the degree of phosphorylated p38, c-Jun 
and pan Serine were determined by SDS-PAGE analysis (sodium dodecyl 
sulphate-poly acryl amide gel electrophoresis) on whole cell extracts. Cells 
were harvested and total cell extracts were prepared by resuspending the cells 
in lysisbuffer (20 mM TrisHCl pH 7.6, 100 mM NaCl, 10 mM EDTA, 1% NP-40, 
10% glycerol, 2 mM Na3VO4, 2 mM PMSF, 1 µM pepstatin and 1 mM DTT) and 
kept for 15 min on ice. Binding of each antibody was detected by HRP labeled 
secondary antibodies using enhanced chemiluminesence (ECL) according to 
the manufacturer’s recommendations (Amersham Life Sciences, 
Buckinghamshire, UK).  
 For cytoplasmic and nuclear extracts, cells were harvested and were 
prepared according to the “mini extracts” method 273. The extracts were 
normalized for protein content prior to SDS-PAGE. Proper fractionation and 
lack of leakage of nuclear proteins to the cytosol was determined by western 
blotting for the nuclear protein Retinoblastoma (Rb). 
 
RNA interference - Short interfering RNA duplexes for HSP27 were made using 
the Silencer siRNA construction kit from Ambion (Austin, Texas, USA) 
according to the manufacturer’s protocol. The HSP27 target sequence used is: 
AAGCTGCAAAATCCGATGAGA. GAPDH control siRNA duplexes are 
provided within the kit. 2x106 TF-1 cells were transfected with a final 
concentration of 25 nM of RNAi duplexes using oligofectamine according to the 
manufacturer’s protocol (Invitrogen, Breda, The Netherlands). Lysates were 
prepared at the indicated time points in lysisbuffer and equal amounts of 
protein were subjected to western blot analysis. 
 
Combined annexin V/PI staining procedure - Viability was assessed using an 
annexin V staining kit (IQ Products, Groningen, The Netherlands) according to 
the manufacturer’s recommendations. Briefly, after 6 hrs of culture in RPMI 
1640 medium supplemented with 10% FBS, with or without addition of VP-16 
(20 µg/ml) or CD95/Fas (2 μg/ml), cells were harvested, resuspended in 100 µl 
calciumbuffer containing 5 µl of annexin V and incubated for 20 min at 4°C in 
the dark. Cells were washed with 5 ml calciumbuffer and subsequently 
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incubated in 300 µl calciumbuffer containing 2.5 µl of propidium iodide (PI) for 
10 min in the dark at 4°C. Finally, binding of fluorescein-conjugated annexin V 
and PI was measured by fluorescence-activated cell sorting.  
 
Immunoprecipitation - 107 AML blasts were cultured for 16 hrs in RPMI 1640 
medium supplemented with 10% FBS. Cells were harvested, washed with ice-
cold PBS containing 1 mM sodium orthovanadate and subsequently lysed in 
500µl lysisbuffer ( 20 mM TrisHCl pH 7.6, 100 mM NaCl, 10 mM EDTA, 1% 
NP-40, 10% glycerol, 2 mM Na3VO4, 2 mM PMSF, 1 µM pepstatin and 1 mM 
DTT) for 15 min on ice. Cell lysates were clarified at 10 000g for 20 min and 
incubated with 5 µl HSP27 antibody. After 4 hours rotating, protein A 
sepharose beads were added and incubated O/N at 4°C.  Immunocomplexes 
were washed 3 times with lysisbuffer and separated by SDS-PAGE. Binding of 
anti-pan-Serine antibody was detected using ECL (Amersham, UK). 
 20x106 TF-1 cells were electroporated with 20 μg of pCDNA3 MYC-FLAG-
DAXX and 20 μg of pCDNA3 HA-ASK1 at 240V and 960 μF. After 24 hours 
cells were harvested, and co-immunoprecipitations were performed as 
described above. Binding of anti-FLAG antibody was detected using ECL. 
 
Cytochrome C ELISA - The Quantikine Human Cytochrome c immunoassay 
from R&D Systems (Minneapolis, MN, USA) was used to measure cytochrome 
c levels in the cytoplasm in response to VP-16 or CD95/Fas treatment, 
according to the manufacturer’s recommendations. Cytoplasmic and 
mitochondrial fractions were separated using the mitochondria isolation kit from 
Sigma (Zwijndrecht, The Netherlands). 
  
Statistical analysis - The student t-test for paired samples was used to 
determine statistical significance of the data about apoptosis induction in the 
TF-1 cell-line. The 2 x 2 contingency test was used to determine association 





HSP27 expression in hematopoietic cells 
To determine whether HSP27 is expressed in different hematopoietic cells, we 
isolated granulocytes, monocytes, mononuclear bone marrow cells and CD34+ 
cells from healthy donors. Mononuclear cells from different donors express 





terminally differentiated granulocytes however, HSP27 could not be detected. A 
differentiation-dependent expression was also observed in cell lines. HSP27 
was highly expressed in the monocytic cell lines THP-1 and U937; moderate 
expression was observed in the erythroleukemic cell line TF-1 and in the 
myeloid cell line HL-60, HSP27 could not be detected in (fig. 1B).  
 
Figure 1 Expression of HSP27 in normal 
hematopoietic cells and cell lines.  
(A) Bone marrow mono nuclear cells, granulocytes 
and monocytic cells from healthy donors were 
isolated and cultured as described in material and 
methods. CD34+ cells were isolated from bone 
marrow from healthy donors by making mononuclear 
cell suspensions followed by incubation of the 
suspension with phycoerythrin-labelled anti-CD34+ 
antibody for 30 minutes at 4°C and subsequent 
FACS sorting using the MoFlo. HSP27 expression 
was investigated by western blot analysis. Actin is 
shown as loading control. A representative 
experiment is shown. (B) HL-60, THP-1, U937 and 
TF-1 cells were cultured as described in the material 
and methods section, and lysates were analyzed for 
HSP27 expression using western blot analysis. Actin 
is shown as loading control. A representative 
experiment is shown. 
 
RNA interference for HSP27 enhances apoptosis after VP-16 treatment 
To investigate whether HSP27 plays a role in the apoptotic process in leukemic 
cells, RNA interference was used to knock down HSP27 protein levels in TF-1 
cells. Figure 2A shows the decrease in HSP27 levels after transfection with 
short interfering RNAs (siRNAs) in time. After two days HSP27 levels were 
reduced with approximately 50% compared to the expression levels in 
untransfected cells (-). A further reduction in HSP27 protein levels was 
observed three, four and five days after RNAi transfection. The siRNAs used 
were specific, since no effect on GAPDH expression was observed using 
HSP27 siRNAs and vice versa (fig. 2B).  
 To investigate whether HSP27 indeed protects against apoptosis, TF-1 
cells were transfected with either HSP27 or GAPDH siRNAs and the 
percentage of apoptotic cells was determined by means of annexinV/PI 
staining followed by flow cytometry, 6 hours after incubation with VP-16 or 
CD95/Fas. VP-16-mediated apoptosis was significantly increased in HSP27-
RNAi treated cells compared with the control GAPDH-RNAi treated cells 
(26.8% ± 8.7 vs. 5.8% ± 3.8, N=5, p<0.005, fig. 2C). HSP27 does not seem to 
be involved in CD95/Fas-induced apoptosis, since knock down of HSP27 did 
not significantly affect the percentage of apoptotic cells upon treatment with 
CD95/Fas. 
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Figure 2 RNA interference for HSP27 
specifically knocks down HSP27 
expression and enhances VP-16-induced 
apoptosis.  
(A) 2x106 TF-1 cells were transfected using 
oligofectamine with RNA duplexes targeting 
HSP27, as described in material and 
methods. On the indicated time points, 
lysates were made and subjected to western 
blot analysis for HSP27 expression. Actin is 
shown as loading control. A representative 
example of 5 experiments is shown. (B) To 
indicate specificity, TF-1 cells were also 
transfected with RNA duplexes targeting 
GAPDH. Western blot analysis on day 4 
indicates that both RNA duplexes are 
specific. A representative example of 5 
experiments is shown. (C) 4 days after 
transfection with either HSP27 RNAi or 
control GAPDH RNAi, TF-1 cells were 
treated with VP-16 (20 µg/ml) or CD95/Fas 
(2 μg/ml) for 6 hours. Apoptosis was 
measured with Annexin V/PI staining using 
flow cytometry as described in material and 
methods. A representative example of 5 
independent experiments performed in 
triplicate is shown. (* = p< 0.005). 
 
RNA interference for HSP27 enhances cytochrome c release from the 
mitochondria in response to VP-16 
Next we investigated at which level HSP27 affected the VP-16-induced 
apoptotic response. HSP27 has been described to interact with pro-caspase 
3,338 and cytochrome c,336 ultimately preventing the activation of pro-caspase 3 
by caspase 9-mediated proteolysis. Co-immunoprecipitation studies could not 
detect complex formation between HSP27 and either pro-caspase 3 or 
cytochrome c in TF-1 cells, which corresponds with observed cleavage of pro-
caspase-3 after CD95/Fas treatment (data not shown).  
 Next we investigated whether HSP27-blocked cytochrome c release from 
mitochondria.345 To investigate whether HSP27 inhibits the release of 
cytochrome c upon VP-16 and CD95/Fas treatment, we performed ELISAs 
(Enzyme Linked Immuno Sorbent Assays) on cytosolic extracts from VP-16 
and CD95/Fas treated cells. Control GAPDH siRNA treated cells showed a 2-
fold increase in cytocrome c release upon VP-16 treatment (fig. 3A) and a 1.5-
fold increase was found after CD95/Fas treatment. Knockdown of HSP27 
resulted in a 4-fold increase in cytochrome c release upon VP-16 treatment, 
















       
Figure 3 RNA interference for HSP27 
enhances the release of cytochrome c and 
modulates the phosphorylation of p38 and c-
Jun in response to VP-16.  
(A) 4 days after transfection with either HSP27 
RNAi or control GAPDH RNAi, TF-1 cells were 
treated with VP-16 (20 µg/ml) or CD95/Fas (2 
μg/ml) for the indicated hours and cytochrome c 
release was measured in cytoplasmic extracts by 
ELISA, as described in material and methods. Relative values, normalized against untreated cells 
are shown. A representative case of three individual experiments is shown. (B) 4 days after 
transfection with either HSP27 RNAi or control GAPDH RNAi, TF-1 cells were treated with VP-16 
(20 µg/ml) or CD95/Fas (2 μg/ml) for 1 or 3 hours and subjected to western blot analysis for 
phosphorylated p38, c-Jun and HSP27. Actin is shown as loading control. A representative 
example is shown. (C) 20 x106 TF-1 cells were electroporated with 20 μg of pCDNA3 MYC-FLAG-
DAXX with or without 20 μg of pCDNA3 HA-ASK1. After 24 hours cells were lysed in 500 µl 
lysisbuffer. By immunoprecipitation (IP) of HSP27 and western blot analysis for anti-FLAG, 
complex formation between HSP27 and DAXX was investigated. Immunocomplexes were detected 
using ECL. A representative example is shown. 
 
RNA interference for HSP27 influences phosphorylation of p38 and c-Jun 
after VP-16 treatment 
Cytochrome c release from mitochondria has been shown to be involved in 
JNK-, c-Jun-mediated cell death.116;346 Therefore we focused on the 
downstream effectors of VP-16- and CD95/Fas-induced apoptosis, i.e. the 
stress-activated protein kinase (SAPK, also known as JNK; c-Jun amino-
terminal kinase) and the p38 MAP kinase.115 TF-1 cells transfected with either 
HSP27 or GAPDH siRNAs were treated with VP-16 or CD95/Fas for one and 
three hours. P38 and c-Jun activation were determined using western blot 
analysis (fig. 3B). VP-16 induced a strong activation of p38 and c-Jun in the 
GAPDH RNAi transfected TF-1 cells after three hours, whereas no activation 
was observed using CD95/Fas (lanes 2 and 3). RNA interference for HSP27 
further increased VP-16-induced p38 phosphorylation levels approximately 3-
fold (compare fig. 3B lanes 5 and 10). In addition, the kinetics of p38 
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phosphorylation were also changed, since phosphorylation of p38 was already 
observed after 1 hour of VP-16 treatment in HSP27 RNAi treated cells 
(compare lanes 4 and 9). A similar effect was found on c-Jun phosphorylation 
after three hours of VP-16 treatment.  
In accordance with the absence of enhanced apoptosis, CD95/Fas had no 
effect on p38 and c-Jun phosphorylation, although JNK has been reported to 
be a downstream target of CD95/Fas-induced apoptosis by caspase-
independent pathways.113 This coincided with an upregulation of HSP27 
expression after CD95/Fas treatment, that was not only observed in the control 
cells, but also in the HSP27 RNAi transfected cells, despite the presence of the 
siRNA (fig. 3B, compare lanes 1, 2 and 3 to 6, 7 and 8 respectively). In non-
transfected HL-60 cells CD95/Fas treatment also induced HSP27 expression 
(data not shown).  In conclusion, these data demonstrate that knock down of 
HSP27 leads to an enhanced activation of p38 en c-Jun in response to VP-16, 
indicating a role for HSP27 upstream from mitochondria. 
 
HSP27 forms a complex with DAXX in an is ASK-1 dependent manner 
Since HSP27 has been described to interact with DAXX,113;114 which is located 
upstream of ASK1, an activator of p38 and JNK,323;347 we performed co-
immunoprecipitation studies to investigate whether HSP27 interacts with 
DAXX. TF1 cells were transfected with FLAG-DAXX and ASK1 expression 
plasmids as indicated. In figure 3C, we show that complex formation between 
DAXX and HSP27 occurs and that this is ASK1 dependent. (fig. 3B, panel IP). 
In the absence of ASK1, FLAG-DAXX could not be detected in the precipitates 
(lanes 1 and 2). Co-expression of both ASK1 and DAXX led to massive cell 
death (data not shown), resulting in lower amounts of protein in the 
ASK1/DAXX transfected samples (totals, lanes 3 and 4).    
 Summarizing, these data indicate complex formation between HSP27 and 
DAXX in TF-1 cells and suggest a protective effect of HSP27 against VP-16-







Figure 4 HSP27 is differently expressed in AML samples.  
Acute myeloid leukemic cells were isolated and cultured as described in material and methods and 
HSP27 expression was investigated using western blot analysis. A representative case of 3 
experiments is shown. The 2 X 2 contingency test was used to determine association between FAB 





HSP27 expression in Acute Myeloid Leukemia 
In the erythroleukemic cell line TF-1 we demonstrated that knockdown of 
HSP27 enhances VP-16 mediated apoptosis via modulation of p38 and c-Jun 
phosphorylation and subsequent mitochondrial cytochrome c release, which 
eventually results in enhanced apoptosis.  
Therefore we questioned whether HSP27 also protects AML blasts against an 
apoptotic insult. In view of the high expression of HSP27 in CD34+ and 
monocytic cells (fig. 1A), we first studied HSP27 expression levels in myeloid 
(FAB M1/M2, N = 5) and monocytic (FAB M4/M5, N = 11) AML samples. None 
of the AML M1/M2 cases expressed HSP27, despite the presence of high 
CD34 antigen levels in 60% of these cases (fig. 4 and table 1). In contrast, 10 
out of 11 AML M4/M5 patients demonstrated distinct, although variable, HSP27 
expression (correlation p<0.005; fig. 4 and table 1). Within these AML patients, 
HSP27 is most prominently expressed within immature AML progenitors 
(CD34+/CD36-) as compared to the more differentiated AML cells (CD34-
/CD36+), investigated through FACS sorting and western blot analysis (N = 2, 
data not shown). To exclude that experimental procedures modulated HSP27 
levels, fresh AML blast and cryopreserved blasts of the same patient were 
compared, directly and several hours after isolation. No effect of 
cryopreservation and isolation procedures were observed on HSP27 levels 
(data not shown). 
 
Table I. FAB classifications, percentage of apoptotic cells, expression patterns and CD34 













n.d. = not determined, spontaneous apoptosis > 90%, FAB = French-American-British 
classification, VP-16 = percentage of apoptosis induced by VP-16; Fas = percentage of apoptosis 
induced by CD95/Fas, HSP27 = HSP27 expression levels; p21 = p21waf1/Cip1 expression levels, % 
CD34+ cells = the percentage of CD34 positive cells as determined by FACS analysis. 
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Expression of HSP27 is not correlated with decreased apoptosis in Acute 
Monocytic Leukemia 
In view of the expression of HSP27 in acute monocytic leukemia we questioned 
whether HSP27 expression was related to sensitivity towards apoptotic stimuli. 
Both myeloid (FAB M1/M2) and monocytic (FAB M4/M5) AML blasts were 
incubated with VP-16 or CD95/Fas. After 6 hours of incubation, the percentage 
of apoptotic cells was determined by Annexin V/PI staining. In the group 
without HSP27 expression more than 15% VP-16-mediated apoptosis was 
found in all cases studied, whereas 60% of the HSP27 expressing cases 
demonstrated less than 15% apoptosis. However, when all samples were 
included, no absolute correlation was observed between VP-16- and 
CD95/Fas-induced apoptosis and HSP27 expression levels. (fig. 5A and table 
1). 
 
Figure 5 VP-16 and CD95/Fas mediated 
apoptosis and HSP27 phosphorylation in 
AML cells.  
(A) Apoptosis was induced by culturing the AML 
cells in the presence of VP-16 (20 µg/ml) or 
CD95/Fas (2 μg/ml). After 6 hours of culture, 
binding of fluorescein-conjugated annexin V and 
PI was measured by fluorescence-activated cell 
sorting. The Mann-Whitney U test was used to 
analyse differences in apoptosis between the 
two groups of differentially expressing HSP27 
AML blasts (presence or absence of HSP27 
expression and M1/M2 versus M4/M5 FAB 
classification), but no significant differences 
could be observed. The dotted line represents 
the 15% apoptosis level. A representative 
example of two experiments is shown. (B) By 
immunoprecipitation (IP) of HSP27, and western 
blot analysis for pan-serine phosphorylation, the 
activation of HSP27 was investigated. As control 
for the HSP27 IP and phosphorylation analysis, 
performed in the AML cases, the procedure was 
tested in TF-1 cells. The first lane shows 
untreated TF-1 cells. Lane 2 shows the IP 
procedure without antibody, indicating specific 
pull down of HSP27 in the other lanes. Lane 3 
shows TF-1 cells treated for 30 minutes with 10 
ng/ml IL-1ß and lane 4 shows 90 minutes of 
treatment with 10 ng/ml IL-1ß, indicating the 
transient phosphorylation in TF-1 cells. The 
HSP27 input is shown here as loading control 
and this is the HSP27 in total cell lysates before 
the IP procedure. A representative example is 
shown. (C) 107 AML blasts were cultured for 16 
hrs in RPMI 1640 medium supplemented with 
10% FBS. Cell lysis and IP of HSP27 is 
performed as described in material and methods. 





described above. Input indicates HSP27 levels in total lysates before IP. 6 representative cases are 
shown. In order to show that indeed phospho HSP27 is detected, AML case 9 is also treated with 
10 ng/ml IL-1ß, a known stimulator of HSP26 phosphorylation. Actin is shown as loading control. 
 
Phosphorylation and activation of HSP27 
Since no distinct correlation between HSP27 expression and decreased 
apoptosis were detected, we wondered whether HSP27 is phosphorylated and 
activated in AML cells. To investigate whether the HSP27 protein detected in 
the monocytic AML samples is phosphorylated, immunoprecipitations (IP) were 
performed on AML lysates using an anti-HSP27 antibody. Following IP, 
western blot analysis was performed with an anti-phosphoserine antibody (fig. 
5B and 5C). Figure 5B shows faint phosphorylation of HSP27 in untreated TF-1 
cells (lane 1). In the absence of HSP27 antibodies, HSP27 was not precipitated 
(lane 2). IL-1 treatment, a known activator of HSP27, resulted in a transient 
increase in HSP27 serine phosphorylation (lanes 3 and 4).117;348;349 The finding 
of phosphorylated and hence activated HSP27 in the TF-1 cell line is in 
accordance with the finding that it interacts with DAXX in these cells, since this 
phosphorylated dimer of HSP27 has been described to interact with DAXX.113 
Finally, figure 5C depicts the results of 6 AML cases. Case nine shows IL-1 
stimulated AML blasts as a positive control. These results demonstrate that 
HSP27 is phosphorylated in all AML cases studied irrespective of apoptotic 
sensitivity. 
 
The cyclin dependent kinase inhibitor p21Waf1/Cip1 is co-expressed with 
HSP27 in monocytic AML blasts and can block the enhanced VP-16-
induced apoptosis after HSP27 RNAi 
The variability in the results of the sensitivity of monocytic leukemic cells 
towards apoptotic stimuli might be related to other (more dominant) factors that 
affect the apoptotic process. As recently described and confirmed in this study 
(table 1, fig. 6A, similar to fig 4B, with western blot for p21), monocytic leukemic 
cells frequently express the cyclin dependent kinase inhibitor p21Waf1/Cip1 in the 
cytoplasm, which counteracts the effects of VP-16 on the apoptotic program.290 
In 70 % of the HSP27 expressing AML cases, p21 was co-expressed, whereas 
in the AML cases with no HSP27 expression, p21 was expressed in 40% of the 
cases, indicating that at least two proteins are protective in many monocytic 
leukemia’s. We therefore investigated whether p21 could inhibit the enhanced 
effect on VP-16-induced apoptosis after HSP27 RNAi by using western blot 
analysis for phosphorylated p38. TF-1 cells were virally transduced with an 
expression construct for cytoplasmic p21 (p21dNLS). This p21dNLS lacks the 
bipartite nuclear localization signal (NLS) and is therefore retained in the 
cytoplasm, where it has been shown to inhibit apoptosis.182;184;290 Figure 6B 
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demonstrates cytoplasmic localization of the p21 dNLS protein in TF-1 cells. 
These cells were transfected with HSP27 or GAPDH siRNAs and treated with 
VP-16 for 3 h. Cell lysates were prepared and subjected to western blot 
analysis for the activation of p38. Figure 6C demonstrates that HSP27 siRNAs 
reduced  HSP27 levels in both mock and p21 infected TF-1 cells and that p38 
phosphorylation is only increased in response to VP-16 treatment in mock 
transfected HSP27 siRNA TF-1 cells. (Compare lanes 2 and 4 with 6 and 8). 
These data suggest that cytoplasmic p21 can compensate for a lack of HSP27 















Figure 6 p21 is co-expressed with HSP27 and cytoplasmic p21 (p21dNLS) inhibits 
enhanced phosphorylation of p38 after RNA interference for HSP27 in response to VP-16. 
(A) Acute myeloid leukemic cells were isolated and cultured as described in material and methods. 
HSP27 (same as fig. 4A) and p21 expression was investigated using western blot analysis. (B) TF-
1 cells were virally transduced with pMSCV-p21dNLS and nuclear and cytoplasmic fractions were 
isolated as described in material and methods. Western blot analysis was performed on p21 to 
demonstrate cytoplasmic localization. Rb is shown to indicate proper fractionation. Actin is shown 
as loading control. (C) 4 days after transfection with either HSP27 RNAi or control GAPDH RNAi, 
TF-1 Mock or TF-1 p21dNLS cells were treated with VP-16 (20 µg/ml) for 3 hours and subjected to 
western blot analysis for phosphorylated p38 and HSP27. Actin is shown as loading control. A 










In this study we investigated the potential mechanisms by which HSP27 
modulates the apoptotic process in AML blast cells, since co-expression of 
HSP27 with additional proteins is linked to an unfavorable prognosis.341;342 Our 
results demonstrate lineage-restricted expression of HSP27 in normal 
hematopoietic cells and their malignant counterparts. Normal CD34+ cells and 
monocytes express high levels of HSP27, whereas in AML cells, HSP27 
expression is predominantly restricted to monocytic leukemia. HSP27 
appeared to be more expressed in more primitive leukemic progenitor cells, i.e. 
the CD34+/CD36- sorted cell fraction, as has been demonstrated for other anti-
apoptotic proteins,350 underscoring a functional relevance of HSP27 in the 
malignant stem cell compartment. 
 However, functional studies with VP-16 did not show a uniform response 
pattern in monocytic leukemia with regard to VP-16-mediated apoptosis, 
although HSP27 was phosphorylated in all AML cases. An explanation for this 
apparent discrepancy is the expression of additional anti-apoptotic proteins 
including p21Waf1/Cip1, which is cytoplasmic localized in monocytic leukemia and 
interferes with the VP-16-mediated p38 and c-Jun phosphorylation.290 
Overexpression of a cytoplasmic form of p21 in the TF-1 cell-line reversed the 
VP-16-induced effect seen on the activation of p38 after HSP27 RNAi, 
indicating that p21 can substitute for HSP27 as an anti-apoptotic factor. 
Functional studies demonstrate that HSP27 is an important anti-apoptotic 
factor in the VP-16-induced apoptotic process. Both VP-16 and CD95/Fas can 
induce apoptosis through the extrinsic signal transduction pathway .117;290 
Induction of apoptosis through this pathway involves translocation of the 
nuclear protein DAXX to the membrane, where it can bind to the cytosolic end 
of the CD95/Fas receptor.351 Following binding to the CD95/Fas receptor, 
DAXX binds to ASK1.117 ASK1 activation in turn leads to activation of the 
stress-activated protein kinase (SAPK, also known as JNK; c-Jun amino-
terminal kinase) and p38 subgroups of MAP kinases,115;347 which have also 
been described to occur upon VP-16 treatment.290 
 The results presented here indicate that HSP27 RNA interference resulted 
in enhanced phosphorylation of p38 and c-Jun (a target of JNK) in response to 
VP-16, but not to CD95/Fas stimulation. In addition, HSP27 RNA interference 
resulted in an increased release of cytochrome c to the cytoplasm, which has 
been shown to require ASK1/JNK activation.116;346;352 The kinetics of these 
results suggest that cytochrome c release is downstream of the 
DAXX/ASK1/JNK pathway. c-Jun and p38 phosphorylation are observed as 
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early as 1 to 3 hours after VP-16 treatment, followed at 5 hours by a release of 
cytochrome c to the cytoplasm. The sequential activation rather than parallel 
activation is confirmed by experimental evidence that ASK1-mediated 
apoptosis can be blocked by the mitochondrial pore opening inhibitor, 
cyclosporin A, whereas activation of p38 MAPK/JNK is left unaltered.353  
Complex formation between HSP27 and DAXX, as confirmed here, further 
underscores a role for HSP27 at the level of DAXX.113;114 Since HSP27-DAXX 
complex formation is ASK1-dependent, it is likely that HSP27 only interacts 
with DAXX when it acquires a proapoptotic function. This is consistent with a 
role for HSP27 in blocking DAXX translocation to the cytoplasm,113 where it 
exerts a proapoptotic function rather then a transcriptional regulatory 
function.354  
 Bcl-2 family members are known to play a role in mitochondrial integrity 
and cytochrome c release.355 DAXX/ ASK1 activation has been shown to 
inactivate the anti-apoptotic protein Bcl-2118 and activate pro-apoptotic proteins 
such as Bax, Bim and Bid356 (and references therein). HSP27 expression and 
hence DAXX/ASK1 inactivation might also influence the balance between pro-, 
versus anti-apoptotic signals at this level. Since HSP27 and Bcl-2 protect 
against apoptosis with different efficiencies and different pathways,357 more 
work needs to be done to clarify the similarities and differences in the affected 
signal transduction pathways. 
A different response pattern was observed with CD95/Fas. HSP27 levels were 
strongly upregulated by CD95/Fas in the studied cases. This elevated level of 
HSP27 subsequently prevented the phosphorylation of p38 and c-Jun. Despite 
the absence of p38 and c-Jun activation, CD95/Fas did induce apoptosis in TF-
1 cells to some extend, although not comparable to VP-16-induced levels (table 
1).  
 It is conceivable that CD95/Fas-induced apoptosis in TF-1 cells does not 
involve the DAXX pathway, but leads to FADD activation and cleavage of pro-
caspase-3.117 It has been demonstrated that overexpression of HSP27 inhibits 
DAXX-mediated apoptosis, but not CD95/Fas-induced FADD/caspase-
dependent apoptosis.113  Indeed, cleavage of pro-caspase-3 is observed after 
CD95/Fas treatment of the TF-1 cells, indicating that CD95/Fas is able to 
induce apoptosis without p38 and JNK activation.  
 Overall, these experiments indicate that HSP27 protects leukemic cells 
from VP-16-induced apoptosis through binding to DAXX and modulation of the 
activation of the p38/JNK pathways, whereas CD95/Fas-induced apoptosis is 
not affected, either through the upregulation of HSP27 or because of DAXX-
independent signaling through a FADD/caspase-dependent pathway. This 





activated47;290;294;341;342 and implicate that strategies should be designed in 
targeting multiple signal transduction pathways in order to treat this highly 
malignant disorder.  
 Recently it has been demonstrated that HSP27 confers resistance to the 
proteasome inhibitor Bortezomib/PS-341358 and blockade of HSP27 restores 
sensitivity towards Bortezomib/PS-341. A similar approach might be relevant in 
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Objective. To examine 1) whether oncogenic Ras affects TGF-β-mediated cell-
cycle arrest in hematopoietic cells; and 2) the downstream signal transduction 
pathway involved in the interference with TGF-β-induced cell-cycle arrest. 
Materials and methods. Two leukemic cell lines bearing N-RasL61 mutations; 
HL-60 and  TF-1, and the M1 cell line with wt Ras were investigated for their 
response to TGF-β. Signal transduction inhibitors, overexpression and RNA 
interference studies were performed to investigate the involvement of the 
various proteins. 
Results. Although TGF-β signal transduction was not affected, G0-G1 arrest 
was absent in HL-60 and TF-1 cells due to the absence of p27. Overexpression 
of p27 restored TGF-β-induced cell-cycle arrest, as well as interfering in Ras-
mediated signaling. The farnesyl transferase inhibitor L744832 and the MEK 
inhibitor U0126 both restored p27 levels and cell-cycle arrest in response to 
TGF-β. The absence of p27 protein is due to elevated levels of the ubiquitin 
ligase SKP2, which complexes with and targets p27 for degradation. RNAi for 
SKP2 and treatment of these cells with the proteasome inhibitor MG132 
restored p27 levels, corresponding with decreasing SKP2 levels after 
interfering in N-Ras signal transduction. P27, phosphorylated at threonine 187, 
is nuclear localized in N-Ras containing cells. Mutation of this residue to 
alanine rendered p27 insensitive to degradation.  
Conclusion. 1) N-RasL61 transformed cells lack a G0-G1 arrest upon TGF-β 
treatment due to absence of p27. 2) p27 is degraded through a MapK-, and 
SKP2-dependent pathway. 3) Overexpression of p27 results in restoration of 
cell cycle arrest upon TGF-β treatment. 
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Introduction 
 
Transforming growth factor-β (TGF-β) and Ras-signal transduction have 
opposite effects on cell proliferation. Where Ras and downstream MEK/Erk 
(mitogen activated protein kinase / extracellular signal regulated kinase kinase) 
signaling are induced in response to growth promoting factors,268;359 cell growth 
is arrested in response to TGF-β.158-160 Binding of TGF-β to its receptor leads to 
the activation of Smad proteins and modulates the transcription of many target 
genes, including genes that affect cell fate.158;159 
 TGF-β-induced cell cycle arrest is mediated by various Cyclin Dependent 
Kinase inhibitors (CDKi) including p15Ink4B,164;165 p21Waf1/Cip1,166;167 p27Kip1 168;169 
and p57Kip2.170 Furthermore, the expression and activity of additional proteins 
such as c-Myc, cyclin A, CDK4/6 and the phosphatase cdc25A are suppressed 
by TGF-β.171;172 These events eventually lead to decreased activity of the 
Cyclin D-CDK4/6 and Cyclin E-CDK2 complexes and ultimately result in cell 
cycle arrest.  
 One of the key intermediates in TGF-β-induced cell cycle arrest is the CDKi 
p27Kip1 and alterations in protein levels or localization interfere with the 
inhibitory activity on CDK2 and TGF-β-induced cell cycle arrest.171;360-362 
Regulation of p27 is primarily controlled by phosphorylation and subsequent 
degradation or proteolysis by two distinct pathways. Phosphorylation of p27 on 
Threonine residue 187 by the CDK2-Cyclin E complex targets p27 for 
ubiquitination in the nucleus by the E3 ubiquitin ligase SKP2.363-369 This 
ubiquitinated p27 is then degraded by the 26S proteasome.367;368;370 
Phosphorylation of p27 on other residues, such as Serine 10, Threonine 157 
and Threonine 198, leads to cytoplasmic translocation where p27 is either 
degraded or stabilized.371-377 Cytoplasmic p27 has no inhibitory effect on the 
cell cycle. 
 Besides inactivating mutations in the TGF-β receptors or Smad proteins,158 
TGF-β-mediated cell cycle arrest can be blocked by oncogenic Ras. This has 
been attributed to Map Kinase-dependent phosphorylation of Smad 2/3 and 
subsequent impaired nuclear translocation, degradation of Smad 4, or 
mislocalization of p27 to the cytoplasm.171;178;179  
 In Acute Myeloid Leukemia (AML), cytoplasmic mislocalization of p27 is 
associated with constitutive Akt phosphorylation and unfavorable prognosis.155 
In addition, Akt phosphorylation might depend upon Ras activation.294 Based 
on these data it is conceivable that oncogenic Ras, which is frequently mutated 
in AML, renders hematopoietic cells insensitive to TGF-β treatment through 





 In this report we demonstrate that the leukemic cell lines TF-1 and HL-60, 
bearing oncogenic N-RasL61 mutations, are insensitive to TGF-β with regard to 
cell cycle arrest. Surprisingly, instead of p27 mislocalization to the cytoplasm, 
we found that these leukemic cell lines were devoid of p27. A 
Ras/MEK/Erk/SKP2-dependent mechanism is responsible for the degradation 
of p27 and overexpression of p27 in these cells restored TGF-β-induced cell 
cycle arrest.   
 
 
Materials and methods 
 
Cell culture, (viral) vectors, and transfections - The human and mouse 
myeloblastic cell lines HL-60 (ATCC, Manassas, VA, USA, Product No. CCL-
240) and M1 (ATCC, Product No. TIB-192) were cultured in RPMI 1640 
(Biowhittaker, Verviers, Belgium) supplemented with 100 U/ml penicillin, 100 
µg/ml streptomycin (ICN Biomedicals, Costa Mesa, CA, USA) and 10% FBS 
(Fetal Bovine Serum) (Bodinco, Alkmaar, the Netherlands). The human 
erythroleukemia cell line TF-1 (ATCC, Product No. CRL-2003) was cultured in 
RPMI 1640 supplemented with 10% FBS and 10 ng/ml GM-CSF (granulocyte 
monocyte-colony stimulating factor; Genetics Institute, Cambridge, MA, USA).  
pBabe FLAG-27 was constructed by ligating the EcoRI-XhoI fragment of 
pCDNA3 FLAG-p27 into the pBabe-Ires-GFP puro plasmid. TF-1 cells were 
transduced with viral particles collected from Phoenix cultures transfected with 
pCL-AMPHO and pBabe Flag-p27 using FuGENE6 (Roche, Almere, The 
Netherlands). Cells stable expressing FLAG-p27 were continuously selected 
with 1 μg/ml puromycine (Sigma, St. Louis, MO, USA).  
 TF-1 cells were electroporated (960 μF, 240V) with 15 μg of pCMV Tag2B 
or pCDNA3 FLAG wt p27 or S10A, T157A, S161A, T162A, S178A or T187A 
mutant p27 in order to study degradation. 
 HL-60 and TF-1 cells were either mock electroporated (960 μF, 240V) or 
(1) with  12.5 μg pGAL4-Elk1, 12.5 μg pGAL4-TK-luc and 5 μg pDM2-LacZ for 
the Elk-Gal4 transactivation assay, (2) with 12.5 μg 7x SBE (smad binding 
element) Luciferase and 12.5 μg pDM2-LacZ for the TGF-ß reporter assay or 
(3) with the p27GL-1609 reporter plasmid 378 in order to study p27 transcription. 
All reporter transfections were collected in 100 μl reporter lysis buffer (Promega 
Corp, Leiden, the Netherlands) and subjected to luciferase and β-galactosidase 
assays as previously described.379 
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Reagents and antibodies - The p16, p27(C-19), p57(C20), P-p27 Ser10, Erk 
(K-23), N-Ras(C20), Rb(C15) and Smad4, antibodies were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Smad3, SKP2, p27 and P-
p27 Thr187 were purchased from Zymed Laboratories (South San Francisco, 
CA, USA). P-Erk antibody was obtained from New England Biolabs (Beverly, 
MA, USA). Flag antibody, p21 antibody and an antibody against Actin (C4) 
were respectivily obtained from Sigma, Transduction Laboratories (Lexington, 
KY, USA) and ICN Biomedicals. All antibodies were reactive for both human 
and mouse isoforms. Horse radish peroxidase (HRP)-labeled secondary 
antibodies were obtained from DAKO (Glostrup, Denmark). The farnesyl 
transferase inhibitor L744832 and the MAP kinase/ERK kinase (MEK) 1 
inhibitor U0126 were obtained from Biomol (Plymouth Meeting, PA, USA) and 
Promega Corp. respectivily. TGF-β was purchased from R&D systems 
(Minneapolis, MN, USA). MG132 was obtained from Calbiochem (Darmstadt, 
Germany). Nocodazole, Actinomycin D, Cycloheximide, Puromycin, RNase A, 
Propidium Iodide and Triton X-100 were obtained from Sigma. Sodium citrate-
dihydrate was purchased from Merck (Darmstadt, Germany). 
 
Ras binding reaction - TF-1, HL-60 and M1 cells (5x106) were incubated in 2 ml 
RPMI 1640 medium supplemented with 0.5% FBS for 24 hours. Cells were 
lysed in 400 µL lysis buffer and a Ras binding reaction was performed as 
previously described.294  
 
Mutation analysis of N-Ras - Mutation analysis of N-Ras was performed by 
single-strand conformation polymorphism (SSCP). Genomic DNA was 
extracted from HL-60 and TF-1 cells and PCR analysis was performed as 
previously described.40;294  
 
Preparation of protein extracts and Western blot analysis - The amount of p27, 
p21, p16, p57, Erk, SKP2, Ras, FLAG, Smad3, Smad4 and actin and the 
degree of phosphorylated p27 and Erk were determined by western blotting on 
whole cell extracts, cytoplasmic or nuclear extracts. Total cell extracts were 
prepared by resuspending the cells in lysisbuffer (20 mM TrisHCl pH 7.6, 100 
mM NaCl, 10 mM EDTA, 1% NP-40, 10% glycerol, 2 mM Na3VO4, 2 mM 
PMSF, 1 µM pepstatin and 1 mM DTT) and kept for 15 min on ice.  
 For cytoplasmic and nuclear extracts, cells were lysed according to the 
“mini extracts” method.273 All extracts were normalized for protein content prior 





Proper fractionation and lack of leakage of nuclear proteins to the cytosol was 
determined with western blotting for the nuclear protein Retinoblastoma (Rb).  
 
Immunoprecipitation - 2x107 cells were cultured for 24 hours in RPMI 1640 
medium supplemented with 10% FBS. Cells were washed with ice-cold PBS 
and subsequently lysed in 500µl lysis buffer (20 mM TrisHCl pH 7.6, 100 mM 
NaCl, 10 mM EDTA, 1% NP-40, 10% glycerol, 2 mM Na3VO4, 2 mM PMSF, 1 
µM pepstatin and 1 mM DTT) for 10 min on ice. Cell lysates were clarified at 5 
000g for 10 min and after preclearing with 30 µl Protein A Sepharose beads for 
1 hour at 4°C, cell lysates were incubated with 5 µL SKP2 or p27 antibody 
(Zymed) and rotated for 4 hours at 4°C. Protein A sepharose beads (30 µl) 
were added to each sample and incubated for 16 hrs at 4°C. The immune 
complex was washed 3 times with lysis buffer. The immune complexes were 
heated in sample buffer, separated by SDS PAGE, immunoblotted on PVDF 
membrane (Millipore) and incubated for 16 hrs with either anti-SKP2 or anti-
p27 antibody. Immunocomplexes were detected using ECL. 
 
FACS analysis - TF-1, HL-60 and M1 cells were synchronised with 0.33 μM 
Nocodazole. After 16 hours cells were washed 3 times and plated at 
0.25*106/1.5 ml and treated with TGF-ß (2 ng/ml), 0.001% DMSO, U0126 (10 
μM) or L744832 (50 μM) as indicated. After 72 hours cells were washed and 
incubated with Propidium Iodide (PI) solution (0.1 μg/μl RNase A, 0.96 mg/ml 
Sodium citrate-dihydrate, 0.02 μg/μl PI, 0.1 % Triton X-100) for 20 minutes at 
room temperature. Binding of Propidium Iodide was measured using FACS 
(fluorescence-activated cell sorting) (Becton Dickinson, Sunnyvale, California, 
USA) and cell cycle analysis was performed using ModFit LT. 
 
Quantitative PCR - RNA extraction, preparation of cDNA and Quantitative PCR 
(Q-PCR) for Smad7, SnoA, SKP2, p15, p18 and p27 were performed as 
previously described.290 Primers used: Smad7 For gcctcggacagctcaattcg; 
Smad7 Rev cgtccacggctgctgcataa; SnoA For cattctcacagatcacctgac; SnoA Rev 
gtcttacttctctcacaggatg; SKP2 For ccagcaagacttctgaac; SKP2 Rev 
ggaggcacagacaggaaa; p15 For cgcgaggagaacaagggcat; p15 Rev 
gcctcccgaaacggttgact; p18 For gattgccaggagactgctac; p18 rev 
cgtgtgcttcaccaggaact; p27 For gcaaccgacgattcttctac; p27 Rev 
gtccattccatgaagtcagc; HPRT For tggcgtcgtgattagtgatg; HPRT Rev 
gatgtaatccagcaggtcag. Primers for SKP2 and the cyclin dependent kinase 
inhibitors were designed against conserved regions between the human and 
mouse genes. Primers for Smad7 and SnoA are human specific. 
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RNA interference - Short interfering RNA duplexes for SKP2 were made using 
the Silencer siRNA construction kit from Ambion according to the 
manufacturers protocol (Austin, Texas, USA). The SKP2 target sequences 
used: AAAGAGGAGCCCGACAGTGAG and AAGTTGCAGAATCTAAGCCTG. 
GAPDH control siRNA duplexes are provided within the kit. TF-1 cells were 
transfected with a final concentration of 50 nM or 100 nM of RNAi duplexes 
using oligofectamine according to the manufacturer’s protocol (Invitrogen, 
Breda, The Netherlands). Lysates were made on the indicated time points in 
lysisbuffer and equal amounts of protein were subjected to western blot 
analysis. 
 
Statistical analysis - The student’s t-test for paired samples was used to 





p27 expression and TGF-ß-induced cell-cycle arrest in cells containing 
oncogenic Ras 
The human myeloid leukemic cell line HL-60 and the erythroleukemic cell line 
TF-1, which have been reported to contain oncogenic N-Ras mutations,294;380 
were studied with respect to TGF-β-mediated cell cycle arrest. As a negative 
control, the myeloid cell-line M1 was used, since this cell line contains wt Ras. 
SSCP analysis confirmed that HL-60 and TF-1 cells are heterozygous for the 
N-RasL61 mutation (data not shown). To determine whether Ras is activated in 
these cells, we performed Ras-pull down assays and determined activation of 
the downstream effector Erk268 (fig.1A). In HL-60 and TF-1 cells activated Ras 
and phospho-p42/44 (P-Erk) were observed, both of which were absent in M1 
cells, although antibodies were capable of recognizing mouse isoforms (Ras 
input lane and Erk, data not shown). To test the effect of TGF-β on the cell-
cycle, cells were synchronized by nocodazole treatment for 16 hours and 
subsequently cultured in the absence or presence of TGF-β. FACS analysis 
demonstrated a minor or no increase in the percentage of cells in G0-G1 phase 
of the cell-cycle in response to TGF-β (HL-60: 46.3 ± 0.7 vs. 53.1 ± 0.4; TF-1: 
42.9 ± 1.2 vs. 42.1 ± 0.4) (fig. 1B). This in contrast to the M1 cell line, which 
demonstrates an increase of cells in G0-G1 phase from 48.9 ± 0.5 % to 76.4 ± 





 Next, western blot analysis was performed in order to determine whether 
the absence of cell cycle arrest in the oncogenic Ras containing cells is related 
to p27 dysfunction.171 In M1 cells, p27 was located in the nuclear compartment 
(data not shown and box fig. 7B). In contrast, no p27 expression was observed 
in the N-Ras containing HL-60 and TF-1 cells (fig. 1A). To exclude cell-cycle-
dependent regulation of p27, presence of p27 was analyzed for all cell cycle 
phases after synchronisation. As expected, M1 cells show a cell-cycle-
dependent regulation of p27, whereas p27 is absent in all cell-cycle phases in 
the HL-60 and TF-1 cell line (data not shown). These observations suggest that 
the absence of p27 in cells containing N-Ras mutations might be involved in 








Figure 1 Cells containing N-Ras mutations are unresponsive to TGF-β and are devoid of 
p27.  
(A) TF-1, HL-60 and M1 cell extracts were western analyzed for activated Ras, P-Erk and p27. 
After synchronisation, cells were harvested and lysed in lysis buffer and a Ras binding reaction was 
performed as described in material and methods. Ras denotes activated Ras which is precipitated 
with Raf-GDS glutathione-S-transferase-Ras binding domain (GST-RBD) precoupled to 
glutathione-sepharose beads. Total lysates show amounts of P-Erk, Ras, Actin and p27 before 
precipitation. (B) M1, HL-60 and TF-1 cells were synchronized in M-Phase with Nocodazole and 
subsequently cultured with or without TGF-ß as indicated. After 72 hours, cells were washed and 
incubated with Propidium Iodide (PI) solution. Binding of PI was measured using fluorescence-
activated cell sorting and cell cycle analysis was performed using ModFit LT. The % of cells in G0-
G1 phase is depicted as mean % G0-G1 ± standard deviation. 
 
TGF-ß signal transduction is not impaired in cells with oncogenic Ras 
First we determined whether HL-60 and TF-1 cells are able to respond to TGF-
β or whether the decreased cell cycle arrest is due to the absence of p27. 
Although oncogenic Ras has been described to be involved in degradation of 
Smad 4,178 figure 2A depicts that Smad 4 protein is present in the HL-60 and 
TF-1 cell lines in comparable levels as in M1 cells.  
 In addition, TGF-β signal transduction can be inhibited by modulating the 
cytoplasmic to nuclear translocation of Smad 2/3 through an Erk 1/2-dependent 
mechanism,179 which has been described to be activated by Ras in 
hematopoietic cells.268 In the N-Ras-containing cells, Smad 3 nuclear 
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accumulation was observed in response to TGF-β treatment (fig. 2B), indicating 
that Ras does not interfere with cytoplasmic to nuclear shuttling of Smad 3.  
Finally, TGF-β responsive target genes (including Smad 7 and SnoA) were 
studied by means of Quantitative PCR (Q-PCR) (fig. 2C). In both HL-60 and 
TF-1 cells, TGF-β treatment resulted in an increased expression of these target 
genes. This observation was confirmed by a TGF-β reporter assay, where HL-
60 and TF-1 cells were transfected with a reporter construct containing 7 
copies of a Smad responsive element (7X SBE-luciferase). Upon TGF-β 
treatment, transactivation of this reporter was observed in both cell lines (fig. 
2D). In conclusion these data show that Smad-mediated TGF-β signaling is 
normal in these N-Ras containing cells. 
 
 
Figure 2 TGF-β signal transduction is normal in N-Ras containing HL-60 and TF-1 cells.  
(A) Smad 4 expression in M1, HL-60 and TF-1 cells. After 24 hours of culture, cell extracts were 
subjected to western blot analysis for Smad 4 and Actin. (B) Smad 3 shows nuclear localization 
after 30 minutes of TGF-β treatment. HL-60 and TF-1 cells were treated with or without 2 ng/ml 
TGF-β. Nuclear fractions were isolated and subjected to western blot analysis for Smad 3 and 
Actin. (C) TGF-β activates transcription of target genes in HL-60 and TF-1 cells. Cells were 
cultured with 2 ng/ml TGF-β for 1 hour and cDNA was prepared as described. Q-PCR for Smad 7 
and SnoA was performed and normalized against expression of the common house hold gene 
HPRT. Fold inductions are presented as sample means ± standard deviation relative to untreated 
samples. (D) TGF-β transactivates transcription from a 7X SBE (Smad Binding Element)-luciferase 
construct. HL-60 and TF-1 cells were electroporated with a 7x SBE Luciferase vector and pDM2-
LacZ. After 24 hours, cultures were split in two and treated for 16 hrs with or without 2 ng/ml TGF-
β. Cell extracts were subjected to luciferase and β-galactosidase assays as described. Luciferase 
values were normalized against β-galactosidase activity and fold inductions are presented as 








Oncogenic Ras regulates  p27 through a MEK/Erk –dependent pathway  
To demonstrate a connection between Ras signal transduction and the 
absence of p27 expression, TF-1 and HL-60 cells were treated with inhibitors of 
the Ras (L744832) and MEK/Erk (U0126) pathways. As depicted in figure 3A, a 
reappearance of p27 expression in TF-1 and HL-60 cells is observed in the 
presence of inhibitors U0126 and L744832. The effectivity of the inhibitors was 
confirmed by reduced phosphorylation of Erk 1/2 (fig. 3A and densitometry fig. 
3B) and reduced downstream Elk signaling, as investigated by an Elk-Gal4 
transactivation assay (fig. 3B). 
 
Figure 3 Inhibition of MapK and Ras 
signal transduction restores p27 levels in 
TF-1 and HL-60 cells.  
(A) Treatment with U0126 and L744832 
restores p27 protein levels in TF-1 and HL-60 
cells. Cells were cultured for 16 hrs in the 
presence of 10 μM U0126 or 50 μM L744832. 
Cell extracts were subjected to western blot 
analysis for P-Erk, Total Erk and p27. (B) 
Densitometry of P-Erk and Elk reporter 
activity indicate inhibition of Ras/ MapK 
signaling by U0126 and L744832. White bars 
indicate P-Erk densitometry belonging to 
fig.3A. Black bars indicate normalized Elk 
reporter luciferase activity against β-
galactosidase activity. HL-60 and TF-1 cells 
were either mock electroporated or with 
pGAL4-Elk1, pGAL4-TK-luc and pDM2-LacZ 
for the Elk-Gal4 transactivation assay. Fold 
inductions are presented as sample means ± 
standard deviation relative to untreated 
samples. 
 
In order to demonstrate that the effect of Ras/MEK/Erk signaling is specific for 
the p27 protein, additional CDKi’s were studied. The CDKi p21Waf1 is absent in 
unstimulated hematopoietic cells,290 which was confirmed for the HL-60 cell 
line. Upon treatment with U0126 no change in the expression of p21 protein 
was observed (fig. 4). TF-1 cells express p21Waf1 (fig. 4, first lane), which 
disappears in the presence of U0126, while no change was observed in the 
expression of the CDKi p57Kip2, as is the same for HL-60 cells (fig. 4). The 
expression of the CDKi p16INK4a is absent in HL-60 cells, without changes upon 
U0126 treatment, whereas in TF-1 cells p16 protein is expressed, which 
appears to decrease slightly upon U0126 treatment (fig. 4). Q-PCR analysis for 
the expression of the CDKi’s p15INK4b and p18INK4c demonstrated no significant 
changes upon U0126 treatment (data not shown).  
 Although some changes are observed for p21 and to a lesser extend p16 
upon U0126 treatment, the most prominent effect was observed on p21 
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expression levels which were strongly reduced by U0126 treatment and this 
would positively affect cell cycle progression. In conclusion, these data strongly 
suggest that the blockade of TGF-β-induced cell cycle arrest by Ras/MEK/Erk 
signaling in TF-1 and HL-60 cells is mediated through modulation of the p27 
expression levels, since none of the other CDKi’s is upregulated after U0126 
treatment.  
 
Figure 4 Inhibition of MapK signal transduction does not 
upregulate other cyclin dependent kinase inhibitors.  
The CDKi p21 disappears upon U0126 treatment and the 
expression of the CDKi’s p16 and p57 is not changed upon 
treatment with U0126. TF-1 and HL-60 cells were cultured for 16 
hrs in the presence or absence of 10 μM U0126. Cell extracts were 
subjected to western blot analysis for p21, p57, p16 and Actin. 
 
TGF-ß-mediated cell-cycle arrest is restored after U0126 and L744832 
treatment and is p27 dependent 
To demonstrate that the reappearance of p27 is associated with TGF-β 
mediated cell cycle arrest, TF-1 cells were stimulated with TGF-β in the 
presence of U0126 or L744832. A significant increase in the percentage of 
cells in G0-G1 phase (fig. 5A, 13.6 % and 7.2 % respectively, * and ** = 
p<0.05) was demonstrated by FACS analysis.  
 To study the specificity of this effect, a TF-1 cell culture was generated in 
which the cells stably express p27 through retroviral transduction with pBabe-
Flag-p27. In these cells, cell cycle analyses were performed with TGF-β in the 
absence and presence of the MEK/Erk inhibitor U0126. Mock (pBabe) 
transfected TF-1 cells have a minor increase in the percentage of cells in G0-
G1 phase after TGF-β treatment (fig. 5B, 7.2 %, p<0.05) and this increase can 
be enhanced by inhibiting the MEK/Erk pathway (20.8 %, ● = p<0.05). TF-1 
cells expressing pBabe-Flag-p27 already show an almost twofold increase in 
the percentage of cells in G0-G1 phase (21.6 %, ●● = p<0.01) in response to 
TGF-β, which was not further enhanced by U0126 treatment (18.3 %, ●●● = 
p<0.01) (fig. 5B). These results clearly indicate that the presence of p27 is 
sufficient to increase the percentage of cells in G0-G1 phase upon TGF-β 
treatment, although the percentages of untreated cells in G0-G1 phase varied 
between the different studied groups. Together, these data demonstrate that 
oncogenic Ras inhibits TGF-β-mediated growth arrest through modulation of 









Figure 5 TGF-β-mediated cell cycle arrest is p27 dependent and can be restored by 
inhibition of MapK and Ras signal transduction.  
(A) TGF-β-mediated cell cycle arrest can be restored upon inhibition of the MapK and Ras signal 
transduction pathways. TF-1 cells were synchronized in M-Phase and subsequently cultured with 
or without TGF-ß in the presence of DMSO, U0126 or L744832 as described. After 72 hours, cells 
were washed and incubated with PI solution. Binding of PI was measured using fluorescence-
activated cell sorting and cell cycle analysis was performed using ModFit LT. The % of cells in G0-
G1 phase is depicted as mean % G0-G1 ± standard deviation. * and ** = p<0.05 (B) Stable 
overexpression of FLAG-p27 is sufficient to restore TGF-β-mediated cell cycle arrest. TF-1 cells 
were either mock (pBabe) stable transfected or with pBabe-FLAG-p27 and selected for positive 
cells with puromycin. The cells were synchronized in M-Phase and subsequently cultured with or 
without TGF-ß or U0126. After 72 hours, cell cycle analysis was performed as described above. 
The % of cells in G0-G1 phase is depicted as mean % G0-G1 ± standard deviation. * and ● = 
p<0.05, ●● and ●●● = p<0.01. Cell extracts were also subjected to western blot analysis for FLAG 
and Actin. 
 
p27 is not regulated at the transcriptional level, but at the degradation 
level 
p27 protein levels can be regulated at different levels e.g. transcription, 
translation or degradation.381 To study how p27 protein levels are modulated, 
cells were pre-treated with the RNA polymerase II inhibitor Actinomycin D. 
Although Actinomycin D was effective since it completely blocked TGF-β-
induced transcription of Smad 7 (fig. 6B), p27 still reappeared after U0126 and 
L744832 treatment (fig. 6A, middle panel, compare with left panel, the control 
for p27 reappearance). No significant upregulation of p27 transcription after 
U0126 treatment was observed with Q-PCR studies for p27 mRNA, which was 
confirmed by reporter assays with the p27GL-1609 construct378 in the TF-1 and 
HL-60 cells (data not shown).  
 Treatment with the proteasome inhibitor MG132 induced reappearance of 
the p27 protein (fig. 6A, right panel), suggesting that oncogenic Ras regulates 
p27 protein levels through degradation. In view of these data, the mRNA and 
protein expression levels of SKP2, the E3 ubiquitin ligase of p27, were 
analyzed. As depicted in figure 6C and D, in the HL-60 and TF-1 cell lines 
SKP2 expression levels are 4-fold increased as compared to M1 cells.  
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Subsequently we determined whether Ras signaling enhanced SKP2 levels via 
an Erk-dependent pathway resulting in p27 degradation. Treatment of HL-60 
cells with the Ras inhibitor L744832 resulted in reduced levels of 
phosphorylated Erk, downregulation of SKP2 expression and the reappearance 
of p27 protein (fig. 6E). In addition, M1 cells transiently transfected with 
pCDNA3-Myc-N-RasL61 demonstrated higher SKP2 protein levels than mock 
transfected control cells (fig. 6F). These data suggest that oncogenic Ras 
promotes p27 degradation through the activation of Erk and subsequent 






















Figure 6 p27 is not regulated at the transcriptional level but at the degradational level in N-
Ras containing cells and SKP2 is regulated by a Ras dependent pathway.  
(A) Actinomycin D does not affect p27 restoration after U0126 and L744832 treatment and p27 
levels are restored after treatment with the proteasome inhibitor MG132. TF-1 cells were cultured 
for 16 hrs in the presence or absence of U0126, L744832 or 0.25 μM MG132 with or without 0.50 
μg/ml Actinomycin D. Cell extracts were subjected to western blot analysis for p27 and Actin. (B) 
Actinomycin D is effective in blocking TGF-β-induced transcription of Smad 7. TF-1 cells were 
cultured with 2 ng/ml TGF-β for 1 hour, with or without pre-treatment with 0.50 μg/ml Actinomycin 
D. cDNA was prepared as described and Q-PCR for Smad 7 was performed and normalized 
against expression of  the common house hold gene HPRT. Fold inductions are presented as 
sample means ± standard deviation relative to untreated samples. (C) Q-PCR for SKP2 indicates 
higher mRNA levels in N-Ras containing HL-60 and TF-1 cells. Cells were cultured and cDNA was 





common house hold gene HPRT. Fold inductions are presented as sample means ± standard 
deviation relative to M1 control cells. (D) Western blot analysis for SKP2 indicates higher protein 
levels in N-Ras containing HL-60 and TF-1 cells. Cells were cultured and cell extracts were 
subjected to western blot analysis for SKP2 and Actin. (E) Inhibition of Ras signal transduction 
decreases P-Erk and SKP2 levels and increases p27 levels. HL-60 cells were cultured with or 
without L744832. After 16 hours, cells were lysed and cell extracts were subjected to western blot 
analysis for P-Erk, total Erk, SKP2 and p27. (F) Overexpression of Myc-tagged N-RasL61 increases 
SKP2 levels. M1 cells were transiently co-transfected with GFP and mock or pCDNA3-Myc-N-
RasL61. After 24 hours, GFP+ cells were sorted on a MoFlo cell sorter. Equal amounts of cells were 
lysed and cell extracts were subjected to western blot analysis for Myc-N-Ras, SKP2 and GFP. 
 
p27 regulation involves degradation 
Degradation of p27 has been described to involve two mayor steps, 
phosphorylation and ubiquitinylation.363 Phosphorylation of p27 at Threonine 
187 has been shown to occur through Cyclin E/CDK2 complexes in the 
nucleus, followed by binding of the F-box protein and E3 ubiquitin ligase 
SKP2.364-368 Phosphorylation of p27 at Serine 10 also has been shown to occur 
by a yet unknown kinase, followed by nuclear export and degradation in the 
cytoplasm.375;376;382-384 In order to investigate the mechanism involved in p27 
degradation in N-Ras containing cells, alanine point mutants from known and 
putative phosphorylation sites, were transiently transfected into TF-1 cells. 
After 24 hours, cultures were split and treated with U0126 (fig. 7A). Although to 
slightly different levels, treatment with U0126 resulted in reappearance of 
wildtype (Wt) and all p27 point mutants proteins. Strikingly, the p27T187A mutant 
was resistant to degradation in TF-1 cells (fig. 7A, upper and lower panel), 
indicating that this phosphorylation site is relevant for p27 degradation in the 
presence of oncogenic Ras.  
 Subsequently, the degradation of p27 was studied in more detail. Virally 
transduced Flag-p27 TF-1 cells were treated with both the proteasome inhibitor 
MG132 and the translation inhibitor cycloheximide. This provides the 
opportunity to investigate steady state levels of p27 in the cell. In addition, it is 
possible to study whether p27 is phosphorylated and whether degradation of 
p27 is a nuclear event.  
 After 18 hours of culture, p27, phosphorylated at serine 10 and threonine 
187, was confined to the nuclear compartment without modulation by U0126 
treatment (fig. 7B). In addition, Flag-p27 was only detected in the nuclear 
compartment (fig. 7B), suggesting that the degradation of p27 occurs solely in 
the nucleus and no nuclear to cytoplasmic translocation takes place. The box 
next to panel B demonstrates the absence of p27 in both nuclear and 
cytoplasmic fractions in untreated parental TF-1 cells. M1 cells are shown as 
control. Moreover, these findings implicate that the phosphorylation of T187 is 
a pre-requisite for p27 degradation, but it is unlikely to be the cause of 
degradation. It is more conceivable that the elevated SKP2 levels are 
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connected with the increased degradation of p27. Subsequently, co-
immunoprecipitation studies were performed in the virally transduced Flag-p27 
TF-1 cell line, to demonstrate complex formation between p27 and SKP2. 
Indeed, p27 can be precipitated with SKP2 (fig. 7C, left panel), and vice versa 
SKP2 precipitates with p27 (right panel), indicating that these two proteins are 
in the same complex in the TF-1 cell line.  
Finally, to study whether SKP2 is involved in p27 degradation in N-Ras 
containing cells, RNA interference (RNAi) studies for SKP2 were performed in 
the TF-1 cell line. Knockdown of SKP2 resulted in a reappearance of p27 
protein, without an effect on GAPDH or actin levels (fig. 7D). Conversely, short 
interfering RNA (siRNA) oligos for GAPDH only affect GAPDH expression 
levels and had no effect on p27. These data further support a role for SKP2 in 
p27 degradation. 
 
Figure 7 p27 protein is degraded in a Phospho Threonine 187/SKP2-dependent manner.  
(A) Mutant p27T187A is resistant to degradation. TF-1 cells were electroporated with pCMV Tag2B or 
pCDNA3 FLAG wt p27 or S10A, T157A, S161A, T162A, S178A or T187A mutant p27. After 24 
hours, cultures were split in two and for 16 hrs treated with or without U0126. Cell extracts were 
subjected to western blot analysis for FLAG and Actin. (B) p27 is phosphorylated on S10 and T187 
and is specific nuclear localized. Stable expressing pBabe-FLAG-p27 TF-1 cells were cultured for 
16 hrs in the presence of 0.25 μM MG132 and 100 μg/ml Cycloheximide (CHX) with or without 10 
μM U0126. Cytoplasmic and nuclear fractions were isolated and subjected to western blot analysis 
for Flag p27, phospho Ser10 p27, phospho Thr187 p27, Rb and Actin. The box demonstrates the 
absence of p27 from both nuclear and cytoplasmic fractions in TF-1 cells. M1 cells are shown as a 
control. (C) SKP2 and p27 form a complex in N-Ras containing TF-1 cells. Stable expressing 
pBabe-FLAG-p27 TF-1 cells were cultured for 16 hrs and cell extracts were subjected to co-
immunoprecipitation (IP) studies between SKP2 and p27 as described in material and methods. 
The precipitates were subjected to western blot analysis for SKP2 or p27. IP indicates samples 
subjected to IP procedure, total indicates samples before IP procedure and beads indicates IP 
procedure without antibody to exclude aspecific binding (D) p27 protein is reappearing after RNA 
interference for SKP2. TF-1 cells were transfected with siRNA oligos for SKP2 and GAPDH as 
described and at the indicated time points cell were lysed and extracts were subjected to western 







Loss of responsiveness to anti-proliferative signals of growth factors, such as 
TGF-ß, might provide a growth advantage to malignant cells.385 Here we show 
that leukemic cells that carry an oncogenic N-RasL61 mutation escape TGF-ß-
mediated cell cycle arrest through nuclear degradation of the cyclin dependent 
kinase inhibitor p27Kip1/Waf1 in a Ras/MEK/Erk/SKP2-dependent manner. This 
finding highlights an alternative pathway that results in TGF-β 
unresponsiveness. Among these alternative pathways are phosphorylation of 
Smad 3 and subsequent inhibition of nuclear translocation of this protein,179 the 
degradation of Smad 4178 and mislocalization of p27 to the cytoplasm.171 
 In this study we demonstrate that cells with N-Ras mutations have elevated 
SKP2 protein levels, a link that has been observed before.386 In other cellular 
settings SKP2-independent regulation of p27 has been reported, that coincided 
with Erk activation and involved translocation of p27 to the cytoplasm.387 
Phosphorylation on different residues has been demonstrated to be involved in 
cytoplasmic localization and or stabilization of p27, e.g. Serine 10, Threonine 
157 and Serine 178.372;374;375;388 In our experiments we observed that alanine 
point mutants of S10 and S178 are upregulated to higher levels then other 
mutants by U0126 treatment (fig. 7A), suggesting additional cytoplasmic 
degradation routes of p27. However, we show that p27 is not translocated to 
the cytoplasm, even though p27 is phosphorylated on residue S10 (fig. 7B). 
The observed differences in expression between the various alanine point 
mutants are therefore likely to be the results of different transfection 
efficiencies. The only phosphorylation mutant that was resistant to degradation 
was the p27T187A mutant, suggesting SKP2-dependent nuclear degradation.363-
368;375;376;384 However, inhibition of the MEK/Erk pathway did not modulate the 
phosphorylation of the T187 residue, suggesting that p27 phosphorylation is a 
pre-requisite for binding to SKP2, but not the primary cause for the degradation 
process. Upregulation of SKP2 expression and binding to p27 in the nucleus 
seems to be the primary cause of the increased degradation of p27. The 
observed difference between our results and additional studies387 is therefore 
likely to be cell type dependent. 
 Recently, TGF-β was demonstrated to destabilize SKP2 by ubiquitin-
mediated proteolysis and decreased levels of Cks1 mRNA.389 This in turn 
stabilized the p27 protein and resulted in cell cycle arrest. In our study, 
however, TGF-β treatment of wt TF-1 cells did not lead to an increase in p27 
levels, probably because oncogenic Ras upregulates SKP2 to such levels, that 
the reduction of SKP2 by TGF-β is not sufficient to prevent p27 degradation by 
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SKP2. Although it is reported that deletion of p27 causes hyperproliferation,390 
overexpression of FLAG-p27 itself is not enough to induce growth arrest in TF-
1 cells. This suggests the activation of an additional signal transduction 
pathway by TGF-β. Alternatively, there is a persistent disbalance in the SKP2 
and p27 levels, resulting in an inappropriate activation of cell cycle progression. 
In the stable FLAG-p27 cells an increased expression of p21 was observed 
and in some experiments p15 (data not shown). Since p27 has been 
demonstrated to enhance Sp1 stability and promoter binding391 and both p21 
and p15 expression is enhanced by Sp1,392 the upregulation of p21 and p15 
could be an effect of p27-mediated Sp1 activation. These two CDKi’s might 
contribute to p27-mediated growth arrest in response to TGF-β, but they are 
downstream of p27. 
 P27 protein degradation is complex and controlled by various mechanisms. 
In this report we show that p27 protein levels are regulated by degradation 
through a T187 phosphorylation-dependent, MEK/Erk-dependent, SKP2 
pathway. Different signaling pathways downstream of MEK/Erk have been 
identified that affect SKP2 expression. Cul1, a critical component of the 
SCF(SKP2) ubiquitin ligase is a direct transcriptional target of c-Myc.393 It has 
been demonstrated that Myc expression and activity is downregulated upon 
MEK1 inhibition in conjunction with upregulation of p27.394 Indeed, inhibition of 
Ras activity with L744832 resulted in decreased c-Myc protein levels (data not 
shown), in accordance with reduced SKP2 levels and restoration of p27 levels 
(fig. 6E). Alternatively, the SKP2 gene has been demonstrated to be a 
transcriptional target of GA binding protein (GABP) 395 and DNA micro array 
studies have indicated that GABP is a target gene of MEK/ERK signaling.396 
Both possibilities support our findings that (1) MEK/Erk signaling does not 
directly influence the phosphorylation status of p27 nor the transcription of p27; 
and that (2), the delayed upregulation of p27 upon inhibition with U0126 and 
L744832 indicates an indirect effect of MEK/Erk signaling. 
 The inhibitory effect of p27 on the cell cycle is not restricted to the effects of 
TGF-β. Similar findings have been observed in solid tumors in response to 
vitamin D and retinoic acid.397;398 Since N-Ras transformed teratocarcinoma 
and prostate epithelial cells are resistant to retinoic acid,399;400 the above 
described mechanism of disturbed p27 degradation widens the extend of 
enhancing the proliferative capacity of cells bearing oncogenic Ras mutations. 
Recently, studies demonstrated that unfavorable treatment results in AML were 
associated with elevated SKP2 levels and with a high cytoplasmic to nuclear 
p27 ratio.155;401 Although in our model cytoplasmic p27 was not observed, the 





degradation of p27 in a SKP2-dependent manner thereby increasing the 
cytoplasmic p27 relative to the nuclear p27 levels. Ras-GTP and downstream 
targets can modulate these pathways in several ways, since Ras activation can 
be triggered directly by mutations in the Ras oncogene, or indirectly by 
mutations in the PTPN11 gene, encoding for the protein tyrosine phosphatase 
SHP-294 (and references therein), indicating the complexity of the mechanisms 
leading to oncogenic transformation and proliferation. 
 Recently, different phase I-II studies have been initiated to interfere with 
Ras-mediated signaling in AML patients and to increase the susceptibility of the 
leukemic cells for the cytotoxic effects of chemotherapy.402-404 This report 
indicates that this is not the only advantage of this approach. AML cells might 
also become more susceptible for negative regulatory molecules that limit cell 
proliferation, including TGF-β.  
 In conclusion, we demonstrate that hematopoietic cells with N-Ras 
mutations do not respond to the inhibitory effects of TGF-β on cell cycle 
progression, as a result of the absence of p27. This is due to a constitutive 
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The transcription factor STAT5 fulfills a distinct role in the hematopoietic 
system, but its precise role in primitive human hematopoietic cells remains to 
be elucidated. Therefore, we performed STAT5 RNAi in sorted Cord Blood 
(CB) and Acute Myeloid Leukemia (AML) CD34+ cells by lentiviral transduction 
and investigated effects of STAT5 downmodulation on the normal 
stem/progenitor cell compartment and the leukemic counterpart. STAT5 RNAi 
cells displayed growth impairment, without affecting their differentiation in CB 
and AML cultures on MS5 stroma. In CB, limiting dilution assays demonstrated 
a 3.9-fold reduction in progenitor numbers. Stem cells were enumerated in 
Long-Term Culture-Initiating Cell assays and the average LTC-IC frequency 
was 3.25-fold reduced from 0.13% to 0.04% by STAT5 downregulation. Single-
cell sorting experiments of CB CD34+/CD38- cells, demonstrated a 2-fold 
reduced cytokine-driven expansion, with a subsequent 2.3-fold reduction of 
progenitors. In sorted CD34+ AML cells with constitutive STAT5 
phosphorylation (5/8) STAT5 RNAi demonstrated a reduction in cell number 
(72%±17%) and a decreased expansion (17±15 vs. 80±58 in control cultures) 
at week 6 on MS5 stroma. Together, our data indicate that STAT5 expression 
is required for the maintenance and expansion of primitive hematopoietic stem 
and progenitor cells, both in normal as well as leukemic hematopoiesis. 
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Introduction 
 
The hematopoietic environment is a highly dynamic system, where multipotent 
hematopoietic stem cells (HSCs) perpetually make decisions regarding self-
renewal, lineage commitment and terminal differentiation in order to provide 
sufficient numbers of mature blood cells. An important transcription factor 
within the hematopoietic system, involved in self-renewal, proliferation and 
apoptosis in response to a wide range of cytokines, is Signal Transducer and 
Activator of Transcription 5 (STAT5).217;225;226 Two isoforms of this STAT family 
member have been cloned, STAT5A and B, and like other STAT proteins 
STAT5 is a latent cytoplasmic transcription factor that dimerizes upon 
phosphorylation by a (cytokine) activated receptor complex. The activated 
STAT complex then translocates to the nucleus where it binds to specific DNA 
sequences and increases transcription of target genes.227  
 In homozygous STAT5AB knock-out mice, the presence of an almost 
normal peripheral blood count suggested that STAT5 is either not necessary or 
redundant for adult hematopoiesis, even though colony assays demonstrated 
reduced numbers of cytokine-responsive myeloid progenitors.239 Instead, 
STAT5 was assigned a role in fetal liver and stress erythropoiesis due to Bcl-XL 
–mediated anti-apoptosis.405;406 In competitive repopulation experiments 
however, STAT5AB-null cells demonstrated a severe impairment in engrafting 
wild-type recipients, which did not appear to be due to a homing deficiency, but 
rather to a failure in post-engraftment hematopoiesis.240;241 Also, the cytokine 
responsiveness was severely impaired in STAT5AB knockout cells.238 Gain-of-
function studies demonstrated that constitutively activated STAT51*6 imposed a 
self-renewal phenotype on human Cord Blood (CB)-derived CD34+ stem and 
progenitor cells.37 These observations were consistent with overexpression 
data in murine HSCs, where the self-renewal phenotype was coupled to the 
development of a myeloproliferative disease (MPD).36 
 In acute myeloid leukemia (AML) constitutive activation of STAT5 has been 
demonstrated in approximately 66% of the cases40;234 and may be attributed to 
activating mutations in upstream kinases, such as FLT3235, KIT236or JAK2237 or 
alternatively be due to autocrine growth factor production.40 This prompted us 
to ask whether AML cells are dependent upon STAT5 activation for their 
survival and proliferation. Recently, we have described an improved method for 
long-term culture of CD34+ AML cells. In this assay expansion, leukemic 
cobblestone area (L-CA) formation and self-renewal can be studied in vitro up 
to 22 weeks (van Gosliga et al., submitted manuscript). In the present study, 





order to introduce STAT5 RNAi hairpins into these expanding AML cells and 
the results were compared with normal CD34+ CB cells.  
 Our data indicate that lentiviral-mediated RNA interference of STAT5 in CB 
CD34+ cells reduced the growth rate of primitive stem- or progenitor cells, 
leading to decreased CFC and LTC-IC numbers and eventually resulted in 
lower expansion rates. Single cell assays with the more primitive CB 
CD34+/CD38- cell population suggested that STAT5 is necessary for 
maintenance of hematopoiesis. Subsequent introduction of the STAT5 RNAi 
hairpin into CD34+ AML cells, a fraction enriched for L-CA forming (stem) cells, 
demonstrated that self-renewal and expansion of leukemic stem cells was also 
dependent upon STAT5 expression. Thus, we conclude that STAT5 expression 
is required for the maintenance and expansion of human stem/progenitor cells 
in both normal and leukemic hematopoiesis.   
 
 
Materials and methods 
 
Long-term cultures on stroma - Cord blood (CB) CD34+ cells were derived from 
neonatal cord blood from healthy full-term pregnancies after informed consent 
from the Obstetrics departments of the Martini Hospital and University Medical 
Center in Groningen, The Netherlands and isolated by MiniMACS (Myltenyi 
Biotec) selection. After transduction, 30.000 cells were expanded on MS5 
stromal cells in Long Term Culture (LTC) medium (αMEM supplemented with 
heat-inactivated 12.5% FCS, heat-inactivated 12.5% Horse serum (Sigma, 
Zwijndrecht, The Netherlands), penicillin and streptomycin, 200 mM Glutamine, 
57.2 µM β-mercaptoethanol (Sigma) and 1 µM hydrocortisone (Sigma). AML 
blasts from peripheral blood cells or bone marrow cells from untreated patients 
with AML were studied after informed consent and the protocol was approved 
by the Medical Ethical Committee. AML mononuclear cells were isolated by 
density gradient centrifugation and CD34+ cells were selected by MiniMACS. 
After transduction, 200.000 cells were plated onto T25 flasks pre-plated with 
MS5 stromal cells. AML cells were expanded in LTC medium supplemented 
with 20 ng/ml Interleukin 3 (IL-3; Gist-Brocades, Delft, The Netherlands), 
Granulocyte Colony Stimulating Factor (G-CSF; Rhone-Poulenc Rorer, 
Amstelveen, The Netherlands) and Thrombopoietin (TPO; Kirin, Japan). 
Cultures were kept at 37ºC and 5% CO2. Cultures were demidepopulated 
weekly for analysis. TF-1 cells were cultures in RPMI 1640 (Biowhittaker, 
Verviers, Belgium) supplemented with 10% FCS and 10 ng/ml GM-CSF 
(Genetics Institute, Cambridge, MA, USA). 
     Downregulating STAT5 in primitive (leukemic) cells 
  125 
 
Flow cytometry analysis - All fluorescence activated cell sorter (FACS) 
analyses were performed on a FACScalibur (Becton Dickinson (BD), Alpen a/d 
Rijn, The Netherlands) and data was analyzed using WinList 3D (Topsham, 
USA). Cells were sorted on a MoFlo (DakoCytomation, Carpinteria, CA, USA). 
Antibodies were obtained from BD. 
 
Lentiviral transductions – 2.5x106 293T Human Embryonic Kidney cells were 
transduced with 3 µg pCMV Δ8.91, 0.7 µg VSV-G and 3 µg of pTRIP Renilla 
RNAi or pTRIP STAT5 RNAi (kind gifts of Prof. Dr. H. Spits, Department of Cell 
Biology and Histology, Amsterdam Medical Center, Division of Immunology, 
Netherlands Cancer Institute, Amsterdam. Target sequences have been 
described by Scheeren et al.407). After 24 hours medium was changed to 
HPGM (Cambrex, Verviers, Belgium) and after 12 hours supernatant 
containing lentiviral particles was harvested and stored at -80ºC. CD34+ AML 
blasts and CB CD34+ cells were isolated with MiniMACS columns and 
subsequently cultured in RPMI supplemented with 10% FCS, 20 ng/ml IL-3, G-
CSF and TPO for 4 hours at 37ºC and 5% CO2 or in HPGM supplemented with 
c-Kit ligand), Flt-3 ligand (both from Amgen, USA) and TPO (100 ng/ml each) 
for 16 hours at 37ºC and 5% CO2 respectively. AML blasts were transduced in 
3 consecutive rounds of 8 to 12 hours with lentiviral supernatant supplemented 
with 10% FCS, 20 ng/ml IL-3, G-CSF and TPO, and Polybrene (4 µg/ml; 
Sigma) and CB CD34+ cells in 2 consecutive rounds of 8 to 12 hours with 
lentiviral supernatant supplemented with c-Kit Ligand/Flt-3 ligand/TPO (100 
ng/ml each) and Polybrene (4 µg/ml). TF-1 cells were transduced in 1 round of 
12 hours with lentiviral supernatant supplemented with 10% FCS, 10 ng/ml 
GM-CSF and Polybrene (8 µg/ml). Transduction efficiency was measured by 
FACS analysis and knock-down was investigated by means of Western blot 
using antibodies against phospho STAT5A/B Tyr 694/699 (Millipore, Bedford, 
MA, USA), STAT5 (C17) and STAT3 (C20) (Santa Cruz, CA, USA ) and Actin 
(C4) (ICN Biomedicals, Zoetermeer, The Netherlands) in a 1:1000 dilution in 
PBS on an Odyssey infrared scanner (Li-Cor Biosciences, Lincoln, NE, USA) 
or using ECL according to the manufacturer’s instructions (Roche Diagnostics, 
Almere, The Netherlands). Alternatively, knock-down was investigated by 
means of quantative RT-PCR (Q-PCR, sequences and conditions are available 
on request). 
 
CFC, CFU-GM, BFU-E and LTC-IC assays - CFC assays and LTC-IC assays 





assays were performed in 1.2% methylcellulose containing 30% FCS, 57.2 µM 
β-mercaptoethanol, and 2 mM Glutamine, supplemented with 20 ng/ml IL-3, 20 
ng/ml IL-6, 20 ng/ml G-CSF, 20 ng/ml c-Kit ligand and 6 U/ml EPO (Cilag: 
Eprex; Brussels, Belgium). Cells were either plated in bulk by 1000 transduced 
cells per plate in duplicate or in 96-well plates in 1, 3, 9, 27, 81, or 243 cells per 
well. CFU-GM and BFU-E assays were performed in 1.2% methylcellulose 
containing 30% FCS, 57.2 µM β-mercaptoethanol, and 2 mM Glutamine, 
supplemented with 10 ng/ml GM-CSF and 10ng/ml IL-3 or 2 U/ml EPO 
respectively. LTC-IC assays were performed by plating transduced CB CD34+ 
cells in limiting dilutions in the range of 10-2400 cells per well on MS5 stromal 
cells in 96-well plates in LTC medium. 
 
Single cell assays – CB CD34+ cells were isolated using MiniMacs columns 
and cultured in HPGM supplemented with c-Kit Ligand/Flt-3 ligand/TPO (100 
ng/ml each) for 8 hours at 37ºC and 5% CO2 and subsequently transduced in 1 
round of 8 hours with lentiviral supernatant supplemented with c-Kit Ligand/Flt-
3 ligand/TPO (100 ng/ml each) and Polybrene (4 µg/ml). CD34+ CD38- 
YFP/GFP+ cells were single sorted into 96-well plates into 100 µl HPGM 
supplemented with c-Kit Ligand/Flt-3 ligand/TPO (100 ng/ml each) and followed 
microscopically for 100 hrs. After this period, methylcellulose for CFC assays 





STAT5 downregulation impairs long-term expansion of CB CD34+ cells on 
MS-5 bone marrow stroma  
In order to address whether downmodulation of STAT5 expression affects the 
proliferation and survival of human stem- and progenitor cells, CB CD34+ cells 
were sorted and transduced with lentiviral vectors containing short interfering 
hairpins against control (Renilla luciferase) or STAT5 mRNA (fig.1A). Flow 
cytometric analysis demonstrated transduction efficiencies ranging between 
50% and 95% (fig. 1B and data not shown). Western blot analysis confirmed 
efficient downregulation of STAT5 in CB CD34+, up to 70%-75% down 
modulation relative to STAT5 expression in control cells (fig. 1C, normalized 
against STAT3 protein, with control cultures arbitrarily set at 100%). STAT3 
protein, as a close homologue of STAT5, is shown to indicate specificity of the 
STAT5 hairpin. Knock-down of STAT5 protein levels correlated well with 
downregulation of STAT5 mRNA levels in transduced cells (fig. 1D, STAT5 
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mRNA values were normalized against GAPDH mRNA values). In addition, in 
TF-1 cells transduced with STAT5 hairpins it was demonstrated that phospho-
STAT5 was comparably downregulated as total STAT5 (fig.1C). 
 To evaluate the effects of STAT5 knockdown on CD34+ cell growth and 
differentiation, transduced cells were plated onto MS-5 stromal cells and 
cultures were weekly demidepopulated and analyzed for 5 weeks by flow 
cytometry. No effects of STAT5 downmodulation were observed on the myeloid 
differentiation program, as no change in the percentage of GFP+ cells positive 
for CD14 (40%±6% vs. 46%±5%), CD15 (47%±11% vs. 38%±14%) and CD11b 
(65%±3% vs. 75%±3%) was observed (fig. 1E, n=3). STAT5 downmodulation 
also did not affect erythroid differentiation, since the percentage of cells 
positive for CD36, CD71 and Glycophorin A was not different from control 
Renilla transduced cells (data not shown). 
The percentage of YFP/GFP+ cells in suspension was also monitored for 5 
weeks. Stable YFP percentages were observed over time in control Renilla 
cultures relative to the YFP percentage at week 1, indicating no negative 
effects of the transduction procedures (fig. 1F). The STAT5 hairpin (GFP), 
however, induced a pronounced reduction of GFP+ cells in suspension over 
time (29% ± 12.7%), indicating that STAT knockdown impairs cell survival or 
proliferation. To test whether increased apoptosis was responsible for the 
reduction in cell numbers, AnnexinV-APC labeling was performed. No 
difference in apoptosis within the YFP/GFP+ population between control and 
STAT5 RNAi MS-5 co-cultures was demonstrated (fig. 1G), as well as in CD34+ 
cells cultured in 100 ng/ml c-Kit Ligand/Flt-3 ligand/TPO (data not shown).   
 Next, we tested whether changes in cell-cycle status could account for the 
differences observed between Renilla YFP+ and STAT5 GFP+ cells. Figure 1H 
shows Hoechst labeling of YFP+ and GFP+ cells (from MS5 co-cultures), 
demonstrating approximately 61% of cells in G1 phase, 30% of cells in S-
phase and 9% of cells in G2/M phase in both cultures Similar results were 
obtained with c-Kit Ligand/Flt-3 ligand/TPO treated cultures (data not shown). 
Together, the reduced growth of STAT5 knockdown cultures and the absence 
of differences in both apoptosis and cell-cycle assays, suggest that knockdown 
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Figure 1 Downmodulation of STAT5 by RNAi decreases growth of CD34+ stem/progenitor 
cells.  
(A) Schematic overview of the lentiviral RNAi vectors used in these studies. (B) Transduction 
efficiency of CD34+ CB stem/progenitor cells, performed as indicated in Material and methods 
(M&M) (C) Western blot analysis of STAT5 levels in control (Renilla) or STAT5 RNAi transduced 
CD34+ cells. Percentages indicate expression of STAT5 relative to control cells, normalized against 
STAT3 levels. Phospho STAT5 levels are shown for the hematopoietic TF-1 cell line. Quantitative 
western blot analysis was performed on an Odyssey infrared scanner or using Quantity One 
imaging software from BioRad (Veenendaal, The Netherlands). (D) Quantative PCR for STAT5 
mRNA in transduced CB CD34+ stem/progenitor cells. STAT5 mRNA was normalized against 
GAPDH mRNA expression. (E) FACS analysis of transduced CB cells on MS5 co-culture. MS5 co-
cultures were analyzed at week 3 for cells positive for CD14, CD15, and CD11b. The average 
percentage (from 3 independent experiments) of YFP/GFP+ cells positive for the respective 
markers is shown with standard deviations. (F) Transduced CD34+ CB cells in long-term co-culture 
on MS5 stromal cells. Shown are average YFP (Renilla control) or GFP STAT5 RNAi percentages 
relative to week 1. A trendline is indicated and error bars denote standard deviations. N = 4. (G) 
AnnexinV-APC stain of transduced CB cells on MS5 co-culture. The average percentage of 
AnnexinV positive cells within the YFP or GFP gate from 3 independent experiments is shown with 
standard deviations. (H) Hoechst (5µg/ml) cell-cycle labelling of YFP+ or GFP+ CB cells on MS5 co-
culture. The average percentages of cells in G1, S or G2/M phase of the cell cycle are shown from 
3 independent experiments with standard deviations. 
 
STAT5 down-regulation reduces progenitor and stem cell frequencies 
To test the effects of STAT5 downmodulation on the progenitor pool, colony 
assays were performed with transduced CB CD34+ cells in methylcellulose. 
Down-modulation of STAT5 levels resulted in a 56.5% ± 25% reduction of 
Colony Forming Unit- Granulocyte Macrophage (CFU-GM) colonies (P= 0.01; 
n=3) and a 43.3% ±31.9% reduction of Burst Forming Unit-erythrocyte (BFU-E) 
colonies (P< 0.05; n=3). In fig. 2A a representative example is shown. The 
reduction after STAT5 RNAi of total colony numbers in Colony Forming Cell 
(CFC) assays relative to Renilla RNAi was 43.3% ±16.2% (P< 0.01; n=3, data 
not shown). 
 The precise progenitor frequency was determined in limiting dilution CFC-
assays using YFP en GFP-sorted cells. Knockdown of STAT5 in CD34+ cells 
demonstrated an almost 4-fold reduction in the frequency of progenitors from 
5.42% ± 0.47% in Renilla control cells to 1.37% ± 0.13% in STAT5 knockdown 
(fig. 2B and 2C. P< 0.02).  
 In order to investigate whether Long-Term Culture- Initiating Cell (LTC-IC) 
frequencies might also be affected, limiting dilution LTC-IC assays were 
performed with YFP and GFP sorted cells in 3 independent experiments. Data 
in figure 2D and E demonstrate a reduction in the percentage of LTC-IC 
colonies formed from 0.23% to 0.037% upon knockdown of STAT5. In two 
additional independent experiments a reduction from 0.044% to 0.023% and 
from 0.1% to 0.048% was observed (Renilla versus STAT5 RNAi, respectively). 
On average this indicates a 3.25-fold reduction in LTC-IC frequency from 
0.13% to 0.04% upon STAT5 RNAi. This decrease in the number of LTC-IC 





of Cobblestone Area Forming Cells (CAFCs; Renilla versus STAT5 
respectively 0.097% and 0.020%, data not shown). Together these data 
suggest that a reduction of STAT5 leads to an impaired maintenance of stem 
and progenitor cells.  
 
Figure 2  Knockdown of STAT5 reduces CFC and LTC-IC frequencies of CB CD34+ cells.  
(A) CFU-GM and BFU-E assays with control and STAT5 transduced CB cells. Assays were 
performed 3 times in duplicate under conditions indicated in M&M. Error bars denote standard 
deviations. (B) Limiting dilution CFC assay performed as described in M&M. Poisson statistics were 
used to calculate CFC progenitor frequencies. N=3, a representative experiment is shown. (C) 
Percentage of CFC-progenitors as calculated from the limiting dilution assays. The average of 3 
experiments is shown, with error bars representing standard deviations. A student t-test was 
performed to calculate statistical differences between the two groups. (D) Limiting dilution LTC-IC 
assay performed as described in M&M. Poisson statistics were used to calculate LTC-IC 
frequencies. N=3, a representative experiment is shown. (E) Percentage of LTC-IC cells as 
calculated from the limiting dilution experiment shown in C. N=3. 
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Knock-down of STAT5 decreases the production of offspring of 
CD34+/CD38-cells  
Apoptosis and the cell cycle distribution analysis did not show a change in the 
majority of the CD34+ cells (fig. 1G and H). However, since both stem cell 
(LTC-IC) and progenitor frequencies decreased in STAT5 knockdown cells (fig. 
2A-DE), we wondered what the effect of STAT5 RNAi would be in a 
subpopulation of CD34+ cells, e.g. primitive CD34+/CD38- cells, a fraction which 
is highly enriched for cells with stem cell activity. 409 After transduction of CD34+ 
isolated cells, CD34+/CD38- YFP+ (Renilla) and GFP+ (STAT5) cells were 
sorted single-cell into 96-wells plates (Fig. 3A) and subsequently monitored for 
100 hours by microscopic evaluation. The number of cells present per well 
were enumerated each 25 hours and classified “quiescent” when still 
containing only 1 cell and “proliferating” when multiple cells were observed. 
Figure 3B demonstrates that the number of quiescent cells was marginally 
increased in STAT5 knockdown cells while the number of wells that contained 
proliferating cells was slightly decreased, but both changes were not significant 
(P>0.1, n=3). However, of the CD34+/CD38- cells that were capable of 
division, wells containing STAT5 knockdown cells demonstrated significantly 
less cells after 100 hours of culture than control wells (fig. 3C, 8 ± 8  vs. 16 ± 7 
cells respectively,  P< 1*10-6, 30 individual cells for each group are shown). 
Furthermore, the average number of daughter cells produced in each well by 
STAT5 knockdown cells was significantly decreased compared to control 
Renilla knockdown cells (fig. 3D, respectively 5.6 ± 0.9 cells vs.7.1 ± 0.9 cells, 
P< 0.01), resulting in a lower total amount of cells per plate (289 ± 64 vs. 198 ± 
72 cells, respectively for Renilla and STAT5 RNAi, P< 0.01, data not shown). In 
addition, methyl cellulose was added to these wells after 100 hours of culture 
and after two weeks the number of CFC colonies was enumerated. The 
number of wells positive for colonies was 2.3-fold lower in STAT5 hairpin 
transduced cells compared to control cells (36 ± 6.5 vs. 16 ± 2.9 colonies, 
respectively for Renilla and STAT5 RNAi, P< 0.05, n=3, fig. 3E), which verified 
the outcome of the limiting dilution CFC assays (fig. 2B and C). Together these 
data demonstrate that at the single cell level in primitive CD34+/CD38- cells, 







Figure 3  STAT5 knockdown impairs outgrowth of primitive CD34+ CD38- cells. 
(A) Sorting scheme for obtaining single CD34+ CD38- YFP+ (Renilla) or GFP+ (STAT5 RNAi) cells in 
96-wells format. NV indicates a non-transduced (No Virus) control to set gates. (B) Percentage of 
wells quiescent or proliferating after STAT5 knockdown. Indicated percentages are averaged from 
3 independent experiments. (C) Cell number per proliferating well at the indicated time points after 
sorting. 30 individual wells per group are shown. Bars indicate average cell number with standard 
deviations at t = 100 hrs. A student t-test was performed to calculate statistical differences between 
the two groups. N=3. (D) The average number of daughter cells (offspring) produced per 
proliferating cell/well. A student t-test was performed to calculate statistical differences between the 
two groups. Error bars denote standard deviations, N=3. (E) The average number of CFC-colonies 
produced by proliferating cells per plate. A student t-test was performed to calculate statistical 
differences between the two groups. Error bars denote standard deviations, N=3. 
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Activated STAT5 is frequently observed in AML cells, which is efficiently 
downregulated after lentiviral-mediated RNAi 
STAT5 knockdown affected the proliferation rate of CD34+/CD38- cells. For 
malignant AML cells, this primitive cell compartment was exclusively shown to 
contain SCID Leukemia-Initiating Cells.32 Since constitutive phosphorylation 
and activation of STAT5 has been described for AML patients410 we were 
interested in the effect of STAT5 knockdown in self-renewing leukemic AML 
stem/progenitor cells. The AML’s were classified, according to FAB-
classification, as M1 (n=3), M2 (n=4), M4 (n=3) and M5 (n=5). PCR studies 
demonstrated that 7 out of 15 AML’s had FLT3-ITD mutations. Figure 4A 
depicts a western blot analysis of 8 primary AML samples and demonstrates 
the presence of phospho-STAT5 in 5 patients (62.5%), thus confirming 
previously published results.40;234 Subsequently, the subpopulation of CD34+ 
AML cells (n=11) were sorted and transduced with our lentiviral vectors. Flow 
cytometric analysis demonstrated comparable transduction efficiencies of AML 
CD34+ cells compared to CB CD34+ cells, ranging between 50% and 95% (fig. 
4B and 1B). Western blot analysis confirmed efficient downregulation of STAT5 
in these AML CD34+ cells (fig. 4C), which varied from 20 to 85% as being 
normalized against STAT3 or Actin protein.  
 
Knock-down of STAT5 impairs long-term growth of leukemic cells on MS-
5 co-cultures 
To evaluate the effects of STAT5 knock-down on the proliferation of AML 
CD34+ cells, transduced cells were plated onto MS-5 stromal cells and 
subsequently followed for growth and expansion (N=11). Cultures of AMLs with 
FAB classification M2 failed to expand and were terminated. Figure 4D 
demonstrates 4 representative cumulative growth cultures of the remaining 
cultures. All expanding CD34+ AML cultures transduced with the STAT5 hairpin 
(N=8) demonstrated an impaired growth compared to control transduced 
cultures, although the level of reduction in growth was variable. The average 
reduction in cell number after STAT5 RNAi compared to control cells was 72% 
± 17%, P< 1*10-5. This reduction was also observed, when relative 
percentages of YFP+ (Renilla control) and GFP+ (STAT5 hairpin) cells were 
calculated in expanding AML cultures. GFP percentages indicated a decline 
similar to the decline in CB CD34+ MS-5 co-cultures (fig. 4E, data shown is an 
average of 7 AML cultures, compare to figure 1F).  
 Furthermore, the expansion of these AML cultures was calculated. Figure 
4F depicts that STAT5 knockdown resulted in an almost 5-fold decreased 
expansion from an average 80-fold expansion (+/- 58) of control transduced 





transduced cultures (P<0.05). Together these data suggest that CD34+ AML 
cells are also dependent upon STAT5 signaling for their long-term growth. 
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Figure 4  Efficient STAT5 knockdown in CD34+ AML cells impairs long-term growth on MS5 
co-culture.  
(A) Western blot analysis for Phospho-STAT5 in 8 AML patients. Actin is shown as loading control. 
(B) Transduction efficiency of CD34+ AML cells, performed as indicated in Material and methods 
(M&M) (C) Western blot analysis of STAT5 levels in control (Renilla) or STAT5 RNAi transduced 
CD34+ cells. Percentages indicate expression of STAT5 relative to control cells, normalized against 
STAT3 or Actin levels. Quantitative western blot analysis was performed on an Odyssey infrared 
scanner or using Quantity One imaging software from BioRad. (D) Cumulative cell counts of control 
(Renilla) or STAT5 RNAi transduced CD34+ AML cells on MS5 co-culture. All cell counts were 
normalized against week 0, the time of plating. 4 representative cultures are shown. N=11. (E) 
Transduced CD34+ AML cells in long-term co-culture on MS5 stromal cells. Shown are average 
YFP (Renilla control) or GFP STAT5 RNAi percentages relative to week 1. A trendline is indicated 
and error bars denote standard deviations. N = 7. (F) Averaged calculated expansion of 7 AML 
MS5 co-cultures, with error bars indicating standard deviations. The average expansion at week 6 





The present study demonstrates that limited reduction of STAT5 expression 
especially affects the hematopoietic stem/progenitor pool. In our MS5 co-
culture experiments we observed a growth reduction, without affecting the 
differentiation program of the myeloid and erythroid lineages. This finding is 
remarkable since a wide variety of hematopoietic growth factors and cytokines, 
including FLT3-L, SCF, G-CSF, GM-CSF, IL-3, EPO and TPO, have been 
shown to induce STAT5 transactivation and affect the differentiation of human 
stem/progenitor cells.218-224 These differences in cell biological effects 
downstream of STAT5 most likely find its origin in differences in cell type, 
(combinations of) cytokine signals and concentrations of cytokines (reviewed 
in225;226). Our observations regarding differentiation correspond to the relatively 
mild phenotype of STAT5AB-/- mice. In steady-state conditions these mice 
displayed normal levels of erythrocytes, platelets, neutrophils and monocytes in 
the peripheral blood 239  
 In contrast, distinct phenotypes were observed by downmodulation of 
STAT5 expression in the HSC and progenitor subpopulations, since a 
significant reduction in progenitor and LTC-IC frequencies was observed. 
Recently, Scherr et al. have reported that normal human CD34+ progenitors 
were less sensitive to STAT5 RNAi then CML CD34+ progenitors,411 but their 
reductions of ~45% for normal CD34+ progenitors are comparable to our 
findings. Furthermore, their and our observed reduction in colony numbers after 
STAT5 RNAi corresponded with the reductions seen in CFU-mix colonies 
(~43%) and in CFU-GM colonies (~53%)  in STAT5AB-/- mice.239 These 
findings suggest that the reduction in STAT5 levels, as obtained by RNA 





100% STAT5 reduction in the STAT5AB knock-out mice, suggesting that our 
observations are not due to differences in transduction rates or RNAi efficiency.  
 Both progenitors and more primitive cells, determined with LTC-IC assays, 
displayed reduced frequencies in STAT5A RNAi transduced cells. In addition, 
single cell experiments with CD34+CD38- cells demonstrated that the number 
of daughter cells produced by STAT5 RNAi cells is lower than in control cells 
and gives rise to fewer colonies in methylcellulose. Therefore, we speculate 
that a more primitive cell, e.g. a common myeloid progenitor (CMP) or a HSC is 
being affected by STAT5 reduction. Interestingly, HSCs from STAT5AB null 
mice with impaired repopulation potential, displayed a reduction in spleen 
colony forming units.240;241 Those CFU-Ss were smaller than those from wild-
type cells, indicating fewer progeny cells produced per colony, which is in line 
with our findings. Whether STAT5 affects both primitive progenitors (CMP) and 
HSCs or only HSCs, with subsequent reductions in downstream progenitors 
needs further elucidation by means of prospective purification steps of STAT5 
RNAi-transduced HSCs versus CMPs.   
 How STAT5 affects these stem/progenitor cells remains unclear. In 
STAT5AB-/- mice increased apoptosis in erythroid progenitors has been 
assigned to decreased transcription of the Bcl-XL gene405;406 and restoration of 
Bcl-XL could fully compensate for this effect.412 In our co-cultures, however, we 
did not detect an increased rate of apoptosis and also STAT5 RNAi-transduced 
CD34+ CB cells did not display a decreased expression of the Bcl-XL gene 
(preliminary data, not shown). On the other hand, preliminary data on Cyclin D1 
gene expression demonstrated a reduction in STAT5 RNAi-transduced CD34+ 
CB cells (data not shown), which is consistent with a defect in proliferation of 
bone marrow-derived macrophages of STAT5A-deficient mice.413 Further 
studies in purified CD34+CD38- cells transduced with STAT5 RNAi should 
provide more insight in the processes of apoptosis and proliferation. 
 Overexpression of a constitutively active STAT5 enhanced the self renewal 
potential of CD34+ cells.36;37 In mice, this was coupled to the development of 
myeloproliferative disease (MPD) or multilineage leukemias.36;414 Detailed 
analysis of derivatives of this constitutive active STAT5 showed that the 
enhanced self-renewal or MPD/multilineage leukemia was potentially due to 
enhanced tetramer formation and hence more stable DNA binding of 
constitutive active STAT5 mutants to promoters of target genes.414 
Interestingly, similar STAT5 tetramers were observed in various AML, chronic 
myeloid leukemia (CML) and acute lymphoid leukemia (ALL) patient 
samples.414 In addition, STAT5 activation has been shown to be critical for 
BCR-ABL dependent transformation of hematopoietic cells.411;415-418  
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 For AML, constitutive activation of STAT5 has been demonstrated,40;234 but 
the role of STAT5 signaling in the pathogenesis of AML remained so far 
elusive. This is predominantly hampered by experimental limitations. Gene 
transfer into primary AML have shown stable targeting efficiencies,419;420 but in 
liquid culture these cells lost their viability after approximately 15 days. 
Although AML SCID-Leukemia Initiating Cells (AML SL-IC) could sustain longer 
growth in (NOD)-SCID mice32;421 this assay was sofar not combined with 
molecular interference in signal transduction pathways. Furthermore, it was 
demonstrated that the in vivo NOD-SCID model also has limitations, as almost 
half of the investigated AML cases did not engraft in irradiated mice.422 
Therefore we used an AML culture assay in which expansion of transduced 
leukemic cells could be followed for prolonged periods of time.  
 The results indicate that by lentiviral transduction RNA interference allows 
us to study the importance of STAT5 activation in sorted CD34+AML cells. 
Knockdown of STAT5 in AML CD34+ cells shows a reduction in cumulative cell 
numbers within 5 to 6 weeks of co-culture on MS5. This reduction in expansion 
of AML cells upon STAT5 RNAi was similar to the decline we observed in 
CD34+ CB cells, suggesting that a comparable cell type, either a primitive 
progenitor or a stem cell is being affected. In addition no changes for myeloid 
and erythroid markers between STAT5 RNAi and control AML cultures were 
observed (data not shown), in line with the results of CB CD34+ cells.  
 Our data indicate that the concomitant reduction in STAT5 phosphorylation 
in the STAT5 RNAi transduced cells is sufficient to limit the expansion of the 
leukemic stem/progenitor pool. From a clinical point of view this is an important 
observation, since a partial reduction of STAT5 already gives a distinct 
phenotype. This would imply that alternative strategies e.g. blocking kinase 
activity, which result in a partial reduction in STAT5 activity, will have distinct 
effects on the leukemic stem cell compartment.  Indeed, a phase 1 clinical 
study with SU11248, a multitarget kinase inhibitor against Flt3, PDGFR, 
VEGFR and KIT, demonstrated marked reductions (>50%) in STAT5 
phosphorylation in peripheral blood (PB) of AML patients and a decreased 
blast count in some of those.423 Although not all patients in that study showed 
significant changes in pheripheral blood blast counts after 48 hours, our in vitro 
culture assay demonstrates that it may require several weeks before a distinct 
effect can be observed. 
 In conclusion, our data indicate that STAT5 expression is required for the 
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The CCAAT/enhancer binding protein (C/EBP) α transcription factor is 
indispensable for myeloid differentiation. In various myeloid leukemias, C/EBPα 
is mutated or functionally impaired due to decreased C/EBPα expression or 
phosphorylation. In order to investigate the functional consequences of 
decreased C/EBPα function in AML, we re-introduced C/EBPα in primary 
CD34+ sorted AML cells using a lentiviral approach. Self-renewal and 
differentiation of primary AML stem cells were studied on long-term MS5-
cocultures. Activation of C/EBPα immediately led to a growth arrest in all AML 
cultures (N=7), resulting in severely reduced expansion as compared to control 
cultures. This growth arrest corresponded with enhanced myeloid 
differentiation as assessed by FACS analysis for CD14, CD15 and CD11b. 
Myeloid differentiation was further confirmed by the upregulation of Neutrophil 
Elastase and G-CSF-Receptor in C/EBPα transduced cells. C/EBPα-
expressing AML CD34+ cells failed to generate 2nd and 3rd leukemic 
cobblestone areas (L-CAs) in serial replating experiments, while control 
cultures could be sequentially passaged for over 4 times, indicating that re-
introduction of C/EBPα impaired the self-renewal capacity of the leukemic 
CD34+ compartment. Together, our data indicate that low C/EBPα levels are 
necessary to maintain self-renewal and the immature character of AML stem 
cells. 
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Introduction 
 
The transcription factor C/EBPα is a major determinant of myeloid 
differentiation. Its expression is low in stem cells and uncommitted progenitors 
and is upregulated when common myeloid progenitors (CMP) and granulocyte-
macrophage progenitors (GMP) develop.8;246 Concomitantly, the expression 
ceases with the arrival of the megakaryocytic-erythroid progenitor and is 
abolished in lymphoid cells.8 Overexpression in cells with GMP potential 
indicated that C/EBPα induces granulocytic differentiation and blocks the 
monocytic differentiation program.246 This is in line with the granulocytopenia in 
C/EBPα-/- mice, without affecting other lineages.245 Although initial studies did 
not show effects on monocyte/macrophage development, conditional knock-out 
mice for C/EBPα have shown that this development is indeed affected as 
well.424 Recently, overexpression studies indicated that C/EBPα could also 
direct monocytic development,247 which is consistent with data demonstrating a 
requirement for C/EBPα in the transition from CMP to GMP,253 but not for 
development towards mature cells. 
 Furthermore, C/EBPα has been implicated in the regulation of HSC self-
renewal. The repopulating ability of C/EBPα-/- HSCs is increased compared to 
wildtype (wt) HSCs.253 Also, these mice demonstrate an accumulation of 
immature myeloid blasts in the bone marrow upon transplantation with C/EBPα-
/- HSCs.253 The block in myeloid differentiation combined with an enhanced 
self-renewal, closely resembled some characteristics of leukemic development. 
Indeed, C/EBPα was suggested to be a common denominator in human 
AML.85 In the last few years various mechanisms have been reported, through 
which C/EBPα is negatively regulated in various AML subtypes. Mutations in 
the N-terminus have been described in patients with a FAB M1 and M2 subtype 
without AML-ETO translocation.81;254;255 These N-terminal mutations give rise to 
a truncated dominant negative form of C/EBPα , which interferes with DNA-
binding and transactivation of the wt C/EBPα.254 C-terminal mutations of 
C/EBPα have been described in FAB subtypes M1, M2 and occasionally in M4 
and result in deficiency in DNA binding of C/EBPα.256;257  AMLs with an AML-
ETO translocation have been demonstrated to downregulate C/EBPα at the 
transcriptional level,81 although some studies have also shown that AML-ETO 
can associate with and inhibit C/EBPα function.258 In AML patients with Flt3-
ITD mutations or inv16, suppression of C/EBPα expression was 
demonstrated,259;425 whereas functional inhibition of C/EBPα through Flt3-ITD-
induced phosphorylation has also been reported.260 Promoter hypermethylation 





fusion gene AML1-MDS1-EVI1 has been demonstrated to suppress DNA 
binding of C/EBPα.261 Together, all these mechanisms lead to decreased 
functionality of C/EBPα in terms of DNA binding and the expression of target 
genes, such as G-CSF Receptor, M-CSF-Receptor and the IL-6 
Receptor.245;424;427 This block at the CMP stage in the differentiation program, 
combined with the enhanced self-renewal potential, may subsequently 
contribute to leukemic transformation.  
 Overexpression studies of C/EBPα in the leukemic AML-ETO expressing 
Kasumi-1 cell-line and in Flt3-ITD expressing 32D and MV4;11 cell-lines have 
demonstrated that impaired myeloid differentiation could be rescued.81;259;260 
Recently, we demonstrated that the STAT5-induced erythroid differentiation 
and the subsequent block in myeloid differentiation of human Cord Blood (CB) 
CD34+ cells involves downmodulation of C/EBPα,37 which could be 
counterbalanced by re-introduction of C/EBPα.244 In studies in which AML 
patients were treated with a Flt3 inhibitor CEP-701, re-expression of C/EBPα 
was observed after 4 weeks of treatment and this was correlated with an 
enhanced expression of surface markers CD11b and CD15.259 However, a 
direct relation between these two events was not yet established in primary 
AML samples. This prompted us to re-introduce C/EBPα into AML blasts. For 
these studies we used the CD34+ sorted subfraction from the blast cell 
population. This cell fraction contains the AML Long Term Culture-Initiating Cell 
(AML-LTC-IC)102 activity and might be most informative regarding the cellular 
functions of C/EBPα in long-term leukemic stem cell cultures. The results 
demonstrate that re-introduction of C/EBPα in primary CD34+ sorted AML cells 
leads to a rapid growth arrest, with an associated increased expression of 
differentiation markers. This enhanced differentiation is accompanied by a loss 
of self-renewal, as assessed by serial replating of leukemic stem cells. We thus 
conclude that downregulation of C/EBPα function in primary human AMLs is 
necessary for maintenance of the leukemic phenotype by keeping them 
undifferentiated and uphold their self-renewal.   
 
 
Materials and methods 
 
Long-term cultures on stroma - AML blasts from peripheral blood or bone 
marrow from untreated patients with AML were studied after informed consent. 
The protocol was approved by the Medical Ethical Committee. AML 
mononuclear cells were isolated by density gradient centrifugation and CD34+ 
cells were selected by MiniMACS (Myltenyi Biotec) or sorted on a MoFlo 
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(DakoCytomation, Carpinteria, CA, USA). After transduction, 200.000 cells 
were plated onto T25 flasks pre-plated with MS5 stromal cells and expanded in 
Long Term Culture (LTC) medium (αMEM supplemented with heat-inactivated 
12.5% FCS, heat-inactivated 12.5% horse serum (Sigma, Zwijndrecht, The 
Netherlands) penicillin and streptomycin, 200 mM Glutamine, 57.2 µM β-
mercaptoethanol (Sigma) and 1 µM hydrocortisone (Sigma)) supplemented 
with 20 ng/ml Interleukin 3 (IL-3; Gist-Brocades, Delft, The Netherlands), 
Granulocyte Colony Stimulating Factor (G-CSF; Rhone-Poulenc Rorer, 
Amstelveen, The Netherlands) and Thrombopoietin (TPO; Kirin, Japan). 
Cultures were kept in the presence or absence of 500 nM 4-hydroxy tamoxifen 
(4-OHT) at 37ºC and 5% CO2. Cultures were demidepopulated weekly for 
analysis. Cord blood (CB) CD34+ cells were derived from neonatal cord blood 
from healthy full-term pregnancies after informed consent from the Obstetrics 
departments of the Martini Hospital and University Medical Center in 
Groningen, The Netherlands and isolated by MiniMACS selection. 
 
Flow cytometry analysis - All fluorescence activated cell sorter (FACS) 
analyses were performed on a FACScalibur (Becton Dickinson (BD), Alpen a/d 
Rijn, The Netherlands) and data was analyzed using WinList 3D (Topsham, 
USA). Cells were sorted on a MoFlo. Antibodies were obtained from BD. 
 
Lentiviral transductions - 2.5x106 293T Human Embryonic Kidney cells were 
transduced with 3 µg pCMV Δ8.91, 0.7 µg VSV-G and 3 µg of pRRL-Venus or 
pRRL-C/EBPα-ER (pRRL-Venus was a kind gift from Prof. Dr. C. Baum). 
pRRL-C/EBPα-ER was cloned by swapping the EcoRI fragment from C/EBPα-
ER from MiNR1-C/EBPα-ER (described previously)244  blunt into the SnaB1 
site of pRRL-Venus. After 24 hours medium was changed to HPGM (Cambrex, 
Verviers, Belgium) and after 12 hours supernatant containing lentiviral particles 
was harvested and stored at -80ºC. CD34+ AML blasts and CB CD34+ cells 
were isolated with MiniMACS columns and subsequently cultured in RPMI 
supplemented with 10% FCS, 20 ng/ml IL-3, G-CSF and TPO for 4 hours or in 
HPGM supplemented with c-Kit ligand), Flt-3 ligand (both from Amgen, USA) 
and TPO (100 ng/ml each) for 16 hours at 37ºC and 5% CO2 respectively. AML 
blasts were transduced in 3 consecutive rounds of 8 to 12 hours with lentiviral 
supernatant supplemented with 10% FCS, 20 ng/ml IL-3, G-CSF and TPO, and 
Polybrene (4 µg/ml; Sigma) and CB CD34+ cells in 2 consecutive rounds of 8 to 
12 hours with lentiviral supernatant supplemented with c-Kit Ligand/Flt-3 
ligand/TPO (100 ng/ml each) and Polybrene (4 µg/ml). Transduction efficiency 
was measured by FACS analysis and overexpression was investigated by 





USA) and GFP (recognizes Venus as well, Molecular probes, Invitrogen, 
Breda, The Netherlands) in a 1:1000 dilution in PBS on an Odyssey infrared 
scanner (Li-Cor Biosciences, Lincoln, NE, USA) or using ECL according to the 
manufacturer’s instructions (Roche Diagnostics, Almere, The Netherlands).  
 
(Quantitative) PCR - gene expression for GCSF-Receptor, neutrophil elastase 
(NE) and C/EBPα was investigated by means of (quantative) RT-PCR (Q-
PCR), sequences and conditions are available on request). For RT-PCR, total 
RNA was isolated from 1 x 105 to 1 x 106 cells using the RNeasy kit from 
Qiagen (Venlo, The Netherlands) according to the manufacturer’s 
recommendations. RNA was reverse transcribed with M-MuLV reverse 
transcriptase (Roche Diagnostics). For PCR, 2 µl of cDNA was amplified 
(sequences and conditions are available on request) in a total volume of 25 µl 
using 2 units of Taq polymerase (Roche Diagnostics). As a negative control 
RNA minus reverse transcriptase (-RT) prepared cDNA was used in PCR 
reactions. 10 µl aliquots were run on 1.5% agarose gels. For real-time RT-
PCR, 2 µl aliquots of cDNA were real-time amplified using iQ SYBR Green 
supermix (Bio-Rad, Veenendaal, the Netherlands) on a MyIQ thermocycler 
(Bio-Rad) and quantified using MyIQ software. GAPDH expression was used to 
calculate and normalize expression of all genes investigated. 
 
Electrophorectic Mobility Shift Assays (EMSAs) - Nuclear extracts of 25.000 
sorted CD34+ (transduced) AML cells were prepared according to the mini-
extracts method.273 EMSA analysis was performed by incubating 5 µl of nuclear 
extract with 5’-IRDye 700 labelled double stranded oligonucleotides for 30 
minutes at room temperature. Binding reactions were run on non-denaturing 4 
% Acrylamide gels in 1 x TBE and the gels were scanned using an Odyssey 
infrared scanner (Li-Cor Biosciences, Lincoln, NE, USA) To check for 
specificity of the reactions, 50 fold molar excess of unlabeled oligonucleotide 
(either self or non-self) was added to the binding reactions. For supershift 
analysis, 1 µl of C/EBPα specific antibody (SC-61, Santa Cruz Biotech, Santa 
Cruz, CA, USA) was added simultaneously with the probe. 
 
Microscopy and cytospins - For morphological analysis, May-Grünwald Giemsa 
(MGG) staining was used to analyze cytospins. Pictures were taken on an 
Olympus BX50 microscope (Olympus Nederland BV, Zoeterwoude, The 
Netherlands) with a 100x/1.3 oil objective. Pictures of MS5 cocultures and 
(Venus+) L-CAs were taken with a Leica DM-IL microscope (Leica 
Microsystems, Rijswijk, The Netherlands) with a 20x/0.30 or 40x/0.60 objective.  
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Replating of leukemic cultures – For assessment of self renewal, 200.000 AML 
cells were transduced and plated onto T25 flasks pre-plated with MS5 stromal 
cells. AML cells were expanded in LTC medium supplemented with 20 ng/ml 
IL-3, G-CSF, TPO and 500 nM 4-hydroxy tamoxifen (4-OHT). At week 1, 3 and 
5 of culture, fresh medium was added. At week 2, 4 and 6 all medium 
containing suspension cells was removed and analysed by flow cytometry for 
the percentage of Venus-expressing cells. The remaining adherent cell layer, 
containing both MS5 cells and leukemic cobblestone area forming cells (LCA), 
was washed twice with PBS and trypsinised for 15 minutes. All trypsinised cells 
were resuspended in 5 ml LTC medium and 10% was replated onto T25 flasks 
pre-plated with fresh MS5 stromal cells. The remaining 90% was stained with 
PE-labelled anti-human CD45 (BD) to distinguish between mouse MS5 and 





Impaired DNA-binding capacity of C/EBPα in CD34+ AML cells  
In order to study C/EBPα DNA binding in the primitive subfraction of AML cells, 
CD34+ AML cells, which have been demonstrated to posses AML Long Term 
Culture-Initiating Cell (AML-LTC-IC) and Leukemic Cobblestone Areas Forming 
Cell (L-CAFC) activity102;428 (and van Gosliga et al., submitted manuscript) from 
FAB subtypes M1 (N=3), M2 (N=2), M4 (N=1) and M5 (N=5) were isolated and 
subjected to nuclear fractionation and gel shift (EMSA) experiments. 7 out of 11 
AMLs tested were Flt3-ITD positive (63.6%, table 1). Figure 1A demonstrates 
that DNA binding of C/EBPα in various AML samples is severely reduced as 
compared to C/EBPα DNA binding from extracts of CB CD34+ cells and the 
myeloid HL-60 cell-line. Sorting of equal cell numbers was used to normalize 
protein content of the extracts. The gel-shift analysis was specific for C/EBPα, 
since competition with an excess of unlabeled probe demonstrated a decrease 
in DNA binding activity (fig. 1A, box on the right, cold competition). 
Furthermore, addition of a C/EBPα specific antibody resulted in a supershift, 
demonstrating the presence of C/EBPα in the protein-DNA probe complex (fig. 
1A, super shift). These data show that the transcription factor C/EBPα has a 








Table 1 Summary of patient characteristics. 
Blasts isolated from bone marrow (BM) or peripheral blood (PB). AMLs were categorized according 
to the French-American-British (FAB) classification. Positivity for Flt3-ITD is indicated as well as 
karyotype and riskgroup. The right part indicates the experiments performed with the AMLs. 
 
 
The role of C/EBPα in AML self-renewal 
  147 
 
Figure 1 C/EBPα has impaired DNA-binding capacity in AML patients and can be restored 
upon transduction into primitive CD34+ AML cells.  
(A) DNA-binding experiment to C/EBPα specific probe with nuclear extracts of 25.000 sorted 
CD34+ AML cells. Nuclear extracts of 25.000 HL-60 and CB CD34+ cells are shown as control. 
Nuclear extracts taken from the same patients, but harvested in independent experiments (marked 
* and #) indicate that decreased C/EBPα DNA binding is not due to the experimental set up or 
experimental variations. The box on the right demonstrates C/EBPα-specific controls on nuclear 
extracts from 33.000 HL-60 cells: A supershift with a C/EBPα-specific ab and a cold competition 
with a 50-fold excess of unlabelled probe. 
 (B) Schematic overview of the lentiviral overexpression vectors used in these studies. (C) Western 
blot analysis of C/EBPα-ER in CD34+ CB stem/progenitor cells. (D) Transduction efficiency of 
CD34+ AML cells. (E) Phase contrast and Venus fluorescence (GFP channel) pictures indicating 
the presence of Venus+ cobblestone areas (CA) (encircled) in week 2 leukemic MS5 cocultures. (F) 
DNA-binding experiment to C/EBPα specific probe with nuclear extracts of 50.000 CD34+ AML 
cells from MS5 cocultures treated for a week with or without 500 nM 4-hydroxy tamoxifen (4-OHT). 
(G) Q-PCR for the C/EBPα target gene G-CSF-Receptor (G-CSF-R) after 1 week of coculture on 
MS5 in the presence of 500 nM 4- OHT. mRNA levels were normalized against GAPDH mRNA 
levels and C/EBPα-transduced values are shown relative to control Venus-transduced values. An 
average of two samples is shown with SEM. 
 
Efficient transduction of CD34+ AML cells using lentiviral vectors 
containing an inducible form of C/EBPα 
In order to investigate the consequences of the reduced C/EBPα DNA binding, 
we employed lentiviral vectors in order to re-introduce C/EBPα into human 
CD34+ AML cells (schematically depicted in fig. 1B). C/EBPα was fused to the 
estrogen receptor ligand binding domain (ER) to create a 4-hydrotamoxifen (4-





sequence. These vectors furthermore contained a Venus (an optimized YFP 
variant) cDNA fused to importin α sequences to target it to the nuclear 
envelope. Western blot analysis of CB CD34+ transduced cells demonstrated 
high expression from the Spleen Focus Forming Virus (SFFV) promoter (fig. 
1C).   
 Primary CD34+ sorted AML cells were transduced with efficiencies between 
20 and 25% (fig. 1D). Fluorescence microscopy on MS5 co-cultures showed 
the presence of Venus positive leukemic Cobblestone Areas (L-CA) (fig. 1E). 
As these L-CAs contained secondary and tertiary plating efficiency these data 
indicate the technical ability to transduce an immature CD34+ cell fraction that 
contained self-renewal capacity (fig. 3A and data not shown). Venus positive 
AML cells were sorted, treated with 4-OHT and nuclear extracts were subjected 
to gel-shift analysis in order to verify the validity of our experimental setup. 
Figure 1F demonstrates DNA binding of exogenous C/EBPα-ER upon 
administration of 4-OHT. Furthermore, a Q-PCR analysis for the C/EBPα target 
gene G-CSF-Receptor (G-CSF-R) was performed on transduced AML cells, to 
verify that the 4-OHT-induced DNA binding is also functional. As is depicted in 
figure 1G, activation of C/EBPα-ER with 4-OHT induced an 1.7-fold 
upregulation of G-CSF-R expression (p< 0.05) in primary CD34+ AML cells, 
indicating that C/EBPα is functionally active in our transduced leukemic cells. 
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The calculated fold-expansion at week 4, as well as the percentages of cells positive for cell 
surface markers as measured by flow cytometry are indicated. The arrows indicate the difference in 
expression between control Venus-transduced cells treated with 500 nM 4-OHT and C/EBPα-ER-
transduced cells after 1 week of coculture on MS5 cells. nd = not determined. 
 
Restoration of C/EBPα expression in CD34+ sorted AML blasts induces a 
cell-cycle arrest, in conjunction with enhanced expression of CD14, CD15 
and CD11b 
Subsequent C/EBPα expression was restored by transduction of AML CD34+ 
cells, followed by plating onto MS-5 stromal cells in order to study proliferation, 
differentiation and expansion (N=7). Figure 2A demonstrates 3 independent 
cumulative growth cultures. Control cultures of Venus-transduced cells 
depicted a clear expansion over a period of 3 weeks, either in the presence or 
absence of 4-OHT, ranging from 4.5-fold expansion in AML no.9 (AML no. 7 
and no. 3 demonstrated a ~88-fold and ~28-fold expansion respectively, table 
2, fig. 2A) to a ~860-fold expansion in AML no. 8 (table 2). 
C/EBPα-ER-transduced cultures demonstrated a similar expansion curve in the 
absence of 4-OHT. Addition of 4-OHT, to activate the C/EBPα transgene in 
these cultures, immediately led to a strong reduction of expansion of all AML 
cultures (N=7, table 1), reflected by a reduction of cumulative cell counts and a 
sharp decrease in the percentage of Venus expressing cells in these cultures 
(fig. 2A and data not shown). Microscopic examination of the cultures verified 
these observations (fig. 2B). Sorting of Venus positive cells from expanding 
untreated control and C/EBPα-ER cultures and stimulating them with 4-OHT, 
rapidly induced a growth arrest in C/EBPα-ER transduced cultures only, 
indicating a cell-intrinsic effect due to C/EBPα activation, rather than 
differences between growth cultures (data not shown). 
 Since growth arrest of hematopoietic cells is frequently accompanied by 
differentiation, flow cytometric analysis on suspension cells was performed 
after 1 week of culture, to investigate the differentiation state of the leukemic 
CD34+ cells. Analysis of myeloid markers specific for  monocytic /macrophage 
(CD14) and granulocytic (CD15) differentiation demonstrated an increase in the 
percentage of cells positive for CD14 in C/EBPα-ER transduced cells as 
compared to control cells or to untransduced (Venus negative) cells within the 
same culture, ranging from 2% to 73% (fig. 2C and table 2). CD15 expression 
increased in 5 AMLs upon C/EBPα activation, ranging from 7% to 41%, 
whereas 2 AML showed a decrease of 2 and 5% of CD15 expression (table 2). 
Whereas almost all investigated AMLs showed changes in the expression of 
CD14 and CD15, in some of those CD36 changed also (table 2). In 3 AML 
cases (no. 8, no. 10, no. 11) CD11b was investigated as well and 





in the percentage of CD71 positive cells in C/EBPα-ER activated cultures was 
observed, compared to control Venus transduced cultures, (fig. 2C and table 
2), although the degree of reduction ranged from 5% to 54%  between AML 
samples (table 2). This is in agreement with the observed growth arrest in 
expanding cultures, since CD71 is a marker of proliferating cells.429 RT-PCR 
studies demonstrated that C/EBPα-ER enhanced the expression of the 
C/EBPα target gene neutrophil elastase, which is induced upon granulocytic 
differentiation (fig. 2D).430   
 Morphological analysis of May-Grunwald-Giemsa stains confirmed the flow 
cytometry data regarding enhanced differentiation in some of these AMLs (fig. 
2E). Control Venus-transduced cells of AML no. 3 (FAB M5) showed an 
immature monocytic morphology, which did not change upon treatment with 4-
OHT. C/EBPα-ER-transduced cells however, showed the presence of more 
macrophage-like cells in untreated cultures, which was markedly increased 
upon activation of C/EBPα-ER wit 4-OHT. Together these data suggest that the 
absence of C/EBPα in AML cells contributes to the immature phenotype of 
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Figure 2 C/EBPα-ER 
impairs growth and 
expansion and induces 
differentiation of leukemic 
cells.  
(A) Cumulative growth 
cultures of AML cells (N=7) on 
MS5 cells in the presence or 
absence of 500 nM 4-OHT. 
Cultures were 
demidepopulated weekly and 
fresh medium was added to 
the culture. (B) Representative 
phase contrast microscopy 
images of AML cocultures in 
the presence or absence of 
500 nM 4-OHT on MS5 cells 
at weeks 3. Note the absence 
of phase bright suspension 
cells from C/EBPα-ER 
transduced culture after 
treatment with 500 nM 4-OHT. 
One representative example is 
shown. (N=7)  
(C) Flow cytometric analysis of 
suspension cells from week 1 
leukemic MS5 cocultures in 
the presence of 500 nM 4-
OHT. One representative 
example is shown. Also refer 
to table 2. Indicated are the 
percentages of CD14, CD15 
or CD71 positive cells within 
the Venus- or Venus+ 
fractions. (N=7).  
(D) RT-PCR analysis of 
Neutrophil Elastase (NE) 
expression in 3 AML samples 
after treatment with 500 nM 4-
OHT in Venus-transduced cells (-) or in C/EBPα-ER-transduced cells (+). GAPDH expression is 
shown as loading control. -RT PCRs were performed as negative control. (E) Morphological 
analysis of suspension cells at week 1 of AML no. 9 was performed by MGG staining of cytospins. 
 
Restoration of C/EBPα activation in primitive leukemic cells decreases 
the self-renewal capacity 
In order to investigate the self renewal potential, we conducted serial replating 
experiments with the expanding AML cultures (N=6). Sorted CD34+AML cells 
were transduced with C/EBPα-ER or empty control vectors and plated onto 
MS5 stroma. Every two weeks, the suspension cells were removed from the 
cultures and the adherent cell layer was washed two times and subsequently 
trypsinised. Leukemic cobblestone forming cells (L-CA) are present in this 
adherent fraction and contain self-renewal capacity as demonstrated by the 
capacity to generate new L-CAs upon each sequential replating onto new 





adherent AML cells were replated and after two subsequent weeks of culture 
the percentage of Venus-expressing cells was determined in the suspension 
fraction and within the CD45+ fraction of the trypsinised adherent MS5 cell 
layer.  
 Two representative replating experiments (AML no.7 and AML no.11) as 
well as the average of 6 independent AML experiments are shown in fig. 3A 
and B. AML no.7 was transduced with Venus (Efficiency 72.3% at initial plating 
and set to 1) and C/EBPα-ER (Efficiency 46.7% at initial plating and set to 1). 
At week 2, the expansion of Venus+ cells was comparable to expansion of non-
transduced cells and thus the relative number of Venus+ cells in suspension 
remained stable (fig. 3A). The adherent L-CAs that had formed were replated 
onto new MS5 stroma and these cells readily gave rise to 2nd L-CAs (fig. 3C) 
that were capable of generating progeny in suspension (fig. 3A and B). Again, 
at week 4 no differences were observed in the expansion of Venus+ cells 
versus untransduced cells in suspension, and the 2nd L-CAs could be 
harvested to give rise to 3rd L-CAs upon 2nd replating (fig. 3A, B and C). At 
week 6, the relative number of Venus+ cells was determined in both the 
suspension as well as adherent fraction, and in both populations Venus+ cells 
behaved comparable to non-transduced cells. Similar results were obtained for 
AML no.11 (fig. 3A, second panels) and the average of replating experiments 
of 6 AMLs is also shown (fig. 3B). 
 In contrast to control Venus-transduced cells, the relative number of 
C/EBPα-ER-transduced cells in suspension dropped significantly as compared 
to untransduced controls (fig. 3A and B). This coincided with a reduction in the 
number of L-CAs that were formed in the initial plating (data not shown). 
Importantly, those remaining L-CAs were impaired in their replating capacity as 
no expanding 2nd cultures could be established with these cells and strongly 
reduced numbers of C/EBPα-ER+ cells were detected upon each replating, 
both in suspension as well as in the adherent population (fig. 3A and B). While 
2nd and even 3rd L-CAs were readily observed in Venus control cultures, these 
L-CAs were absent from replated C/EBPα-ER cultures (fig. 3C). Collectively, 
these data indicate that restoration of C/EBPα activity in primitive AML CD34+ 
cells decreases their self-renewal capacity. 
 In view of the declining self-renewal potential we studied expression of self-
renewal genes such as BMI-1 and Meis1, which are highly expressed in CD34+ 
primitive leukemic cells.186;431 Tranduced cells were sorted after 1 week of 
MS5-coculture and subjected to RT-PCR studies. Of three investigated AML 
samples (AML no.11, no.2 and no.3), only AML no.3 demonstrated a decrease 
in expression of BMI-1 upon introduction of C/EBPα (fig. 3D). The same AML, 
also demonstrated lower Meis1 expression, while Meis1 expression was 
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unaltered in the other two AMLs investigated (fig. 3D). Furthermore, in view of 
the reduced proliferation capacity, the expression of the cyclin dependent 
kinase inhibitors (CDKi) p16, p18, p21 and p27 was investigated. Although no 
effects were seen on the expression of p18 and p27 in all three AMLs 
investigated (data not shown), the CDKi p16 showed an upregulation after 
C/EBPα-ER activation in AML no.3, while no effect was observed in the two 
other AMLs (fig. 3D) Expression of p21 was absent AML no. 11, while present 
in the other two AMLs. This expression was downregulated upon activation of 





































Figure 3 C/EBPα-ER impairs self-renewal of leukemic cells.  
(A) Transduced AML cells were subjected to serial replating experiments in the presence of 500 
nM 4-OHT (N=6) with cells from the adherent fraction. Every two weeks suspension cells were 
removed and analyzed by flow cytometry for Venus expression. 10% of the adherent fraction was 
replated onto fresh MS5 cultures. The Venus percentage within the human CD45+ fraction was 
analyzed as well (Boxes on the right). Two representative experiments are shown (upper and 
middle panel). Venus percentages in suspension cultures at initial plating (Week 0) are set to 1 and 
subsequent weeks are shown relative to initial plating. The relative number of Venus + cells in the 
CD45+ adherent fraction is shown relative to control Venus-transduced cells. (B). The average with 
SEM from 6 individual AMLs is shown. Venus percentages in suspension cultures at initial plating 
(Week 0) are set to 1 and subsequent weeks are shown relative to initial plating. The relative 
number of Venus + cells in the CD45+ adherent fraction is shown relative to control Venus-
transduced cells. (C) Representative phase contrast microscopy images of AML cocultures in the 
presence of 500 nM 4-OHT on MS5 cells after the first replate at week 4 (upper panels, AML no. 
10), or after the second replate at week 6 (lower panels, AML no. 7). Cobblestone areas are 
encircled. (D) RT-PCR analysis of p16, BMI-1, Meis-1, p21 and Neutrophil Elastase (NE) 
expression in 3 AML samples after treatment for 1 week with 500 nM 4-OHT in Venus-transduced 
cells (V) or in C/EBPα-ER-transduced cells (C). GAPDH expression is shown as loading control. -
RT PCRs were performed as negative control. 
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Discussion 
 
Impairments in C/EBPα signaling such as reduced mRNA or protein 
expression, aberrant phosphorylation profiles, or the presence of (dominant 
negative) mutations are often observed in human myeloid leukemias.81;254-
257;260;261 We studied DNA-binding activities of C/EBPα throughout a panel of 
AML patients and showed that C/EBPα DNA-binding was reduced. On the 
basis of our rescue experiments in which C/EBPα was reintroduced into 
primary human CD34+ AML blasts we conclude that restoration of C/EBPα 
expression in AML blasts is sufficient to inhibit both leukemic expansion as well 
as self-renewal of the leukemic cobblestone area (L-CA)-forming stem cell 
pool. In concert with the pronounced proliferation block, a partially restored 
differentiation program was observed by C/EBPα reintroduction.  
Our data suggest that loss of C/EBPα function facilitates the self-renewal 
capacity of leukemic stem cells. In our C/EBPα-transduced cultures, leukemic 
cobblestone areas (L-CAs) were only rarely observed. Serial replating 
experiments established an impaired self-renewal potential as 2nd and 3rd 
cultures could mostly not be initiated. In contrast, the L-CAs that were 
generated from control-transduced cells contained self-renewal capacity as 
demonstrated in serial replating experiments. New L-CAs were generated upon 
sequential replating onto new bone marrow stromal cell layers and a robust 
leukemic expansion was obtained. Mouse knockout studies have already 
shown that C/EBPα deficiency enhances the self-renewal and repopulating 
capacity of HSCs. This results in hyperproliferation of hematopoietic 
progenitors and blocks the transition from the CMP to the GMP stage.253;424 In 
normal human stem/progenitor cells, overexpression of C/EBPα resulted in 
exhaustion of the stem/progenitor cell pool, while myelopoiesis is induced at 
the expense of erythropoiesis244;432 (and unpublished observations by ATJW, 
HS, EV and JJS). Together, these observations firmly establish C/EBPα as a 
critical regulator of stem/progenitor cell fate in both mice and humans. 
 Recently, C/EBPα was also reintroduced into primary Chronic Myeloid 
Leukemia (CML) cells at blast crisis, and although self-renewal of the stem cell 
compartment was not addressed upon C/EBPα reintroduction, myelopoiesis 
was restored upon IL-3 or G-CSF treatment.433 These data coincide with our 
observations in our primary AML models in which myelopoiesis was also 
partially restored upon re-expression of C/EBPα. Besides these primary human 
leukemic models, a number of - mostly mouse - leukemic cell-line models have 
been established in which it was demonstrated that forced expression of 





differentiation.259;433 Previously, we demonstrated that expression of activated 
STAT5 in human CD34+ stem/progenitor cells resulted in enhanced self-
renewal and impaired myelopoiesis. This coincided with a strong 
downmodulation of C/EBPα expression.37 Importantly, re-expression of 
C/EBPα in this model strongly alleviated STAT5A(1*6)-induced self-renewal, 
while myelopoiesis was restored.244 Together, these data firmly establish the 
importance of disturbed C/EBPα signal transduction in a variety of 
hematological malignancies and pinpoint to the therapeutic potential of 
restoring C/EBPα activity in both acute and chronic myeloid leukemia. 
 As it is likely that disturbed C/EBPα signaling is only one of multiple factors 
involved in the pathogenesis of acute myeloid leukemia, it is not surprising that 
not all tested AMLs demonstrated a similar pattern. All investigated AMLs 
responded with a growth arrest and decreased expansion, while restoration of 
the differentiation program was much more variable, suggesting that cell-cycle 
arrest and differentiation are not affected in a similar fashion by the leukemic 
transformation. Experiments with various mutants of C/EBPα have indeed 
established that cell-cycle arrest is required, but not sufficient for granulocytic 
differentiation,434 while the reverse experiment indicated that loss of cell-cycle 
control is sufficient to initiate AML-like transformation.435 When (partial) 
differentiation was restored, in most cases both CD14 and CD15 were 
upregulated. This is consistent with findings that C/EBPα controls the CMP to 
GMP transition, but is not required beyond the GMP stage.253 Therefore, it is 
not surprising that monocytic differentiation can be observed upon activation of 
C/EBPα. While C/EBPα deficiency had already been shown to block 
macrophage development,424 only recently was C/EBPα shown to direct 
monocytic commitment, presumably through upregulation of PU.1 mRNA.247;436 
Although we did not detect an upregulation of PU.1 mRNA in that particular 
AML, preliminary observations in CB CD34+ transduced cells with C/EBPα 
indicated elevated expression of PU.1 (data not shown).  
 The question by which mechanisms low C/EBPα levels enhance self-
renewal of stem cells remains to be addressed. It was demonstrated that 
C/EBPα-/- mice express elevated levels of BMI-1 in Fetal Liver Lin-/Sca-1+/C-
Kit+ hematopoietic stem cells.253 BMI-1 has an essential role in controlling the 
proliferative activity of both normal and leukemic stem cells.186 Mouse HSCs 
engineered to express both HOXA9 and MEIS1 develop leukemia and require 
BMI-1 to transplant the disease into secondary recipients.186 Indeed, 3 AMLs 
investigated demonstrated high expression of BMI-1, although only in one AML 
we observed that C/EBPα re-expression resulted in reduced BMI-1 and MEIS1 
levels. This suggests that although C/EBPα leads to a partial restoration of 
differentiation with a reduction in growth and self-renewal, this does not 
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necessarily involve BMI-1 or MEIS1, indicating variability in the mechanisms 
involved. In that particular AML, downmodulation of BMI-1 coincided with an 
upregulation of the CDKi p16 and a downregulation of the CDKi p21, which has 
been described to be upregulated by a complex of Meis1 with PBX1 and 
HOXA10.437 Although downregulation of p21 does not correlate with an 
enhanced cell-cycle arrest, the absence of p21 has been described to lead to a 
loss of self-renewal of HSCs,29 which is consistent with our findings. 
Interestingly, p16 (Ink4a) is upregulated in the AML where BMI-1 is 
downmodulated by C/EBPα activation. Loss of Ink4a-Arf in HSCs has been 
proposed to lead to a loss of reconstitution potential upon serial 
transplantation438 and high levels of p16 have been correlated to high levels of 
C/EBPα.251 However, future experiments will have to provide evidence for such 
a link.  
In conclusion, we demonstrate that re-introduction of C/EBPα in primary 
CD34+ AML cells leads to a rapid growth arrest, which in some cases is 
paralleled by an enhanced differentiation. Furthermore we demonstrate that 
C/EBPα activation in the leukemic stem cells leads to a loss of self renewal 
capacity, thereby indicating the important function of loss of C/EBPα in the 
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Summarizing discussion and future 
perspectives  




Acute Myeloid Leukemia (AML) is a clonal hematopoietic malignancy, 
characterised by the accumulation of immature blasts in the bone marrow 
(BM). Approximately 40% of all leukemias are AMLs (In the Netherlands, the 
annual incidence is ~1/40.000 persons) and without treatment AML patients 
rarely survive more than 6 to 12 months. Treatment of AML patients usually 
consists of high intensity chemotherapy to induce complete remission (CR), 
followed by consolidation chemotherapy which might include an autologous or 
allogenic stem cell transplantation. However, the majority of the patients 
develop relapse of the AML, although the relapse rate strongly depends on the 
risk group. Patients belonging to the low-risk group have a relapse rate of 
~25%, while patients of the high risk group have a relapse rate of ~80%.20;439 
These results indicate that cellular properties of the AML cells strongly dictate 
the patient’s perspectives. In this thesis various aspects of AML were 
investigated: the development of AML and the difference between 
chemotherapy-resistant AML cells over normal stem/progenitor cells. 
 
In chapter two we examined the involvement of Ras signal transduction in the 
activation of Nuclear Factor of Kappa B (NF-κB). First we demonstrated that 
NF-κB is activated in 73% of the AML patients. Subsequently, we provided 
evidence for an anti-apoptotic role of NF-κB, since AML samples with high NF-
κB activity demonstrated a lower rate of spontaneous apoptosis, as well as a 
reduction in etoposide-induced apoptosis. This etoposide-induced apoptosis 
could be enhanced by inhibition with the NF-κB inhibitor SN-50. We 
demonstrated that constitutive Ras activation correlated with NF-κB activation, 
which could be inhibited by the Ras farnesyl-transferase inhibitor L744328 and 
the PI3K inhibitor Ly294002. Inhibition of MEK-Erk signalling with the inhibitor 
PD98059 did not affect NF-κB activity, indicating that downstream of Ras, PI3K 
signalling played a more important role than MEK-Erk signalling. In addition, 
PKB, the downstream effector of PI3K, was activated in AML blasts with 
constitutively activated NF-κB, suggestive for a Ras-PI3K-PKB signal 
transduction cascade upstream of active NF-κB. L744832 and Ly294002 
inhibition indeed led to reduced phospho-PKB levels. The enhanced Ras 
activation was in part due to Ras mutations. The autocrine / paracrine secretion 
of growth factors might be an alternative pathway for Ras activation, but we did 
not detect activation of NF-κB via such a pathway. Finally, we demonstrated 
that constitutive NF-κB DNA-binding activity correlated with constitutive Flt3 
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phosphorylation. Although Flt3 signal transduction could be impaired with the 
inhibitor AG1296, this did not affect the NF-κB DNA-binding. This suggests that 
Flt3 signal transduction is sufficient to induce NF-κB activity, but it is not 
required and other signal transduction pathways also influence the activity of 
NF-κB. 
These results appear to be in contrast to a recent report, where Flt3 
activation was shown to activate IL-6 expression through NF-κB.440 In that 
report, NF-κB activation was more dependent upon a MEK-Erk pathway than 
on PI3K-PKB. Although we detected no differences in NF-κB DNA binding 
upon MEK-Erk or Flt3 inhibition, Takahashi et al440 reported similar findings, but 
they stated that the expression of NF-κB target genes is abrogated. This 
suggests that different pathways downstream of Flt3/Ras cooperate. PI3K-PKB 
is necessary for DNA binding of NF-κB, whereas MEK-Erk might be necessary 
for transactivation of NF-κB. Indeed, it has been demonstrated that 
overexpression of Ras can activate an NF-κB reporter, which can be abrogated 
by both MEK-Erk and PI3K inhibitors.264;440 These and our findings are hence 
consistent with other reports stating that phosphorylation of different sites in 
p65 are involved in release, translocation, DNA-binding and transactivation of 
NF-κB.441-443 Our data demonstrate that NF-κB DNA-binding is frequently 
activated by a Ras-PI3K-PKB pathway in AML cells and interferes with 
chemotherapy-induced apoptosis, but the precise signals that elicit Ras 
activation seem to be variable.  
 
To investigate whether active NF-κB could play a role in the disturbance of 
steady state hematopoiesis of normal Hematopoietic Stem Cells (HSCs), in 
chapter three we introduced active mutants of NF-κB into cord blood-derived 
hematopoietic stem and progenitor cells. Since phosphorylation of p65, one of 
the major subunits of NF-κB in AML, plays an important role in the activation of 
this transcription factor, we designed and constructed various activating point 
mutants of both p65 and the Inhibitor of IκB Kinase 2 (IKK2), its upstream 
kinase. The activity of these mutants was investigated in various activation 
assays, such as reporter studies, DNA-binding experiments and quantative RT-
PCR studies. This indicated that overexpression of wildtype p65 or the 
constitutive active mutant of IKK2 resulted in activation of the NF-κB pathway. 
Subsequent retroviral overexpression of these mutant proteins in cord blood-
derived CD34+ hematopoietic stem/progenitor cells was followed by various 
culture assays to assess whether proliferation, differentiation, self-renewal or 
apoptosis were affected. In long-term culture assays on bone marrow stromal 
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cells, we demonstrated that constitutive activation of the NF-κB pathway is not 
sufficient to impose a proliferative advantage on these stem/progenitor cells. 
Moreover, no differentiation block could be demonstrated. These results were 
confirmed in various colony assays, specific for common myeloid progenitors 
(CMP), megakaryocytic/erythroid progenitors (MkEP) and granulocyte 
macrophage progenitors (GMP) respectively. Finally, we addressed the 
question whether activation of NF-κB could enhance the number of primitive 
long term culture-initiating cells (LTC-IC), representative for HSCs. In these 
experiments we did not find evidence for a role of NF-κB activation in disturbing 
steady state hematopoiesis.  
 These experiments demonstrated that cells with activated NF-κB behaved 
similarly to normal control cells. This suggested that, although NF-κB activation 
may play an important part in resistance to chemotherapy-induced apoptosis 
(Chapter two), as a single hit, NF-κB activation is not sufficient to transform 
primary hematopoietic stem/progenitor cells. This is consistent with a report by 
Romano et al,299 suggesting that NF-κB is not necessary for basal cell survival. 
The effect of NF-κB activation might be elicited when exposed to stress 
(chemotherapy) or, alternatively, might only be observed in combination with a 
second or third hit. Double transductions of constitutive active NF-κB with 
oncogenes/translocation such as for example AML-ETO, should be performed 
to gain more insight in such a hypothesis. It is important in such studies that 
second hits are chosen that do not activate NF-κB themselves, like for example 
Ras or Flt3. Although multiple studies have suggested that NF-κB plays an 
important role, most of these have used the strategy of inactivating NF-κB. 
Work in (cell-line) models that have been selected for NF-κB activation, and 
hence probably depend on it, not surprisingly lead to this conclusion, but are 
incapable of discriminating between additive or synergistic effects of NF-κB 
activation. 
 
In primary monocytes, the cyclin-dependent kinase inhibitor p21 had been 
described to be a downstream mediator of NF-κB-induced inhibition of 
apoptosis. Since NF-κB is so frequently activated in AML, in chapter four we 
investigated whether p21 was involved in resistance to apoptosis of monocytic 
leukemia. We demonstrated that p21 was not expressed in unstimulated 
hematopoietic cells, but could be induced by growth factors, such as GM-CSF, 
IL-3 or PMA in an NF-κB-independent manner. Although expression of p21 
could not be inhibited by U0126, Ly294002 or SB203580, inhibitors of the 
MEK-Erk, PI3K and p38 kinase pathways respectively, it could be inhibited by 
Summarizing discussion and future perspectives 
  163 
BIM and Chelerythrin, inhibitors of PKC. When we investigated p21 expression 
in primary cells from monocytic FAB M4/M5 leukemias, we found that p21 was 
constitutively expressed in the majority of the M4/M5 leukemias, this in contrast 
to AML cells from M1/M2 leukemias. Furthermore, p21 appeared to be 
exclusively localised in the cytoplasm, which has been demonstrated to be 
necessary for its anti-apoptotic function. Indeed, we demonstrated that 
cytoplasmic p21 in M4/M5 leukemias was correlated to a decreased 
percentage of apoptotic cells. In order to unravel signal transduction pathways 
involved, we demonstrated that in some AMLs p21 expression could be 
inhibited by BIM and Chelerythrin, suggesting that activation of a PKC-
dependent pathway is required. This is consistent with a report showing that 
PKC phosphorylates p21 and directs its nuclear exclusion.444 Conditioned 
medium, which was used to culture cells from M4/M5 leukemias, was added to 
leukemic cell cultures from myeloid M1/M2 classifications to investigate 
whether autocrine production of growth factors was responsible for PKC-
mediated p21 expression. These studies indicated that autocrine growth factor 
production might be involved in this activation. In addition, induction of p21 in a 
monocytic leukemia-derived cell-line inhibited apoptosis by inactivation of the 
MAPKinases JNK and p38. This suggested that cytoplasmic p21 might inhibit 
the upstream kinase ASK1. Immunoprecipitation assays from monocytic 
leukemia extracts indicated that p21 forms a complex with ASK1, which led us 
to propose that in monocytic leukemias part of their resistance to apoptosis is 
mediated via cytoplasmic p21. This then interferes with activation of p38 and 
JNK pathway-mediated apoptosis by inhibition of ASK1.  
The effects of cytoplasmic localisation of p21 are not only observed at the 
level of apoptosis. Our own observations with a p21 variant that lacks the 
nuclear localisation signal (NLS) indicate that it no longer is capable of inducing 
growth arrest, which is consistent with other reports.445 Thus the cytoplasmic 
localization of p21 in M4/M5 leukemias may also contribute to a growth 
advantage, due to the lack of a negative feedback system. P21 knock-out 
HSCs have a decreased self-renewal property,29 which is correlated with an 
increased cell-cycle progression. Based on these findings it is of interest to 
investigate whether FAB M4/M5 monocytic leukemias have an altered self-
renewal capacity or in vitro growth characteristics as compared to FAB M1/M2 
myeloid leukemias. Expansion of AML cells on MS5 stroma indeed suggested 
that M4/M5 leukemias initially expand faster than M0-M2 leukemias, but after 
10 weeks of long-term culture this difference disappeared (D. van Gosliga, J.J. 
Schuringa personal communication, manuscript submitted). It is however 
unclear whether this is due to p21 localisation and hence effects on growth or 
self renewal, or an inherent property of monocytic AMLs. Furthermore, it can 
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not be excluded that p21 only affects apoptosis and cell-cycle and not self-
renewal, since the self-renewal phenotype of p21-deficient HSCs appears to be 
mouse strain-dependent.185 It would be interesting to study the cellular 
properties of CB-derived CD34+ cells transduced with a p21 construct lacking 
the NLS. Similar, it might be relevant to study the effects of PKC inhibitors on 
the growth characteristics of AML cells. It is known that the PKC-inhibitor UCN-
01 with various other inhibitors can enhance the apoptotic potential of 
monocytic U937 cells, but UCN-01 alone has marginal effects regarding 
apoptosis.446-448 This would thus make it possible to study the effects of p21 on 
cell-cycle and self-renewal in the absence of apoptosis in both normal cells as 
well as in monocytic leukemias.   
 
The above described DAXX-ASK1 pathway has also been shown to be 
modulated by chaperone proteins such as HSP27. Since HSP27 had been 
demonstrated to be upregulated in AML blasts, in chapter five we investigated 
the role of Heat Shock Protein 27 (HSP27) in compensating apoptosis in AML 
cells via the ASK1-p38-JNK pathway. First we demonstrated that 
downregulation of HSP27 by means of RNA interference (RNAi), increased 
etoposide-mediated apoptosis in leukemic-derived TF-1 cells. To explore 
whether HSP27 exerted its effects downstream in the apoptotic pathways or 
upstream, co-immunoprecipitation studies were performed to study its 
interaction with pro-caspase 3, cytochrome c and DAXX. We failed to detect 
HSP27 in complex with either pro-caspase 3 or cytochrome c, which suggested 
that HSP27 exerts its effects higher up in the apoptotic pathway. Complex 
formation with DAXX confirmed this suggestion and this interaction depended 
upon the presence of ASK1. Since cytochrome c release into the cytoplasm 
was enhanced after HSP27 RNAi, we examined the effects on phosphorylation 
of the upstream kinases involved in mitochondrial integrity, p38 and JNK. 
These are downstream of DAXX-ASK1 signalling. Western blot analysis 
revealed that upon downregulation of HSP27, activation of p38 and JNK (as 
measured through phosphorylation of the downstream target c-Jun) was 
enhanced upon treatment with etoposide. Together, we concluded that HSP27 
is able to inhibit DAXX-ASK1-p38/JNK-mediated apoptosis.  
 The results described in chapters four and five demonstrate that p21 and 
HSP27 can associate with the same apoptosis-inducing protein complex, 
DAXX and ASK1. However, p21 and HSP27 were not simultaneously detected 
in the same complex. We examined whether HSP27 expression was correlated 
with decreased levels of apoptosis in primary AML cells, as the cell-line model 
predicted, but no correlation between HSP27 expression and apoptosis could 
be demonstrated. Interestingly, HSP27 expression correlated with p21 
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expression, both of which were mainly expressed in M4/M5 leukemias and 
absent in M1/M2 leukemias. The strong anti-apoptotic effect of cytoplasmic p21 
might compensate for the absence of HSP27. This would seriously hamper 
attempts to correlate HSP27 expression to decreased levels of apoptosis. To 
test this, we created a TF-1 cell-line, which constitutively expressed a 
cytoplasmic form of p21, and performed HSP27 RNAi in these cells. 
Subsequent western blot analysis demonstrated that the enhanced activation 
of p38 after HSP27 RNAi could be impaired when p21 was expressed in the 
cytoplasm, providing evidence for our hypothesis.  
 Interestingly, HSP27 demonstrated only a cytoprotective effect after 
treatment with etoposide, but not with CD95/Fas. Although CD95/Fas treatment 
did result in pro-caspase 3 cleavage, arguing for a Fas-FADD apoptotic route 
independent of p38 and JNK, this did not result in apoptosis. Examination of 
HSP27 levels revealed that upon CD95/Fas treatment HSP27 levels were 
drastically increased. This is suggestive for an anti-apoptotic effect of HSP27 in 
the CD95/Fas pathway as well, in a way that CD95/Fas treatment induces 
HSP27 and thereby impairs its own apoptotic induction. The upregulation of 
HSP27 however was so massive, that attempts to downregulate HSP27 failed 
in this setting and we therefore could not further explore this hypothesis. 
 
Leukemic cells have different properties that give cells a growth advantage 
over their normal counterparts. Besides defects in apoptotic pathways, the cells 
might be less susceptible for the effects of negative regulators. Therefore in 
chapter six we examined the mechanism through which N-RasL61 transformed 
cells escaped negative growth regulation by TGF-β. Two Ras-transformed cell 
lines, HL-60 and TF-1, were compared to a cell line without the Ras mutation, 
M1 cells. These Ras cell lines were unresponsive to TGFβ with regard to a cell 
cycle arrest, whereas TGF-β-induced transcription was normal. Interestingly, 
p27 was absent from Ras-transformed cells, which suggested that p27 was the 
central protein through which TGF-β-mediated cell cycle responses could be 
modulated. Using the L744632 and U0126 inhibitors, we demonstrated that a 
TGF-β response could be restored, which coincided with restoration of p27 
expression. Overexpression of p27 indeed was sufficient to restore cell-cycle 
arrest upon TGF-β treatment. Further investigations with transcription, 
translation and degradation inhibitors, established that Ras-MEK-Erk signal 
transduction was involved in degradation of the p27 protein, rather then 
suppression of transcription or translation.  A well known protein involved in 
degradation of p27, SKP2, indeed proved to be upregulated in Ras-
transformed cells, and this could be inhibited by inhibiting the Ras pathway 
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using the inhibitor L744832. Moreover, overexpression of N-RasL61 in M1 cells 
resulted in an enhanced expression of SKP2. Further involvement of SKP2 in 
p27 degradation downstream of Ras signal transduction was demonstrated by 
overexpression of various p27 phosphorylation mutants. Interestingly, only 
mutation of the phospho-site known to be involved in SKP2-mediated 
degradation, left p27 resistant to degradation. This in contrast to observations 
that multiple sites were phosphorylated. U0126 treatment did not alter the 
phosphorylation status of p27, which was in line with our observations of an 
indirect effect of Ras-MEK-Erk signalling. Subsequent immunoprecipitation 
studies established complex formation between SKP2 and p27, and RNAi 
against SKP2 restored p27 levels in these cells. These data demonstrated 
another mechanism by which Ras signal transduction could render cells 
unresponsive towards the negative regulatory effects of TGF-β and contribute 
towards the advantage of leukemic cells over normal cells. 
 In four AML patients with N-RasL61 mutations, we indeed observed 
absence of p27 or mislocalisation to the cytoplasm. In other studies 
mislocalisation of p27 in AML patients was attributed to PKB 
phosphorylation,155 which is consistent with Ras activation as observed in 
chapter two. However, in our cell line models we could not correlate p27 
phosphorylation with PKB activation. In those AML patients with PKB 
activation, the poor disease free and overall survival was not correlated to the 
level of p27 protein, but to a high cytoplasmic to nuclear ratio. Although these 
results seem different from our model it may actually result in a similar 
phenotype, since p27 degradation in the nuclear compartment will yield a high 
cytoplasmic to nuclear ratio. Indeed, Min et al did detect a heterogeneous 
pattern of p27 localisation, arguing that different models can be present in 
AML. Furthermore, in conjunction with high cytoplasmic to nuclear ratios of p27 
they also demonstrated that SKP2 was highly expressed in the majority of the 
AML patients and correlated to both poor disease free survival and overall 
survival.401  
 
The above described degradation of p27 was attributed to the activation of the 
Ras-MEK-Erk pathway, but in chapter two we demonstrated that Ras 
activation is not necessarily due to Ras mutations. Mutations in the Flt3 
receptor have been demonstrated to lead to Ras-MEK-Erk activation as well. 
These mutations are very common in AML (~30%) and frequently also activate 
PI3K and STAT5 signal transduction pathways. To examine the effects of 
STAT5 on the cellular properties in normal primary cells, in chapter seven we 
lentivirally introduced a RNAi hairpin against STAT5 in CD34+ CB-derived 
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stem/progenitor cells. This enabled us to downregulate STAT5 protein levels by 
up to 85%. In long-term cultures with stromal bone marrow cells, we 
established that downregulation of STAT5 severely reduced expansion of CB 
CD34+ cells, without altering the differentiation capacity. This in contrast to 
overexpression of an activated form of STAT5, which skewed differentiation of 
progenitors towards an erythroid fate.37 Interestingly and paradoxically, the 
observed reduction in expansion was not due to an increased apoptosis or an 
increased cell-cycle arrest in bulk cultures. Limiting dilution analysis of both 
progenitor numbers as well as the more primitive LTC-IC, indicated that STAT5 
knockdown resulted in a 5-fold reduction in progenitor and LTC-IC frequency. 
To further assess how the primitive cells were affected, CD34+CD38- cells were 
transduced and followed individually in culture for 100 hours by microscopic 
examination. The results indicated that transduction of STAT5 RNAi reduced 
the number of cell divisions with a subsequent reduction in offspring 
production, compared to control cells. In line with the limiting dilution progenitor 
assays, this eventually resulted in a lower output of colony numbers. Finally, 
STAT5 downregulation was studied in primary AML cells. CD34+-sorted AML 
cells were transduced with the STAT5 RNAi lentiviral vectors, long-term 
cultures were initiated, and we observed a reduced expansion of these cells 
similar to what was observed in CB-derived CD34+ cells. Furthermore, FACS 
analysis demonstrated no effect on the differentiation pattern of these AML 
cells.  
Our observations regarding differentiation correspond to the relatively mild 
phenotype of STAT5A/B-/- mice. These mice displayed normal levels of all 
blood cell types in the peripheral blood.239 In contrast, a significant reduction in 
progenitor and LTC-IC frequencies was observed by downmodulation of 
STAT5 expression in the HSC and progenitor subpopulations. The results are 
compatible with the observation published by  Scherr et al, who have reported 
similar reductions in CD34+ progenitors.411 Furthermore, their and our observed 
reduction in colony numbers after STAT5 RNAi corresponded with the 
reductions seen in CFU-mix colonies and in CFU-GM colonies in STAT5AB-/- 
mice.239 These data demonstrate that very primitive hematopoietic cells are 
dependent upon STAT5 for normal growth. It suggests that leukemic stem cells 
benefit from constitutive STAT5 activation, which is frequently observed in 
AML. Although overexpression of a constitutively activated STAT5 can skew 
differentiation towards an erythroid fate, downregulation does not affect this 
differentiation, arguing that either STAT5 is sufficient, but not necessary, or that 
redundancy exists among STAT family members. The possibility that RNAi is 
not effective enough in downregulating STAT5 is highly unlikely, given the 
similar phenotypes of the STAT5AB-/- mice. Overexpression of STAT5 also 
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enhances the self-renewal potential of HSCs, which is consistent with the 
decreased repopulation potential of STAT5AB-/- HSCs.240;241 Future 
experiments will be focused on self-renewal properties by replating assays with 
RNAi-transduced leukemic cells.  
 
It was recently demonstrated that activation of STAT5 results in downregulation 
of CCAAT enhancer binding protein alpha (C/EBPα) and re-introduction of 
C/EBPα restored progenitor cell differentiation.244 Different studies have 
recently shown that C/EBPα is frequently mutated or otherwise inactivated in 
AML cells. In chapter eight we therefore examined the effects of re-
introduction of C/EBPα in primary AML stem cells. First we demonstrated that 
C/EBPα DNA binding was severely diminished in CD34+ sorted primary AML 
cells, which underscored the reduced C/EBPα expression observed in various 
AMLs. Long-term culture on stromal bone marrow cells after lentiviral 
introduction of an inducible form of C/EBPα, demonstrated an immediate 
growth arrest upon induction. This growth arrest was accompanied by a partial 
restoration of differentiation, as measured by FACS analysis for markers 
demonstrating monocytic and granulocytic differentiation (CD11b, CD14 and 
CD15). In one AML, MGG stains also indicated the presence of more fully 
differentiated macrophages, confirming the observed FACS profile. 
Interestingly, almost no leukemic cobblestone area forming cells (L-CA), a 
measure for stem cell activity, were observed in C/EBPα induced cultures, 
whereas control cultures did. This suggested that the self-renewal property of 
LSCs might be affected, since it was already known that C/EBPα knockout 
HSCs show an enhanced self-renewal.253 To test this, replating experiments 
were performed by sequentially passaging adherent leukemic cells onto fresh 
bone marrow stroma and subsequently the ability to repopulate a new leukemic 
culture was measured. Strikingly, whereas control cultures were able to start a 
new culture for up to 3 times at least, with the appearance of new L-CAs, 
C/EBPα induced cultures were incapable of doing so. Subsequently, self-
renewal and cell-cycle genes were studied in response to C/EBPα restoration. 
In one AML, we demonstrated that C/EBPα activation correlated with the 
reduced expression of self-renewal genes BMI-1, Meis1 and the CDKi p21, 
whereas upregulation of the CDKi p16 was observed as well. This would fit with 
data from C/EBPα-/- HSCs. However, two other AMLs studied did not indicate 
such an effect of C/EBPα restoration on these genes, indicating that more 
experiments need to be performed to establish a link between C/EBPα 
restoration and the downstream events involved in decreasing the self-renewal 
capacity.  
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Interestingly, the AML that showed a reduction in BMI-1 and Meis1 expression 
upon introduction of C/EBPα also had the highest increase in differentiation 
markers, suggesting that differentiation and self-renewal are directly related to 
each other. Future experiments using more AML samples are required to 
generalize our findings, but it is interesting to note that there is not only a 
distinction between cell-cycle arrest (observed for all AMLs) and differentiation 
(observed in some AMLs), but also with self-renewal (decreased replating was 
observed for all AMLs) and differentiation. The fact that cell-cycle arrest is 
observed in all AMLs along with a decrease in self-renewal capacity, 
demonstrated that C/EBPα was functionally introduced into these cells. 
However, this is in sharp contrast to observations that self-renewal is impaired 
if cell-cycle progression is stimulated, as has been postulated for the p21-/- 
HSCs.29 Experiments designed to modulate the expression level of C/EBPα 
would give more insight in the various functions of C/EBPα. Future studies 
should also include the analysis of a larger cohort of AML samples in which 
C/EBPα is re-introduced. 
 
 
Models for signal transduction-targeted inhibitors 
 
During the last decades the understanding of the genetic background, activated 
signal transduction pathways and signal transduction intermediates involved in 
the etiology of AML has expanded exponentially. Despite this enormous 
increase in the amount of knowledge and the subsequent progress in AML 
treatment, standard induction therapy still fails to induce remission in up to 20-
30% of the AML patients. Furthermore, relapse is common in approximately 
60% of these patients in remission.449 Of adult AML patients up to 60 years of 
age, only 30% demonstrate long-term disease-free survival and this prognosis 
is much worse for older patients.439 In the upcoming years, with an increasing 
mean age of our population, the number of AML patients is likely to rise and, 
without treatment improvements, AML-related morbidity and mortality as well.  
 Due to the low treatment success rate and the increased amount of 
knowledge regarding AML, in recent years a plea for more signal transduction-
targeted therapies can be heard. The drugs that are currently entering (clinical) 
trials can be grossly divided into two classes: Inhibitors that target receptor 
tyrosine kinase signalling and inhibitors that interfere with genetic remodelling. 
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Flt3 inhibitors, such as PKC-412, CEP-701, ML-518 and SU5416439 are 
expected to enhance apoptosis and lead to cell cycle-arrest, since the 
downstream Ras pathway is inactivated, which will lead to a subsequent 
inactivation of NF-κB and an upregulation of p27. As STAT5 is implicated to be 
downstream of Flt3 in inducing early cobblestone formation,450 effects are also 
expected on self-renewal and differentiation. Indeed, Zheng et al were able to 
demonstrate that inhibition of Flt3-ITDs using CEP-701, resulted in partially 
restored myelopoiesis, due to restoration of C/EBPα.259 Recently, both STAT5 
as well as MEK-Erk signalling have been shown to downregulate C/EBPα and 
may thus be responsible for these observed effects.244;260  
 Inhibitors that act on the Ras pathway, the so-called farnesyl transferase 
inhibitors, including R115777 (Tipifarnib or Zarnestra), L-778,123, BMS-
214,662, CP-609,754 and SCH66336, have entered phase I and II trials449 and 
are expected to act in a similar fashion. In contrast to both Flt3 and 
farnesyltransferase inhibitors that act upstream to inhibit these pathways, the 
proteasome inhibitor Bortezomib (Velcade), also interferes with growth and 
survival of AML cells through the upregulation of both p27 and the inhibitor of 
NF-κB protein IκB. Recently, a report suggested that prolonged exposure to 
Flt3 inhibitors leads to resistance, due to the activation of parallel pathways and 
bypassing the necessity of Flt3 for activation of downstream signal transduction 
components.451 This suggests that inhibiting numerous downstream targets 
would be preferred over more upstream targets in these signal transduction 
pathways.  
 Two of the Flt3 inhibitors mentioned previously, PKC-412 and CEP-701, 
have also been used as PKC inhibitors,439 which might be used to inhibit p21 
expression in monocytic leukemias. The compound 7-hydroxystaurosporine 
(UCN-01), which is currently involved in various clinical I and II trials, has also 
been suggested to serve as a PKC inhibitor and indeed, its use has 
demonstrated to enhance JNK and p38 activation.446-448;452;453 UCN-01 has 
furthermore been assigned a role in reducing PKB activation, which contributes 
to the induction of apoptosis along with activation of p38 and JNK.447;448;452 
However, the use of UCN-01 enhances Raf1-MEK-Erk signalling, but 
combinations with a farnesyltransferase inhibitor or the clinical HSP90 inhibitor 
17-AAG, have been shown to reverse this effect and potentiate mitochondrial 
induced apoptosis and inhibition of NF-κB.447;454 Although no effects on HSP27 
have been described for both UCN-01 or 17-AAG, potentiating p38 and JNK 
would bypass HSP27-DAXX-ASK1 and lead to apoptosis.  
 The second group of inhibitors interfere with proteins that modulate the 
accessibility of the DNA, the histone deacetylases (HDACs) and DNA methyl 
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transferases (DNMTs). HDAC inhibitors (Valproic acid, SAHA, butyrate, 
depsipeptide and MS-275) and inhibitors of DNMTs, such as azacitidine and 
decitabine, are currently undergoing clinical trials.455 Deacetylase activity has 
been demonstrated to be required for STAT5-dependent transcription.456;457 
Furthermore, translocation products in AML also use chromatin remodelling as 
a means of gene repression and in the majority of those C/EBPα is 
downregulated as well.81;261;425;426 If these events are somehow linked, 
treatment with HDAC and DNMT inhibitors can restore C/EBPα expression and 
control constitutive activation of STAT5 in AML, with subsequent effects on 
self-renewal, differentiation and cell cycle. However, some caution should be 
taken using such inhibitors as well, since upregulation of p21 has been 
demonstrated to occur.458 In monocytic leukemias this might have adverse 
effects, since it interferes with apoptosis, instead of potentiating it. 
In analogy to the multiplicity of potential molecular targets in AML, many 
inhibitors have been designed and are currently under evaluation for their 
efficacy. Regarding the heterogeneity of the disease, it is likely that future 
therapy will involve a combination of various inhibitors, depending upon patient-
specific parameters. 
Figure 1 Inhibitors in clinical trial and their possible actions. 








Based on genomic alterations in the process of leukemic transformation, a 
number of signal transduction pathways are affected that regulate apoptosis, 
proliferation, differentiation and self-renewal of AML cells. The current view of 
leukemic transformation involves mutations affecting differentiation and self-
renewal as first hit (group 1 mutations), combined with second hit mutations 
that affect survival and proliferation (group 2 mutations). This model is also 
known as the multiple hit model. In some cases (chapter 8) it might appear that 
interfering with one single hit is sufficient to restore some elements of 
hematopoiesis. However, not all AMLs behaved in the similar way, indicating 
that multiple “hits” make use of different, yet unknown pathways.  
The usage of PCR-techniques has provided additional information regarding 
clonal abnormalities, such as mutations of Flt3, c-Kit, Nucleophosmin (NPM), 
Ras and C/EBPα to the current cytogenetics, based on metaphase banding 
and FISH techniques, which only detect relatively gross abnormalities, 
including chromosomal translocations and deletions. However, heterogeneity is 
still common amongst groups of AML patients, even within groups with a 
defined genetic make-up, such as t(8;21)(q22;q22) or inv(16)(p12;q22).459 In 
order to improve our current knowledge of AML, various approaches should be 
taken to further subdivide and increase the homogeneity of these subgroups in 
order to unravel the underlying mechanisms. 
 
Gene expression profiling and PCR 
A powerful tool in characterisation of large cohorts of AML patients is gene 
expression profiling. Valk et al. and Bullinger et al. identified seven novel 
subgroups of AMLs based on gene expression profiles.460;461 The clustering of 
patients with known chromosomal aberrations, such as t(8;21) (AML-ETO), 
t(15;17) (PML-RARα) and inv(16) (CBFβ-MYH11), demonstrate the validity of 
this approach, but is hardly surprising, given the effects on gene expression of 
most of these translocations. However, the subgroups of patients with t(8;21), 
inv(16), 11q23 abnormalities as well as the AML subgroups with C/EBPα 
mutations, EVI1 expression and the AML subgroup with a normal karyotype 
were further subdivided in two or more classes. The explanation of this 
segregation within these groups lies probably in the fact that additional genetic 
defects add to a distinct gene expression profile. The challenge is therefore to 
characterise these additional hits and further subdivide into groups with a more 
homogenous character. 
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Based on this, both groups designed a set of predictor genes, with which they 
could predict clinical outcome in an unsupervised clustering analysis. Although 
both groups have some overlapping and some diverging results, it is interesting 
to note that a few genes are present in both of their predictor gene sets and 
may serve as novel targets for future therapy. Amongst these are homeobox 
genes of the HOX family as well as the homeobox gene PBX3. Whereas the 
role of HOX family members in self-renewal and leukemia becomes more and 
more understood, the precise role of PBX3 has yet to be discovered. Especially 
the PBX3C isoform is an interesting target since its expression is favoured in 
leukemic cells and may contribute to the process of leukemogenisis.462 To 
assess this, overexpression of this isoform in cord blood stem and progenitor 
cells may reveal its involvement in the enhanced self-renewal capacity of 
leukemic progenitors.  
 Furthermore, members of the CTNNA1 and CTNNAL1 are amongst the set 
of predictor genes. These genes encode for catenin family members α-catenin 
and the α-catenin related protein α-catulin. Both proteins inhibit or attenuate 
the synergy between Ras and β-catenin and their expression may therefore 
play an important role in regulating catenin signalling.463 Since the downstream 
mediator TCF4 was on one of the prediction sets and recently γ-catenin was 
implicated in leukemia,464;465 it would be interesting to investigate the role of 
these regulators of catenin signalling in AML.  
 A third set of genes within these predictor sets with possible implications 
for our understanding of the leukemic clone are ANGPT1 and ANGPTL4. The 
angiopoietins and angiopoietin-like proteins were recently shown to affect 
hematopoietic stem cell expansion,55;466 and it may therefore be rewarding to 
downregulate these proteins in the leukemic stem and progenitor cell 
compartment. 
 Although these findings demonstrate that gene expression profiling is a 
valuable prognostic tool and may indicate several relevant gene-products for 
drug targeting, knowledge about small (point) mutations can also be relevant. 
Although Valk et al. showed that gene expression from patients with C/EBPα 
mutations clustered together, they could not show similar results for patients 
with Ras or Flt3 mutations.460 This either implicates that additional mutations 
add to the gene expression profile; or, the effects of high expression of wt 
genes resembles the downstream effects of the mutated gene. This latter 
possibility has been suggested for high wt Flt3 expression in relation to Flt3-
ITD and prognosis.461 In cases where Flt3 mutations associated with NPM1 
mutations, the favourable outcome, correlated to NPM1 mutations, was lost.96 
Whether this is also true for high Flt3 expression in combination with NPM 
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mutations, needs further investigation. Since more than 50% of the patients 
with a normal karyotype have NPM1 mutations and approximately 30% have 
Flt3 mutations, combining gene expression profiling with mutation analysis may 
have prognostic value for the patients in this group.  
 
Protein levels and activation 
In defining risk-groups of AML patients, it may also be useful to know the 
activation status of the proteins involved. Gene expression does not always 
correlate with protein expression or activation, due to post transcriptional and 
post translational modifications. P27 for example, was expressed at the mRNA 
level in N-Ras mutated cell-lines, but was absent at the protein level due to 
enhanced degradation. We also observed that the expression of C/EBPα 
mRNA in various AMLs did not always correlate with the level of C/EBPα 
protein on DNA binding. Furthermore, some of the C/EBPα transduced AMLs 
did not differentiate, although all responded with a growth arrest. This suggests 
that the protein level or its activation is of utmost importance for the cell 
biological outcome.  
 Such dose-response outcome is supported by studies in mice with various 
expression levels of the transcription factor PU.1. Downregulation of PU.1 by 
80% induces a pre-malignant state with an expansion of myeloid progenitors, 
this in contrast to knock-out PU.1-/- or heterozygous PU.1+/- mice.467 This may 
also be important for human hematopoiesis and leukemia, since PU.1 is 
necessary in both MPP to CMP differentiation, as well as in lineage 
commitment via the CLP stage. Although mutations in the PU.1 gene (Sfpi1), 
affecting DNA binding or transactivation are found in only 7% of all AML 
patients,468 multiple cytogenetic abnormalities have shown to result in PU.1 
downregulation. Reintroduction of PU.1 into leukemic stem cells should be 
performed to confirm its involvement in the leukemic process and graded re-
introduction might shed some light upon its regulation of cell-cycle vs. 
differentiation and self-renewal.  
 The above described gene expression profiling has implicated the 
homeobox family of HOX genes in the leukemic process460;461 as well as in a 
recent model of MLL-AF9-induced leukemia.106 Indeed, HOX expression 
enables the identification of a subset of AML patients with intermediate 
cytogenetics,469 but the precise manner in which the HOX genes contribute is 
still unclear. Transient overexpression of HOXB4 in CB CD34+ cells has 
revealed that myeloid differentiation is promoted, whereas proliferation is not 
impaired.470 On the other hand, continuous expression of various HOXB4 
(protein) levels has demonstrated that high levels actually impair differentiation 
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and showed an enhanced proliferation.471 This apparent dichotomy needs 
further clarification, since a better understanding may lead drug development 
towards lowering HOXB4 levels.  
 However, care should be taken when it comes to lowering proteins levels of 
highly expressed genes. The H-Ras protein for example, reduces proliferation 
of human hematopoietic progenitors and enhances monocytic differentiation 
when highly expressed. But upon farnesyl transferase treatment of these H-
RAS expressing progenitors, not only their  proliferation was increased, but 
their self-renewal  as well.472 Similar data has been observed in mice 
expressing PML-RARα, for which it was shown that the development of APL in 
mice could be enhanced from an incidence of 20% to 90%, when its expression 
was lowered.473;474 Although these two models seem counterintuitive in their 
behaviour, e.g. lower activation, but enhanced leukemic potential, in 
combination with the other examples they nicely illustrate the point that 
activation levels itself hold important information regarding the outcome. 
 Data using 4-OHT-inducible STAT5-ER proteins suggest that the cell 
biological phenotype indeed highly depends on the level of STAT5 activity ( 
A.T.J. Wierenga and J.J. Schuringa, personal communication) and 
observations that constitutive STAT5 activation in AML is lower than cytokine-
induced STAT5 activation, further underscore the necessity of future 
investigations into modulating expression and activation levels of the proteins 
mentioned above. Obtaining knowledge regarding the proteomic make up of 
AML patient cohorts, should add to our current understanding of the 
heterogeneity of the disease.  
 
Studying the leukemic stem cell compartment 
Part of the heterogeneity in AML in the response to therapy may be due to the 
fact that the leukemic stem cell that gives rise to the observed bulk of blast 
cells is very rare. Although the observed bulk of blasts cells share some degree 
of similarity with the leukemic stem cell, e.g. mutations and translocations, high 
relapse rates indicate a failure to eradicate this cell and suggest that it is 
different then the observed blast cells. Since many studies of AML cells have 
involved blast cells, it may not always be possible to extrapolate the information 
from these studies towards the leukemic stem cell. This is in part due to our 
lack of knowledge regarding the leukemic stem cell and therefore it is of crucial 
importance to gain more insight into the nature of this cell. Bonnet et al. have 
greatly enhanced our view of the phenotype of this leukemic stem cell, in 
showing that this cell resides in the pool of CD34+ CD38- cells and is capable of 
engraftment in immune deficient mice.32 The phenotype of these NOD/SCID 
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engrafting cells, has since been extended to CD34+ CD38- CD33+ CD123+ 
CD71- CD90- c-Kit- HLA-DR-.102-104;475;476 Our leukemic long-term cultures have 
been performed with CD34+ cells, in which the frequency of stem cells is 
already enhanced, but further fractionation would be desirable, in order to gain 
more insight in the events that drive the leukemic process.  
 The long term stromal co-culture system, as used in some of our 
experiments, is an easy accessible system to screen various fractions of 
leukemic cells for their clonogenic “stem cell” capacity, which subsequently 
must be evaluated by engraftment studies in NOD/SCID mice. However, 
approximately 50% of all AMLs do not engraft NOD/SCID mice, which has 
been correlated to the karyotype of the AML.422 This might be due to the 
possible stem cell origin of those particular AMLs that do engraft and the 
possible progenitor origin of those that do not. Alternatively, it may be due to 
the transforming event, e.g. the resulting translocation product or mutation. It is 
worth while to investigate these possibilities by modulating translocation 
products, mutated proteins and other potential targets obtained from the above 
described gene expression and proteomic profiles. Transduction of AML stem 
cells with (inducible) RNAi vectors and investigating the differentiation and 
replating capacity in vitro and the engraftment of NOD/SCID in vivo should 
shed more light on the nature of the leukemic stem cell.  
 In conclusion, gene expression profiling as well as proteome expression 
profiling should provide us with potential targets for future studies. Interfering 
with these potential targets, preferably in leukemic (stem) cells, will provide us 
with a better understanding of their role in the various AML subtypes. This 
knowledge can subsequently be used to develop patient-tailored therapies as 







   
C
hapter 10




Hematopoiese is een hiërarchisch proces van bloedcelontwikkeling dat start bij 
de  hematopoietische stamcel (HSC). Deze HSC is de moedercel, van waaruit 
alle dochterbloedcellen voortkomen. De HSC is zeer zeldzaam, wordt 
voornamelijk gevonden in het beenmerg en heeft eigenschappen waardoor het 
kan kiezen tussen zichzelf vernieuwen (een proces dat self-renewal heet), of 
veranderen (differentiëren) naar een van de vele dochtercellen die ons bloed 
rijk is. Self-renewal zorgt ervoor dat na deling minstens één HSC behouden 
blijft. Dit wil zeggen dat tenminste één van de ontstane dochtercellen de 
capaciteit behoudt om elke gewenste dochtercel te worden. Dit in tegenstelling 
tot het proces van differentiatie, waarbij de dochtercel dit vermogen verloren 
heeft en zich specialiseert in een bepaalde richting.  
 Het proces van hematopoiese voorziet het lichaam van miljarden 
bloedcellen per dag en moet flexibel genoeg zijn om zich aan te kunnen 
passen om de juiste cel op het juiste tijdstip te produceren. Hematopoiese is 
daarom een strak geregisseerd proces, waarbij extracellulaire mechanismen, 
zoals beïnvloeding door groeifactoren en cel-cel interacties, samen met 
intracellulaire mechanismen een belangrijke rol spelen. Veranderingen in het 
doorgeven van de daarbij behorende signalen (signaaltransductie) en de 
daaropvolgende veranderingen in de activiteit van genetische programma’s 
zullen uiteindelijk leiden tot een zeer goed afgestelde balans tussen de 
processen die bij bloedcelontwikkeling een belangrijke rol spelen. 
 
Acute myeloide leukemie 
Acute myeloide leukemie (AML) is een klonale hematopoietische afwijking in 
de bloedcel-ontwikkeling, die gepaard gaat met ophoping van onrijpe blasten 
(vroege cellen) in het beenmerg. Deze blasten zijn verstoord in hun vermogen 
om te differentiëren tot verschillende uitgerijpte dochtercellen. Ongeveer 40% 
van alle leukemieën valt onder de categorie AML. 
 De behandeling van patienten met AML bestaat uit chemotherapie, 
zonodig gevolgd door een stamcel transplantatie. Bij veel patiënten komt de 
ziekte op een zeker moment weer terug. De kans hierop varieert tussen 
verschillende AML-typen en wordt sterk bepaald door genetische afwijkingen 
die aanwezig zijn in de AML cellen. In hoofdstuk 1 wordt een overzicht 
gegeven van de processen die deze eigenschappen mede bepalen en een 
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Geprogrammeerde celdood en AML 
Geprogrammeerde celdood of apoptose is één van de processen die de 
hematopoiese reguleren. Signaaltransductie als gevolg van 
groeifactorstimulatie heeft niet alleen effect op de groei van, en differentiatie tot 
verschillende typen bloedcellen, maar verandert tevens overlevingssignalen 
door genen te beïnvloeden die ingrijpen op het proces van apoptose. Vaak zijn 
deze signalen op een dusdanige wijze in leukemische cellen verstoord, dat de 
balans tussen apoptose en overleving in het voordeel van de laatste uitvalt. 
Chemotherapeutische behandeling is dan ook vaak gebaseerd op het principe 
van het induceren van apoptose. Echter, in leukemie cellen zijn vaak eiwitten 
geactiveerd die het proces van apoptose tegen gaan. Hierdoor kunnen AML-
cellen chemotherapie resistent zijn of resistentie ontwikkelen.  
 In dit proefschrift hebben we gekeken naar de effecten van verschillende 
eiwitten op het proces van apoptose in leukemische cellen. Het eiwit Nuclear 
Factor of kappa B (NF-κB) is één van de eiwitten die in AML-cellen veelvuldig 
geactiveerd is, terwijl in normale cellen dit uitsluitend voorkomt na 
groeifactorstimulatie. In hoofdstuk 2 laten we zien dat AML- cellen met een 
geactiveerd NF-κB eiwit, een lagere spontane apoptose hebben dan AML-
cellen zonder een geactiveerd NF-κB eiwit. Tevens is de chemotherapeutisch-
geïnduceerde apoptose verlaagd in de cellen met een geactiveerd NF-κB eiwit. 
Door een remmer van het eiwit NF-κB te gebruiken konden we de effectiviteit 
van chemotherapie verhogen in cellen waarin NF-κB actief is als gevolg van 
een signaaltransductieroute die RAS, PI3-Kinase en PKB omvat.  
 De continue activatie van NF-κB in een hoog percentage van de AML-
cellen roept de vraag op of NF-κB-activiteit niet alleen betrokken zou kunnen 
zijn bij chemoresistentie, maar misschien ook bij maligne ontaarding. 
Verschillende signaaltransductieroutes die betrokken zijn bij leukemische 
transformatie, leiden tot activatie van NF-κB. Maar of continue NF-κB-activatie 
voldoende is of dat andere signaaltransductieroutes, alleen of in combinatie 
met NF-κB, een rol spelen, is niet opgehelderd. In hoofdstuk 3 zijn de effecten 
bestudeerd van een geactiveerd NF-κB op de normale hematopoietische stam- 
en voorloper cel. Overexpressie in CD34+ stam- en progenitorcellen had 
echter, ondanks de continue activatie, niet tot gevolg dat de cellen zich anders 
ontwikkelden. Er werden geen verschillen waargenomen in groei, overleving, 
differentiatie of stamcelactiviteit. Deze experimenten laten zien dat, ondanks 
een mogelijke rol voor NF-κB in chemoresistentie, continue activatie van NF-
κB op zich zelf niet genoeg is om een stam- of progenitorcel te laten afwijken 
van zijn normale ontwikkelingsprogramma. Dit betekent echter niet dat NF-κB 
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in samenwerking met andere mutaties niet zou kunnen leiden tot maligne 
ontaarding. De overexpressie van NF-κB in combinatie met andere eiwitten 
zou hierin meer inzicht moeten verschaffen. 
 Een ander eiwit waarvan bekend is dat het een rol speelt in apoptose is 
p21, mogelijk als gevolg van NF-κB-activatie. In hoofdstuk 4 is de rol van p21 
in AMLs onderzocht. In vergelijking met normale bloedcellen bleek dat p21 
zeer sterk en uitsluitend in het cytoplasma tot expressie kwam in 75% van de 
onderzochte monocytaire AMLs. Juist deze cytoplasmatische variant had een 
beschreven anti-apoptotische werking. Vergelijking van AMLs met 
cytoplasmatisch p21 en AMLs zonder p21, bleek een aanmerkelijk verschil in 
chemotherapeutisch geïnduceerde apoptose op te leveren. Experimenten in 
cellijnmodellen bevestigden vervolgens dat cytoplasmatische expressie van 
p21 leidt tot een verminderde apoptose via de ASK1-p38-JNK route. De 
cytoplasmatische lokalisatie van p21 voorkomt eveneens dat er een groeiarrest 
optreedt. Beide processen zouden dus kunnen bijdragen aan de voortgaande 
groei van de leukemische cel.  
 In hoofdstuk 5 wordt aangetoond dat de hierboven beschreven ASK1-
p38-JNK route niet alleen door p21 geremd kan worden, maar eveneens door 
het chaperonne eiwit HSP27. Echter, in blasten van AML-patiënten konden we 
een dergelijke correlatie tussen HSP27 expressie en verlaagde apoptose niet 
aantonen, wat het gevolg is van een maskerende werking van p21.  
 Gezamenlijk laten hoofdstuk 2 tot en met 5 zien, dat in AML-cellen er 
verschillende signaaltransductieroutes geactiveerd zijn. Deze gegevens maken 
duidelijk dat voor de behandeling van AML-patienten meerdere routes zullen 
moeten worden geattaqueerd om tot een effectieve behandelingsstrategie te 
komen. Bovendien lijkt de aanwezigheid van één geactiveerde 
signaaltransductie route niet verantwoordelijk voor de leukemische 
transformatie, en dat hiervoor meerdere signalen nodig zijn. Echter het 
blokkeren of remmen van één van die signaaltransductieroutes kan wel bij 
dragen aan het anti-leukemische effect van chemotherapie. 
 
Gecontroleerde groei en AML 
In normale hematopoiese worden primitieve stam-/progenitorcellen inactief 
gehouden door remmende groeifactoren, zoals Transforming Growth Factor β 
(TGF-β), en interacties met stromale cellen in het beenmerg. Dit gebeurt om 
excessieve groei en daarmee uitputting van het hematopoietische systeem te 
voorkomen. Verstoring van dergelijke controle mechanismen kan de cyclische 
activiteit van leukemische cellen verhogen en daarmee een voordeel geven ten 
opzichte van normale cellen.  
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 Om dit verder te onderzoeken, is in hoofdstuk 6 gekeken naar het 
mechanisme waarmee N-RasL61 getransformeerde leukemische cellen 
ontsnappen aan TGF-β geïnduceerde groeiremming. Daarbij zijn twee 
leukemische cellijnen met een N-RasL61 mutatie (HL-60 and TF-1) vergeleken 
met een hematopoietische cellijn zonder Ras mutaties (M1). Het ontbreken van 
een respons op TGF-β ging gepaard met de afwezigheid van p27 in cellen met 
de N-RasL61 mutatie. Verschillende experimenten wezen vervolgens op de 
centrale rol voor p27 in de interactie tussen de Ras en TGF-β signaal 
transductie routes. Daarnaast bleek het eiwit SKP2, een bekende component 
van de p27 afbraak machinerie, sterk tot expressie te komen als gevolg van de 
Ras-mutatie en een rol te spelen in de afbraak van p27. Concluderend tonen 
deze data aan dat de N-RasL61 mutatie in staat is om de negatieve 
groeiremming als gevolg van TGF-β-signaaltransductie te blokkeren door 
middel van afbraak van p27. In ongeveer 10% van de AMLs wordt deze 
mutatie waargenomen, waarbij onze experimenten een nieuw mechanisme 
beschrijven, waarmee deze AML-cellen een groeivoordeel zouden kunnen 
verkrijgen als gevolg van het ontbreken van negatieve controlerende factoren. 
 
Self-renewal, differentiatie en leukemie 
Daar waar normale hematopiese een polyklonaal proces is, wat wil zeggen dat 
meerdere HSCs bijdragen aan de totale hematopoiese, is AML een klonale 
afwijking. In normale hematopoiese bestaat er een goede balans tussen self-
renewal in het stamcelcompartiment en differentiatie richting meer uitgerijpte 
cellen. In AML bestaat het stamcelcompartiment uit de leukemische stamcel 
(LSC), die een uitgebreide self-renewal capaciteit, maar een zeer beperkte 
differentiatie capaciteit bezit. Hierdoor hebben zij een voordeel ten opzichte 
van normale HSCs.  
STAT5 is een transcriptie factor waarvan recentelijk door overexpressie-
experimenten is aangetoond dat het een rol speelt in de verhoogde self-
renewal van stamcellen. Dit wordt gecombineerd met een afname in expressie 
van transcriptiefactoren die een rol vervullen in de myeloide differentiatie. 
Omdat in AML-cellen frequent een geactiveerd STAT5 wordt waargenomen, is 
in hoofdstuk 7 onderzocht of afname van STAT5-expressie, doormiddel van 
RNA-interferentie, effecten heeft op normale- en leukemische-stamcellen. 
Verlaging van STAT5 met zo’n 80% in CD34+ stam- en progenitorcellen zorgde 
ervoor dat in lange termijn kweken op stromale beenmerg cellen de expansie 
sterk achterbleef in vergelijking met cellen waarin STAT5 niet verlaagd was. 
Deze verminderde groei/expansie was niet het gevolg van apoptose of een 
verhoogde blokkade in celcyclusprogressie. Eveneens bleef de 
C
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differentiatiecapaciteit van deze cellen onveranderd. Uit verschillende 
progenitor- en stamcelkweken bleek dat de STAT5-verlaging aanleiding gaf tot 
een verminderd aantal celdelingen op het niveau van één enkele cel. 
Vervolgens hebben we STAT5 ook verlaagd in CD34+ AML-cellen. Ook in deze 
blasten bleek STAT5-verlaging een verminderde expansie te geven, 
vergelijkbaar met de vermindering die ook in normale cellen werd gezien. Er 
werden echter geen effecten op het differentiatieblok waargenomen. De 
resultaten tonen aan dat zeer onrijpe hematopoietsiche stam- of 
progenitorcellen afhankelijk zijn van STAT5 voor hun groei. Verder suggereren 
deze experimenten dat AML-cellen eveneens afhankelijk zijn van STAT5 voor 
hun groei. Of dit het gevolg is van een verminderde self-renewal zal uit verdere 
experimenten moeten blijken, maar het feit dat de differentiatie als gevolg van 
STAT5-verlaging niet veranderde, maar na overexpressie wel, laat zien dat de 
mate van STAT5-expressie bepalend is voor deze processen.  
 Onlangs is aangetoond dat de blokkade in myeloide differentiatie na 
STAT5-overexpressie het gevolg was van verlaging van de CCAAT enhancer 
binding protein alpha (C/EBPα) expressie. Omdat verschillende studies ook 
hebben laten zien dat C/EBPα gemuteerd of geïnactiveerd is in AML-cellen, 
hebben we in hoofdstuk 8 gekeken naar de effecten van herintroductie van 
een induceerbare vorm van C/EBPα in CD34+ AML-cellen. In lange-
termijnkweken op stromale beenmergcellen wordt aangetoond dat AML-cellen, 
waarin dit C/EBPα geactiveerd is, onmiddellijk stoppen met groei. Deze 
groeistop ging gepaard met een gedeeltelijk herstel van myeloide differentiatie. 
Een interessant detail van deze kweken was dat er bijna geen cellen 
aangetroffen werden met eigenschappen van de LSCs nadat we C/EBPα 
geactiveerd hadden, terwijl controle kweken dit wel liet zien. Deze gegevens 
wijzen erop dat de self-renewal eigenschappen van LSCs beïnvloed worden 
door C/EBPα. Daarom zijn er vervolgens experimenten uitgevoerd, waarbij 
gekeken werd of in vitro ‘getransplanteerde’ cellen hieruit naar een nieuwe 
kweek in staat waren om een nieuwe leukemische kweek te genereren. Daar 
waar controle AML-cellen inderdaad in staat waren dit tenminste driemaal te 
doen, bleken de C/EBPα geactiveerde cellen hiertoe, niet in staat. Tot slot zijn 
enkele genen, die betrokken zijn bij self-renewal en celgroei, bestudeerd. In 
één AML vonden we inderdaad dat C/EBPα activatie correleerde met een 
verlaging van self-renewal genen, zoals BMI-1, Meis1 en p21. Echter, andere 
AMLs lieten dit beeld niet zien, dus verdere experimenten zullen moeten 
worden uitgevoerd om een verband tussen self-renewal en activiteit van 
C/EBPα aan te tonen.  
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In hoofdstuk 9 wordt tenslotte een samenvatting gegeven van de in dit 
proefschrift uitgevoerde onderzoeksprojecten. De resultaten worden daarbij in 
een breder perspectief geplaatst en vergeleken met andere gepubliceerde 
studies. Tevens wordt  aangegeven in welke mate deze nieuwe inzichten naar 
de toekomst vertaald kunnen worden naar andere en mogelijke betere 
behandelstrategieën voor AML-patiënten en waar het toekomstig onderzoek 
zich zou op moeten richten. 
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ALL    Acute Lymphoid Leukemia          
AML   Acute Myeloid Leukemia         
APL   Acute Promyelocytic Leukemia         
AML SL-IC  AML SCID-Leukemia Initiating Cells         
Apaf-1  Apoptosis Protease Activating Factor-1        
ASK1  Apoptosis Signal Regulating Kinase-1        
C/EBPα   CCAAT Enhancer Binding Protein α          
CML   Chronic myeloid leukemia         
JNK   c-Jun N-terminal Kinase         
CAFC   Cobblestone Area Forming Cell        
CLP    Common Lymphocyte Progenitor       
CMP    Common Myeloid Progenitor        
CB     Cord Blood         
CDK    Cyclin-Dependent Kinase        
CDKi    Cyclin-Dependent Kinase inhibitor       
EMSA     Electrophoretic Mobility Shift Assay       
Erk     Extracellular signal Regulated Kinase      
FACS     Fluorescence-Activated Cell Sorting       
FAB     French-American-British        
GMP     Granulocyte Macrophage Progenitors       
GM-CSF   Granulocyte Macrophage-Colony Stimulating Factor      
G-CSF   Granulocyte-Stimulating Factor       
HSP27     Heat Shock Protein 27        
HSC     Hematopoietic Stem Cell        
IKK     IκB Kinase         
IκB     Inhibitor of NF-κB         
IL     Interleukin         
ITD     Internal Tandem Duplication        
JAK     Janus Kinase         
L-CA   Leukemic Cobblestone Area         
LSC    Leukemic Stem Cell        
LTC     Long Term Culture        
LTC-IC   Long-Term Culture-Initiating Cell         
LMPP    Lymphoid primed Multipotent Progenitor      
M-CSF   Macrophage-Colony Stimulating Factor        
MEK1    Map kinase/ERK kinase 1        
MkEP     Megakaryocytic/Erythroid progenitor       
MAPK     Mitogen-Activated Protein kinase       
MAPKKK    Mitogen-Activated Protein Kinase Kinase Kinase      
MPP    Multipotent Progenitor        
MDS    Myelo Dysplastic Syndrome        
MPD    Myeloproliferative Disease        
NE     Neutrophil Elastase        
NRE    NF-κB Responsive Element        
NF-κB   Nuclear Factor kappa B          
NLS     Nuclear Localization Signal        
NPM    Nucleophosmin         
PMA     Phorbol 12-Myristate 13-Acetate       
PKB    Protein Kinase B         
PKC     Protein Kinase C         
Q-PCR   Quantitative PCR           
Rb     Retinoblastoma         
RNAi     RNA interference         
STAT    Signal Transducer and Activator of Transcription      
SAPK     Stress-Activated Protein Kinase       
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Hehe, eindelijk is het boekje dan af! Nu kan ik dan eindelijk beginnen met 
iedereen te bedanken die op wat voor wijze dan ook een rol heeft gespeeld bij 
het tot stand komen van dit boekje.  
Allereerst natuurlijk mijn promotor. Beste Edo, bedankt dat je zo’n vijfeneenhalf 
jaar geleden het vertrouwen in me stelde om mij als AiO aan te nemen. Je hebt 
het wetenschappelijk enthousiasme de afgelopen jaren zeer aanstekelijk weten 
over te brengen en je kritische houding heeft me veel geleerd om mee te 
nemen in mijn verdere carrière. Bedankt voor alle begeleiding gedurende de 
afgelopen jaren. Verder mijn co-promotores. Bart, ondanks dat ik de meeste 
tijd heb doorgebracht op het ziekenhuis, heb ik je begeleiding op afstand altijd 
zeer gewaardeerd. Je commentaar op mijn manuscripten, zowel inhoudelijk als 
op noodzakelijk politiek correct taalgebruik, heb ik altijd zeer op prijs gesteld en 
je commentaar heeft mijn manuscripten zeker verbeterd. En dan JJ. Allereerst 
als stagebegeleider tijdens de studie, daarna na twee jaar ook als AiO-
begeleider in het lab. Zelden heb ik iemand gezien die zo enthousiast kon 
worden van een experiment als jij. Of het nou ging om “ideetjes” of de eerste 
groene AML-cellen, overal zie je mogelijkheden, vervolgexperimenten en al de 
outline van een nieuw manuscript. Een manier van denken en werken die mij 
veel geholpen en geleerd heeft.  
 
De leden van de leescommissie, Prof. dr. P.J. van Haastert, Prof. dr. H.H. 
Kampinga en Prof. dr. I.P. Touw ben ik zeer erkentelijk voor het beoordelen 
van mijn manuscript. 
 
En niet te vergeten mijn collega’s van de hematologie research die de 
afgelopen jaren op het lab mijn ‘aanwezigheid’ hebben meegemaakt.  
Speciale dank gaat daarbij uit naar Marjan. Zonder al jouw werk zou ik drie 
artikelen minder hebben en daarnaast was het natuurlijk leuk om met je samen 
te werken. In voor een geintje, een roddel, een praatje en altijd enthousiast 
over de proefjes. Bedankt voor alles! Vanzelfsprekend mag ik ook BJ niet 
vergeten! Ondanks dat het onmogelijk voor mij was om de kenniskloof te 
overbruggen die er gaapte tussen jou en mij, heb je me in het begin heel veel 
kneepjes, shortcuts, overbodige handelingen en juiste controles geleerd om 
experimenten tot een goed einde te brengen. Je humor kon ik altijd waarderen, 
ook wanneer ik tot het onderwerp van spot werd. Alle andere collega’s van de 
hematologie wil ik ook graag bedanken voor de leuke tijd: Marcel, Djoke, 
Susan, Karin, Sandra O, Monica, Gwenny, Szabolcz, Lyndsay, Ingrid, Irene, 
Sandra R en Nel; verder de voormalige collega’s: Gerlinde, Dolf, Kyrjon, 
Dorina, Bettie, Arjen-Kars, artsachtige Inge en natuurlijk Mariet: je dacht toch 
niet dat ik je vergeten was!? Jouw ‘Wat moet je en wat kom je hier doen?’ 
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intimiderende houding heeft van af het begin nooit op me gewerkt, maar heeft 
jouw aanwezigheid wel tot een prettige bijkomstigheid van het lab gemaakt. 
De labcollega’s van de kinderoncologie verdienen eveneens een bedankje voor 
de leuke uurtjes op het lab: Esther, Frank, Gineke, Jessica, Tiny (alhoewel, op 
het lab?), Sabine, Arja, Berber, Rony, Evelien, Inge, Henk-Marijn, Jenny en 
Alida.  
 
Het samengaan met het oncologielab tot M.O.L de vitrine heeft naast 
diepgaande integratie van sommige leden ☺ ook geleid tot leuke momenten op 
het lab. Alle onco’s dan ook bedankt. Hetty moet even speciaal bedankt, 
vanwege haar “genereuze” financiële steun bij de totstandkoming van dit 
boekje. 
Verder wil graag alle collega’s van de stamcelbiologie, ontwikkelingsgenetica 
en biochemie bedanken voor alle discussies voor, tijdens en na de 
werkbesprekingen. Susanne, Vincent, Bart en Loes, ik was er wel niet vaak, 
maar toch bedankt voor leuke discussies bij de koffie, in de kroeg, BBQ en 
borrels. 
Zonder de onmisbare hulp op het secretariaat van Sylvia, Bianca en Gretha 
lagen veel manuscripten nu nog steeds op versturen te wachten. Bedankt voor 
de administratieve hulp op cruciale momenten.  
Verder is veel dank verschuldigd aan de FACS operators Geert, Henk en soms 
Douwe vanwege hun flexibiliteit als ik plotseling weer eens een FACS sort 
verschoof. 
 
Voor de hoognodige afleiding waren daar de momenten waarop wetenschap 
op de tweede plek kwam en ontspanning met vrienden de overhand nam: 
Beste Roos, tijdens onze studie trokken we steeds vaker met elkaar op en 
heeft geresulteerd in een hechte vriendschap. Echte vrienden kun je midden in 
de nacht bellen en zijn op een hand te tellen. Bedankt voor alle momenten en 
het feit dat je vandaag als paranimf naast me staat. Robert, op die hand sta jij 
natuurlijk ook, eigenlijk al vanaf het moment dat we samen het bestuur van 
TJAS in gingen. Bedankt dat je vandaag eveneens als paranimf naast me staat 
(en mijn nederlandsch gechecked hebd). Verder bedankt: Anneke, die de 
eerste jaren van mijn promotie van dicht bij heeft meegemaakt en lief en leed 
gedeeld heeft. Meike en David, de saunabezoeken, weekendjes weg, 
spelletjes en etentjes samen met Roos waren altijd heerlijk ontspannend. Beste 
Mariska, af en toe net zo’n politiek correct dranghek als ik, maar dat maakte 
sommige avonden tot onvergetelijke momenten. Jasper, ondanks dat we elkaar 
een jaar of wat uit het oog verloren waren, heeft een helder en oplettend 
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moment op straat onze agenda’s weer functioneel doen ritselen. Esther en 
Bart, de flesjes wijn worden dan wel per doosje open getrokken, de etentjes 
worden er nooit minder gezellig om. Bedankt voor de Bourgondische etentjes. 
En verder bedankt voor alle interesse, afleiding en steun: Petra en Erwin, 
Lieveke, Djoeke, Jos en Anke, Piet, en niet te vergeten Jan, Manny en Bart. 
 
Pap en mam, ondanks mijn “switch” van diergeneeskunde naar biologie, 
hebben jullie me altijd gestimuleerd om datgene te gaan doen wat ik leuk vond. 
Het onderwerp van mijn promotie heb ik wel geprobeerd uit te leggen, maar 
was toch voornamelijk een ver-van-jullie-bed-show. Toch heeft jullie dat nooit 
tegen gehouden om me hierin te steunen en interesse te tonen in datgene wat 
ik aan het doen was. Dit geldt overigens ook voor Gerben, Ruud en Ana. 
Bedankt voor alles in de afgelopen jaren en het voornaamste: dat jullie me 
hebben geleerd dat heel veel dingen wel degelijk mogelijk zijn, mits je maar de 
beslissing maakt om ze te gaan doen!  
 
Lieve Hilde, integreren met het oncologielab was denk ik wel het beste wat me 
drie jaar geleden heeft kunnen overkomen, al hebben wij dat misschien wat erg 
ver doorgevoerd ☺. Er resten mij nog slechts drie woorden voor jou om dit 
boekje af te sluiten: Jag älskar dig! 
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